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Structural coupling between the cytoplasmic (CP), transmembrane (TM) and extracellular (EC) 
domains of G protein coupled receptors (GPCRs) is crucial for their functioning in signal transfer 
from the extracellular to the intracellular side of the membrane. The focus of this thesis was to 
test the hypothesis that ligands can bind in each of the three domains. Depending on the location 
of the endogenous ligand binding site, the other two sites would become allosteric ligand binding 
sites. To test this hypothesis, we investigated the binding of accessory ligands to each of the 
three domains, CP, TM and EC. The major contributions of this thesis are as follows: 
I. The anthocyanin Cyanidin-3-glucoside (C3G) and the chlorophyll-derivative chlorin e6 
(Ce6), were shown to physically interact with rhodopsin. These studies demonstrated the 
presence of a novel CP allosteric ligand binding site in rhodopsin. Biophysical evidence 
indicated differential effects of binding of these ligands on rhodopsin function, structure and 
dynamics.  
II. The allosteric TM ligand binding pocket in metabotropic glutamate receptors 
(mGluRs) was shown to be analogous in structure and function to the orthosteric TM retinal 
ligand binding pocket in rhodopsin. Docking of known allosteric modulators to structural models 
 iv 
of mGluRs based on rhodopsin conformations was used to predict allosteric modulatory effects. 
Structural comparison of the mGluR and rhodopsin binding pockets revealed high overlap and 
preliminary evidence was obtained showing that an mGluR ligand can bind to rhodopsin. 
III. Evidence for the existence of an EC ligand binding domain was presented. Rhodopsin 
was shown to bind the extracellular chemokine ligand, CXCL11, an event which interfered with 
both rhodopsin and chemokine functions.  
IV. As part of the above efforts, it became necessary to develop and improve NMR 
spectroscopic methodology to study ligand binding of membrane proteins such as GPCRs. Thus, 
1H and 19F based NMR methods to screen for novel ligands that bind to GPCRs were developed 
and applied to rhodopsin.   
Collectively, the studies presented in this thesis enhance the understanding of allosteric 
modulation of GPCRs in general, and of the molecular mechanism of rhodopsin and mGluR 
activation in the presence of allosteric ligands in particular. The results could help in the 
identification of new ligands to allosterically modulate receptor structures and in turn their 
functions at different binding pockets, thus paving new ways to selectively target this 
pharmacologically important class of receptors. 
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1.1. BACKGROUND 
 
 
1.1.1. Introduction 
 
 
The largest family of cell surface receptors responsible for transducing signals from the 
outside to the inside of the cell are G Protein Coupled Receptors (GPCRs) and the focus 
of this thesis is modulation of their structure and function through binding of allosteric 
ligands.  In this section, a background is provided on GPCRs in general, their 
classification based on sequence and pharmacology, and specific details are provided for 
representative members from each major family.  Principles for allosteric modulation of 
GPCRs and the advantages associated with using allosteric modulators as opposed to 
orthosteric ligands are also discussed.  
 
 
1.1.2. G-Protein Coupled Receptors and Their Classification 
 
 
GPCRs form the largest and most diverse family of cell surface receptors.  The primary 
function of these membrane bound receptors is to mediate the communication between 
the cell and its environment by responding to signals via binding and activation of 
intracellular G proteins, in turn, initiating cellular responses (Figure 1.1).  These receptors 
respond to a wide variety of signals including light, ions, peptides, hormones, odorants 
and neurotransmitters.  GPCRs are structurally characterized by seven transmembrane 
(TM) helices, dividing each GPCR protein into extracellular (EC), cytoplasmic (CP), and 
transmembrane (TM) domains (Figure 1.1).   For this reason, GPCRs are also known as 
7TM proteins or serpentine receptors.  The seven TM segments are interlinked with EC 
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loops (E1, E2, and E3) and CP loops (C1, C2, and C3), and the amino (N) and carboxy 
(C) termini of GPCRs are located at the EC and CP sides of the receptors, respectively.  
 
 
 
 
 
 
Figure 1.1: Schematic representation of the generic structure of GPCRs. 
 
 
When specific ligands bind to GPCRs in the EC or TM regions, the event causes 
conformational changes in the receptors, which act like a switch transducing the ligand 
binding signal to the G proteins.  The G protein then acts to either stimulate or inhibit the 
production of intracellular secondary messengers, which in turn trigger various signal 
transduction cascades.  In general, the top one-third of the TM helices, along with the EC 
loops and N-terminus, play a major role in ligand binding.  The rest of the TM helix 
region with CP domain (including loops and C-terminus) is very important for the 
interaction with downstream signaling proteins.  With more than 1000 human sequences 
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deposited (Kolakowski 1994; Vassilatis, Hohmann et al. 2003), and more than 8000 
sequences including other organisms (Finn, Tate et al. 2008), GPCRs are one of the most 
important family of receptors. They are associated with various disease conditions 
including diabetes (Winzell and Ahren 2007), cancer (Yowell and Daaka 2002; Li, 
Huang et al. 2005; Dorsam and Gutkind 2007), central nervous system disorders (Conn, 
Christopoulos et al. 2009), obesity (Yeo and Siddle 2003), inflammation (Lomas-Neira 
and Ayala 2005), cardiac diseases (Tang and Insel 2004) and others.  Based on sequence 
homology and pharmacological considerations, the GPCR super-family is subdivided into 
six sub-families (Kolakowski 1994; Fredriksson, Lagerstrom et al. 2003).  They are:  
Class A or the rhodopsin like or adrenergic receptor like family, Class B or the secretin 
receptor family, Class C or the metabotropic glutamate receptor like, Class D or the 
Fungal mating pheromone receptors, Class E or the cyclic AMP (cAMP) receptors, and 
Class F the frizzled or smoothened receptors.  Very little sequence homology is observed 
between these different subfamilies; the greatest homology is observed within the TM 
regions.  Major differences are observed in the lengths of their N-termini (Figure 1.2).  
Other differences pertain to the endogenous ligand binding sites between different 
members across the subfamilies and sometimes within a subfamily.  The endogenous 
ligand typically binds at the TM domain near the EC domain in Class A GPCRs.  In 
contrast, for Class B and C the ligand pocket is located in the EC domain.  For some of 
the members of Class A GPCRs, the endogenous ligand binding site is also localized in 
the EC domain, but the majority of the members bind ligands in the TM domain.  For 
example, chemokine receptors bind to their respective endogenous chemokine ligands at 
the EC domain similar to Class B and C receptors.  The details of the structural features, 
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lengths of N-termini and the endogenous ligand binding sites for each of the major 
subfamilies, Class A, B and C, along with a representative member are discussed below. 
 
 
 
 
 
 
Figure 1.2: Schematic diagram of representative structural organizations of GPCRs 
highlighting the most common endogenous ligand binding site locations for each of 
the major GPCR family members.  Extracellular and cytoplasmic loops are colored in 
green and yellow, respectively.  Transmembrane helices are colored in red and 
represented as cylinders. The membrane bilayer is shown in blue color.  The endogenous 
(orthosteric) ligand binding site in each family is represented by an ellipse colored in 
grey. 
 
 
1.1.2. (a) Class A: Class A is the largest subfamily of GPCRs with 918 identified 
members in humans (Kolakowski 1994; Okuno, Tamon et al. 2008).  Class A GPCR bind 
to ligands as diverse as amines, peptides, hormones, lipids, and viral proteins to name a 
few (Chalmers and Behan 2002). The members of this family are characterized by the 
presence of D/ERY and NPXXY motifs in the CP domain at the ends of helices 3 and 7, 
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respectively (Baldwin, Schertler et al. 1997).  Residues Asp/Glu and Arg that are part of 
the D/ERY motif, are conserved across family A GPCRs, and are critical for receptor 
activation (Arnis, Fahmy et al. 1994; Acharya and Karnik 1996).  Previous studies with 
mutants involving residue Asp/Glu often resulted in constitutively-active receptors of this 
family (Acharya and Karnik 1996; Kim, Altenbach et al. 1997; Morin, Cotte et al. 1998; 
Ballesteros, Jensen et al. 2001).  The NPXXY signature motif is important for receptor 
internalization, activation, and also phosphorylation (Bouley, Sun et al. 2003; Fritze, 
Filipek et al. 2003; Kalatskaya, Schussler et al. 2004).  In addition to these conserved 
motifs, a disulphide bond connecting EC loop 2 with the EC end of TM helix 3 is also 
highly conserved within the family (Findlay and Pappin 1986; Karnik, Sakmar et al. 
1988; Karnik and Khorana 1990; Rader, Anderson et al. 2004).  Disruption of this 
disulphide bond highly destabilizes the receptors (Davidson, Loewen et al. 1994) and, as 
described in more detail for rhodopsin below, is associated with receptor misfolding 
(Hwa, Reeves et al. 1999; Hwa, Klein-Seetharaman et al. 2001).  Finally, the Class A 
family has the smallest N-terminus as compared to other subfamilies and the endogenous 
ligand binding domain in the majority of the receptors is situated in the TM domain, at 
the interface between TM and EC domains (Figure 1.2A).  Rhodopsin is the 
representative member of this subfamily of receptors. 
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Figure 1.3: Details of light-activation in rhodopsin. (A) Isomerization of 11-cis to all-
trans retinal by light. (B) Intermediate states of rhodopsin upon light-activation. 
 
 
Representative Class A Receptor Rhodopsin: Rhodopsin, the prototypical 
member of the GPCR Class A family, belongs to the opsin sub-family within Class A 
GPCRs.  The opsins represent a subgroup of proteins that function as photoreceptors in 
different cell types and organisms.  All opsins covalently bind to the chromophore retinal 
through a protonated Schiff base linkage to a lysine residue (Lys-296 in rhodopsin) found 
in the TM domain, close to the interface between the TM and EC domains.  11-cis retinal 
plays a pivotal role in rhodopsin activation.  Upon absorbing a photon, the chromophore 
isomerizes to all-trans retinal. This event triggers the rearrangement of the TM helices to 
give rise to the series of photo-intermediates shown in Figure 1.3.  Each intermediate has 
a characteristic absorption in the visible range (Lewis and Kliger 2000; Sakmar, Menon 
et al. 2002; Schertler 2005).  The Meta II state of rhodopsin is considered to be the active 
state of the protein and is an initiator of the visual signal transduction cascade.  The Meta 
II state is characterized by conformational changes in the protein that initiate these 
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events.  As a first step, Meta II binds to the G protein transducin (Gt).  Gt then activates 
phosphodiesterase (PDE), which, in turn, hydrolyzes cyclic GMP (cGMP).  Once 
hydrolyzed, cGMP initiates a cascade of events leading to the hyperpolarization of the 
cell through the closure of Na+-Ca2+ channels.  When the cell is hyperpolarized, the 
electrical potential inside the cell is negative.  In contrast, in the dark state, cGMP keeps 
the channels in the photoreceptor membrane open, and Na+-Ca2+ influx depolarizes the 
membrane potential.   
There are two ways of shutting down the visual signal transduction cascade:  
through Meta II decay, a process of dissociation of protein and ligand to opsin and free 
all-trans retinal (Figure 1.3), or through binding of arrestin to the phosphorylated C-
terminal end of rhodopsin (Chabre, Bigay et al. 1988).  The phosphorylation can occur at 
any of seven threonine and serine sites in the C-terminus (Figure 1.4).  The ligand free 
opsin formed when Meta II decays can readily uptake 11-cis-retinal, a critical step 
required in the regeneration of the rhodopsin dark state which allows for the continuation 
of visual perception.   
Mutations in the rhodopsin gene and dysfunctions lead to the diseases retinitis 
pigmentosa and congenital night blindness (Dryja, Berson et al. 1993; Dryja, Finn et al. 
1995).  Most of these mutations were found to be localized in the EC domain and TM 
domains.  Previous studies from the Khorana lab (Kaushal and Khorana 1994; Ridge, Lu 
et al. 1995; Garriga, Liu et al. 1996; Liu, Garriga et al. 1996; Hwa, Garriga et al. 1997) 
provided conclusive evidence that most of these mutations lead to the formation of an 
incorrect disulphide bond between Cys185 – Cys-187, instead of the native Cys-110 – 
Cys187.  The formation of this aberrant disulphide bond leads to the stabilization of 
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incorrectly folded protein that lacks the ability to bind 11-cis retinal (Kaushal and 
Khorana 1994; Ridge, Lu et al. 1995; Liu, Garriga et al. 1996), suggesting a structural 
coupling between the EC and TM regions.  The mutants G90D, T94I and A292E that 
cause congenital night blindness were shown to constitutively activate Gt, even in the 
absence of the 11-cis retinal (Dryja, Berson et al. 1993; Rao, Cohen et al. 1994; Gross, 
Rao et al. 2003).  Some of these mutants were found to disrupt the interaction between 
Glu-113 and Lys-296, important for locking the receptor in the ground, inactive state 
(Rao, Cohen et al. 1994). 
  
 
 
 
 
Figure 1.4: Secondary structure representation of rhodopsin.  The disulphide bond 
between Cys-110 and Cys-187 is represented with a black dashed line.  The conserved 
D/ERY and NPXXY motifs are indicated in red and blue rectangles, respectively.  
Phosphorylation sites located in the C-terminus are colored in red. 
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In this thesis we used bovine rhodopsin as a model system. Bovine rhodopsin is 
one of the most thoroughly studied receptors among GPCRs, and using it as a model 
system is beneficial for the following reasons: 1) rhodopsin can be purified easily and in 
large quantities from bovine retinae. 2) There is a large body of literature reporting 
biochemical and biophysical studies which can be used for reference (Klein-Seetharaman 
2002). 3) Changes upon light activation in rhodopsin’s structure have been investigated 
in great detail for bovine rhodopsin (Kusnetzow, Altenbach et al. 2006). Several groups 
have focused their efforts on studying rhopdopsin stability and function in the presence of 
different lipids and detergents (Williams, Baker et al. 1974; Pontus and Delmelle 1975; 
Stubbs, Smith et al. 1976; Plante, Maude et al. 1977; Davoust, Bienvenue et al. 1980; De 
Grip 1982; Margry, Jacobs et al. 1982; Sefcik, Schaefer et al. 1983; Yeagle, Selinsky et 
al. 1984; Motoyama, Hamanaka et al. 1985; Tiurin, Korol'kov et al. 1987; Renk, Crouch 
et al. 1988; Wiedmann, Pates et al. 1988; Boesze-Battaglia, Hennessey et al. 1989; 
Gibson and Brown 1991; Gibson and Brown 1991; Brown 1994; Albert, Boesze-
Battaglia et al. 1996; Albert, Young et al. 1996; Bubis 1998; Jastrzebska, Maeda et al. 
2004; Bennett and Mitchell 2008). Many biophysical studies such as high-resolution 
NMR spectroscopy depend on solubilization of rhodpsin in detergent micelles. 
Rhodopsin exhibits maximum stability in n-dodecyl-β-D-maltoside (DM) micelles (Cha, 
Reeves et al. 2000) and this detergent has therefore been the most widely employed. 
Recent EPR spectroscopic measurements have provided evidence that the conformational 
changes observed in DM closely resemble those observed in lipid environments 
(Kusnetzow, Altenbach et al. 2006), further supporting the validity of using DM. 
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Therefore, bovine rhodopsin, reconstituted in DM detergent micelles (unless otherwise 
mentioned) was used for the studies reported in this thesis.  
 
 
1.1.2. (b) Class B: Class B is the second largest sub-family of GPCRs; 48 receptors have 
been identified in humans (Vassilatis, Hohmann et al. 2003; Finn, Tate et al. 2008; 
Okuno, Tamon et al. 2008). The N-terminus is with 60-80 amino acids generally larger as 
compared to Class A, but smaller than Class C (Soudijn, Van Wijngaarden et al. 2004). 
The members of this sub-family usually bind to peptide hormones such as secretin and 
glucagon (May, Leach et al. 2007).  The ligand binding site for these endogenous ligand 
peptides is situated in the EC domain, typically involving the N-terminus as well as the 
EC loops in the interaction (Hoare 2005).  This peptide ligand binding domain is 
composed of three or four cysteine residues and two tryptophan residues that are highly 
conserved across all members of the Class B GPCRs (Harmar 2001).  In addition to this, 
the N-terminal domain contains a highly conserved signal peptide region that targets 
these receptors to the plasma membrane (Harmar 2001).  The parathyroid hormone 
(PTH) receptor is the prototypical member of the hormone receptors in this family. 
 
 Representative Class B Receptor – Parathyroid Hormone (PTH) Receptor:  
The PTH receptor is member of sub-family B1 of Class B GPCR (Harmar 2001).  There 
are two subtypes of this receptor, PTH1 and PTH2. The PTH1 receptor is the best studied 
member of hormone receptors and plays a major role in regulating calcium levels and 
bone growth in humans, and as such, the PTH1 receptor is expressed abundantly in bone 
and kidney cells (Lee, Deeds et al. 1994; Lee, Deeds et al. 1995; Lee, Brown et al. 1996).  
The PTH1 receptor initiates signaling by binding to the endogenous hormone PTH 
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secreted by parathyroid glands.  PTH is a 84 amino acid peptide and interacts at the N-
terminal domain of the PTH1 receptor.  Upon binding to the hormone, the receptor 
undergoes conformational changes and initiates the binding of the G protein at its CP 
domain.  Previous studies have identified that this receptor can couple to both Gs and Gq 
(Offermanns, Iida-Klein et al. 1996), thus activating protein kinase A and protein kinase 
C pathways (Muff, Born et al. 1994; Partridge, Bloch et al. 1994; Yang and Gerstenfeld 
1996).  Mutations that lead to constitutive activity in this receptor have been implicated 
in the genetic disease Jansen's metaphyseal chondrodysplasia (Schipani, Kruse et al. 
1995).  In contrast to this, mutations that result in inhibiting activity lead to a disease 
condition called Blomstrand's lethal chondrodysplasia (Jobert, Zhang et al. 1998; 
Karperien, van der Harten et al. 1999).  
  
 
1.1.2. (c) Class C: A total of about 40 human receptors constitute the Class C GPCRs 
(Kolakowski 1994; Finn, Tate et al. 2008; Okuno, Tamon et al. 2008), with metabotropic 
glutamate, calcium sensing and γ-aminobutyric acid (GABA) receptors as the major 
receptor subtypes.  The Class C GPCR sub-family in general, with the exception of 
GABA receptors, is structurally characterized by the presence of a large extracellular N-
terminal domain comprising about 600 amino acids and a cysteine rich domain (CRD) 
connecting the TM with this EC domain. The only  exception are GABA receptors.  The 
endogenous ligand binding domain of Class C GPCRs is located in this long N-terminal 
EC domain, often referred to as a “Venus flytrap” (Acher and Bertrand 2005).  This 
ligand binding pocket location is unusual when compared to other GPCR family 
members where the small molecule ligand binding domain is typically located in the TM 
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domain near its interface with the EC domain (Class A GPCRs) or in the EC loops and 
N-terminus close to the TM domain (Class B GPCRs).  The representative members of 
Class C GPCRs are the metabotropic glutamate receptors. 
 
Representative Class C Receptors – Metabotropic Glutamate Receptors: 
Glutamate is the most important excitatory neurotransmitter in the brain.  Glutamatergic 
neurotransmission proceeds primarily via ion gated channels (ionotropic glutamate 
receptors).  In addition, there are metabotropic glutamate receptors (mGluRs), which 
belong to the GPCR family.  Both types of glutamate receptors share a common EC 
ligand binding architecture, albeit different topology and protein family membership.  X-
ray crystallographic structures are available for the soluble EC domains of mGluRs 
(Hampson, Huang et al. 1999; Kunishima, Shimada et al. 2000; Tsuchiya, Kunishima et 
al. 2002; Muto, Tsuchiya et al. 2007) and ionotropic glutamate receptors (Armstrong, Sun 
et al. 1998; Armstrong and Gouaux 2000; Mayer 2006).  In humans, there are eight 
subtypes of mGluRs that are further divided into three groups based on their 
pharmacological and signaling properties.  Group I mGluRs (subtypes 1 and 5) are 
primarily localized post-synaptically where they modulate ion channel activity and 
neuronal excitability.  Groups II (subtypes 2 and 3) and III (subtypes 4, 6, 7, and 8) are 
primarily located pre-synaptically and regulate the release of neurotransmitters, including 
glutamate (Conn and Pin 1997).  
mGluRs play modulatory roles in neuronal processes such as anxiety, learning, 
memory and perception of pain (Swanson, Bures et al. 2005).  Because of these roles they 
are attractive drug targets for treatment of neuronal dysfunctions including seizures, 
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epilepsy, Parkinson’s Disease and night blindness (Parmentier, Prezeau et al. 2002; Kew 
2004; Dryja, McGee et al. 2005). 
 
 
1.1.3. Allosteric Modulation in G Protein Coupled Receptors 
 
 
With almost 50 - 60% of drugs in the market targeting GPCRs, they are one of the most 
important families of receptors in the drug discovery field.  Most of the drugs developed 
in the past decade are agonists or antagonists that bind competitively to GPCRs, where 
“competitive” indicates the molecule binds at the same binding site as the endogenous 
ligand.  Such drugs are often found to exert side effects.  Recently, attention has been 
given to the development of drugs that do not target the orthosteric ligand binding site, 
but instead, bind to other sites on receptors and modulate receptor signaling.  Such types 
of drugs are referred to as allosteric modulators.  Binding of these modulators at the 
allosteric site is communicated to the endogenous or orthosteric ligand binding pocket via 
long-range conformational changes and these, in turn, affect receptor function.  The 
modulation of receptor function is either positive or negative, stabilizing the active or 
inactive conformations of the receptors, respectively.  Depending on whether the receptor 
function is enhanced or inhibited, the allosteric modulators are referred to as positive or 
negative allosteric modulators, respectively. 
Developing allosteric modulators as opposed to orthosteric agonists and 
antagonists that directly target the endogenous or orthosteric ligand binding site is 
advantageous for several reasons.  In the absence of the endogenous ligand most 
allosteric modulators do not exert any effect, thus preserving the physiological effects of 
the receptor (Christopoulos, May et al. 2004; May, Leach et al. 2007).  As allosteric 
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modulators only act when the endogenous ligand is bound to the receptor, these ligands 
have the potential to exert fewer side effects, even when added in large excess, as 
compared to orthosteric ligands that directly affect signaling (Christopoulos, May et al. 
2004).  Further, as allosteric ligand binding sites are generally found to be located in non-
conserved regions of receptors, as opposed to the highly conserved orthosteric ligand 
binding sites, it is possible to develop highly-selective ligands that can target subtypes of 
the receptors that are otherwise difficult to differentiate between (Christopoulos, May et 
al. 2004; Raddatz, Schaffhauser et al. 2007).  In addition to this, allosteric modulators 
also provide a unique advantage in modulating the receptors that have peptides or small 
proteins as endogenous ligands.  As these endogenous ligands are large and span an 
extensive area of interaction interface on the receptor, it is difficult to develop synthetic 
molecules that could directly target the orthosteric or endogenous ligand binding pocket 
(Jensen and Spalding 2004; Langmead and Christopoulos 2006; May, Leach et al. 2007).  
Recent studies have reported allosteric modulators for almost all major 
subfamilies of GPCR (Table 1.1).  For Class A receptors, allosteric modulators have been 
identified for many receptors and their subtypes including muscarinic, adenosine and 
adrenergic receptors. In particular, the muscarinic acetylcholine receptors are the best 
studied receptor type among the Class A receptors identified (Christopoulos, Lanzafame 
et al. 1998; Christopoulos and Kenakin 2002).  As described above, in most members of 
Class A GPCRs, the endogenous ligand binding site is located in the TM domain near the 
EC side (Figure 1.2).  Several structural studies have identified that the allosteric site 
comprises EC loops 2 and 3 and part of TM helix 7 (Krejci and Tucek 2001; Huang, 
Prilla et al. 2005; Prilla, Schrobang et al. 2006).  In contrast, for the chemokine receptors 
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belonging to the same family where the endogenous ligand binding site is situated in the 
EC side, two allosteric binding sites have been proposed. One of them was located in TM 
helices 1, 3, 5 and 7 (Dragic, Trkola et al. 2000) and the other in the CP domain 
(Andrews, Jones et al. 2008). 
Evidence presented in this thesis is mounting that there are also allosteric ligands 
for rhodopsin, the prototypic Class A GPCR (see above).  This thesis work is the first 
indication of the presence of secondary ligands for rhodopsin, apart from the endogenous 
ligand 11-cis retinal.  This discovery was triggered by two recent studies. First, it was 
shown that the presence of the anthocyanin compound, cyanidin-3-glucoside (C3G) 
enhanced the rate of reaction of opsin with 11-cis retinal, such that regeneration in rod 
outer segment preparations was increased (Matsumoto, Nakamura et al. 2003).  Further, 
the chlorophyll derivative chlorin e6 (Ce6) enhances the sensitivity of deep-sea fish 
rhodopsin to light (Douglas, Partridge et al. 1999; Isayama, Alexeev et al. 2006).  
However, prior to the work reported in this thesis it was not known whether Ce6, C3G or 
any other secondary ligand apart from 11-cis retinal physically binds to rhodopsin.   
In the case of family B receptors, it was shown by mutagenesis studies that the 
allosteric small molecule ligand binding site is composed of TM helices 3, 5 for the 
corticotrophin releasing factor receptor (Liaw, Grigoriadis et al. 1997; Hoare, Sullivan et 
al. 2003) and helices 2, 3 for glucagon-like peptide receptor (Cascieri, Koch et al. 1999), 
towards the EC side of the receptors. 
Finally, for family C GPCRs, in particular for mGluRs, it was shown by 
mutagenesis that allosteric modulators bind at the interface between the TM and EC 
domains similar to most of the endogenous ligand binding sites in class A GPCRs.  The 
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allosteric ligand binding site was localized to TM helices 3, 5, 6 and 7 (Malherbe, 
Kratochwil et al. 2003; Malherbe, Kratochwil et al. 2003).  It was also shown that 
allosteric mGluR ligands can either act as positive or negative modulators of mGluR 
activity in response to glutamate or glutamate analogs, enhancing or suppressing the 
responses, respectively (Goudet, Gaven et al. 2004).  Small changes in the chemical 
structures of ligands were shown to switch their modulatory effects.  For example, 4,4’-
difluorobenzaldazine (DFB-4,4`) is a negative modulator for mGluR5, while 3,3’-
difluorobenzaldazine (DFB-3,3`) is a positive modulator for the same receptor (O'Brien, 
Lemaire et al. 2003).  For another member of this family, calcium sensing receptors, 
previous studies have shown that the allosteric ligand binding site is composed of the TM 
helices 2, 3, 6 and 7 (Hu, Mora et al. 2002; Petrel, Kessler et al. 2003; Miedlich, Gama et 
al. 2004). 
 
 
1.1.4. G Protein Coupled Receptor Structures  
 
 
Availability of three-dimensional structural information is central for structure based drug 
design studies. The first crystal structure of any GPCR was that of rhodopsin, a class A 
GPCR, published in 2000 (Palczewski, Kumasaka et al. 2000). Until 2007, rhodopsin, 
was the only GPCR with atomic level information available for the whole family of 
GPCRs. Recently, the atomic structures of 3 other class A GPCR members, A2A 
adenosine receptor (Jaakola, Griffith et al. 2008), β1 (Warne, Serrano-Vega et al. 2008) 
and β2 (Rasmussen, Choi et al. 2007) adrenergic receptors has been published. In addition 
to these structures, the crystal structure of rhodopsin from an invertebrate organism, squid 
and other states of the vertebrate bovine rhodopsin, the activated Meta II (Salom, 
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Lodowski et al. 2006) and opsin (Park, Scheerer et al. 2008) state were also obtained. The 
overall structure of the transmembrane regions of the different crystal structures 
superimposed very well with the rhodopsin x-ray structure with the exception of squid 
rhodopsin. Squid rhodopsin did not align as well with either the dark state or opsin state 
structure of rhodopsin as compared to other crystal structures (Lodowski, Angel et al. 
2009). TM helices 5 and 6 were extended and the CP loop 3 of squid rhodopsin had extra 
sequence in comparison to vertebrate rhodopsin. These differences were attributed to 
invertebrate specific signaling mechanisms (Mustafi and Palczewski 2009). The β1 and β2 
adrenergic receptor (AR) was crystallized in complex with an antagonist, cyanopindolol 
and partial inverse-agonist, carazolol (Warne, Serrano-Vega et al. 2008). The major 
differences between the adrenergic receptor and the rhodopsin structures were mostly 
localized to CP loops, and were especially found in loops 2 and 3 and the EC loop 2. 
While the CP loop 2 of β1 – AR adopts an alpha helical structure (Warne, Serrano-Vega 
et al. 2008), the same region in β2- AR (Rasmussen, Choi et al. 2007) still remains in an 
extended conformation similar to rhodopsin CP loop 2 structure (Mustafi and Palczewski 
2009). Furthermore, TM helix 1 of β2- AR is straight and does not have a kink in the 
center of the helix as compared to rhodopsin. Remarkably, the EC loop 2 of both β1 and 
β2- AR forms an alpha helix towards the EC side in comparison to a beta sheet in 
rhodopsin. Furthermore, this loop is exposed to solvent in the adrenergic receptors but is 
highly buried in rhodopsin. In contrast to the rhodopsin and adrenergic receptor 
structures, the EC loop 2 of the A2A adenosine receptor lacks secondary structure entirely 
(Jaakola, Griffith et al. 2008). Further, the ligand binding pocket of the adenosine 
receptor is located closer to helices 6 and 7, instead of helices 3, 5, and 6 in the case of 
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rhodopsin and adrenergic receptors. Apart from these differences the overall structural 
organization of the different receptors was similar to that of rhodopsin. 
 
 
Table 1.1: Members of the major subfamilies of GPCRs exhibiting allosteric 
modulation. The data shown in the table is summarized from the work of other groups 
(May, Leach et al. 2007). The location of the orthosteric and allosteric ligand binding 
sites established for some of the receptors are mentioned respectively. 
 
 
 
 
GPCR Family Receptor Details 
Endogenous 
Ligand 
Binding Site 
Allosteric 
Ligand  
Binding 
Site 
Adenosine A1, A2A, A3  TM helices 3, EC 
Adrenoreceptors α−1, -2A, -2B, -2D   
Chemokines CXCR1-4, CCR1,3,5 EC domain TM and 
Dopamine D1, D2   
Muscarinic M1-M5  TM helices 3, EC and 
Family A 
Serotonin   
Corticotropin Releasing Factor 1  EC domain  TM 
Glucagon  EC domain  Family B 
Glucagon Like Peptide-1 EC domain TM 
Metabotropic Glutamate Receptors 1-5 and 7
EC domain TM 
helices 3, 
5, 6 and 7
Calcium Sensing Receptor 
EC domain TM 
helices 3, 
5, 6, and 
7 
Family C 
GABA-B  EC domain  
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1.2.  GOALS AND ACCOMPLISHMENTS 
 
 
1.2.1. Open Questions 
 
 
Previous studies have shown that the activity of many GPCRs is modulated by secondary 
ligands, which bind at a different site in comparison to the orthosteric ligand binding 
pocket.  This may suggest that there are multiple ligand binding sites on GPCRs, 
conveying differential signaling effects.  It is an important and unsolved general question 
to what extent the allosteric ligand binding pockets of different membrane receptors are 
conserved, as the homology between sequences is often very low, even when belonging 
to similar subtypes.  In this thesis, I have focused on studying the binding and the effects 
of secondary or accessory ligands on the structure and dynamics of different GPCRs.  
Towards this end, I used a combination of computational and experimental biophysical 
and biochemical approaches.  The questions addressed in this thesis are: 
 
1. Where and how do allosteric ligands bind to GPCRs? 
2. Is there a preferential binding of allosteric ligands to different structures/states of 
receptors? 
3. How does ligand binding change receptor structure and dynamics? 
 
We focused our efforts on studying the binding of the novel ligands, Ce6 and 
C3G to rhodopsin and the modulation of mGluRs by TM ligands.  Addressing the above 
questions will help in understanding the mechanisms of conformational flexibility 
available in these receptors to accommodate different ligands. The long term goal is to 
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contribute to the mechanistic understanding of allosteric modulation in different types of 
GPCRs in general, with mGluRs and rhodopsin of particular interest. 
 
 
1.2.2. Significance of the Study 
 
 
The GPCR family is pharmacologically important as they allow targeting numerous 
biological functions through ligands that bind to them. Furthermore, dysfunctions and 
mutations of GPCRs are genetic causes for numerous diseases.  They also play a role in 
cancer by cross-talking with epidermal growth factor receptors (Bhola and Grandis 2008) 
and are over-expressed in many tumor cells (Li, Huang et al. 2005).  Despite being a 
major target in the drug discovery field, efforts focused on designing synthetic drugs that 
act as either agonists or antagonists for a specific subtype of receptor have failed to result 
in potential drugs. Previous efforts have mostly focused on drugs that bind in the same 
binding pocket as the natural ligand, which is highly conserved across different GPCRs 
and therefore difficult to target specifically.   Recently, increased attention has been given 
to the understanding and development of drugs that bind at other sites, i.e. allosteric 
modulators.  Studies on understanding the mechanisms of allosteric modulation may 
provide insights necessary for developing new therapeutic drugs that can selectively 
target subtype specific members of GPCRs.   
 The goal of this thesis was to enhance understanding of allosteric modulation of 
GPCRs in general, and of the molecular mechanism of rhodopsin activation in the 
presence of accessory ligands in particular. The results have significantly advanced the 
theory of conformational flexibility in different GPCR members to accommodate 
allosteric ligands in general. In this theory, we integrate the idea of structural coupling 
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between the three – EC, TM and CP – domains of GPCRs and allosteric modulation 
(Figure 1.5). While it is clear that every GPCR transmits the ligand binding signal 
occurring in the EC and/or TM domain to the CP domain via the TM domain, we propose 
the novel idea that it is possible to modulate this process at different points along this 
pathway using allosteric ligands. We propose that there are general ligand binding 
pockets that should in principal be available in all GPCRs (Figure 1.5). In some 
receptors, a particular pocket is orthosteric, while the same pocket becomes allosteric in 
others, depending on where the endogenous ligand binds. This implies a conservation of 
ligand binding pockets and the effects of ligand binding on conformational flexibility of 
the receptors. We have found evidence for this conservation in an in-depth study of the 
allosteric TM binding pocket of the Class C GPCR family mGluRs. We show that the 
allosteric ligand binding pocket is similar to the orthosteric TM binding pockets in Class 
A GPCRs. Furthermore, we provide evidence that active and inactive conformations are 
similarly stabilized in both cases. This finding has important implication for drug 
development in general, because we can potentially predict if a ligand would potentially 
inhibit or activate a particular GPCR, or serve as a negative or positive allosteric 
modulator, depending on the location of the orthosteric ligand binding pocket. Such 
ligands could be designed in a highly specific manner. 
On the other hand, based on the structural coupling hypothesis above, we also 
proposed that there should be a allosteric ligand binding pocket in the CP domain (Figure 
1.5), where normally the G protein binds. We provide experimental evidence that such a 
ligand binding pocket does exist in rhodopsin and can serve to allosterically modulate the 
receptor. Because all GPCRs bind the G protein in the CP domain, it is likely that this 
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binding pocket will be general for different GPCRs. Targeting this binding pocket could 
be developed into a novel way of activating or inhibiting this pharmacologically 
important class of receptors on a broad specificity basis.  This may be useful for example 
in cancer drug development, where it could be useful to inhibit several GPCRs 
simultaneously to down regulate all pathways for crosstalk with the EGF receptor. 
 
 
 
Figure 1.5:  Schematic representation of structural coupling between EC, TM and 
CP domains in GPCRs. The different ligand binding sites are represented by blue filled 
ellipses. 
 
1.2.3.  Summary of Thesis Contributions 
 
 
While allosteric modulators were known previously for all three major classes of GPCRs 
(Table 1.1), these were all ligands that bound mostly in the TM domain, at or near the 
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interface with the EC domain. Although the CP ligand binding allosteric site was 
predicted recently also by other groups for muscarinic receptors (Espinoza-Fonseca and 
Trujillo-Ferrara 2005), chemokine receptors (Andrews, Jones et al. 2008) and rhodopsin 
(Taylor, Barda et al. 2008), direct experimental evidence for binding has not yet been 
provided. Thus, further evidence for the existence of such allosteric sites in the CP 
domain is needed. The first major contribution of this thesis, contribution I, was to 
confirm the existence of a CP domain allosteric ligand binding pocket for rhodopsin. 
Furthermore, there was previously no framework to understand the relationship between 
orthosteric and allosteric binding pockets in GPCRs. In contribution II, I showed that the 
allosteric TM ligand binding pocket in mGluRs corresponds in structure and function to 
the orthosteric TM ligand binding pocket in rhodopsin. To further test the idea of the 
generality of ligand binding pockets across GPCR, in contribution III, I showed that 
rhodopsin whose orthosteric ligand binds in the TM domain binds chemokine, a ligand 
that binds in the EC domain. The approaches used for my studies were a combination of 
computational and experimental methods, but not all of the methodology was ready to be 
applied to the systems investigated. In contribution IV, I therefore combined different 
NMR spectroscopic approaches developed in other contexts to create a suite of NMR 
spectroscopic tools suitable to study ligand binding and conformational changes in 
membrane receptors.  
 
Each contribution I-IV is summarized below, and is described in detail in 
subsequent chapters 2-5. 
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I. The existence of a cytoplasmic, allosteric ligand binding site in rhodopsin was 
demonstrated.  
a. Rhodopsin as a primary target of interaction for two ligands, C3G and Ce6, 
was demonstrated using fluorescence and selective excitation 1H NMR 
spectroscopy.  These studies showed differential interaction affinities of Ce6 
and C3G for dark and light-activated states of rhodopsin.  
b. The location of interaction of these accessory chromophores was localized to 
the CP domain.  Docking studies of these accessory ligands showed a strong 
preference for docking of ligands to the CP domain.  This prediction is 
experimentally supported by evidence from 1D 1H NMR of unlabeled 
rhodopsin and 2D 15N-lysine labeled rhodopsin studies.  These studies also  
suggest that binding modulates rhodopsin’s structure and dynamics in both the 
dark and light-activated states.   These studies in the case of Ce6, were further 
validated by labeling with 19F at specific sites in the CP domain. 
c. An effect of C3G and Ce6 ligands on rhodopsin function was also established.  
C3G binding enhanced the regeneration rate of rhodopsin from opsin and 11-
cis retinal as monitored by absorbance spectroscopy.  However, C3G binding 
exhibited little to no effect on Gt interaction with rhodopsin.  In contrast, 
GTPγS filter binding and fluorescence studies showed that Ce6 binding 
greatly interferes with Gt binding to rhodopsin.  Molecular modeling studies 
suggested that the predicted Ce6 ligand binding pocket highly overlaps with 
the Gt interaction site on rhodopsin, serving as evidence for the observed 
effects on Gt activation. 
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d. Stability and thermal denaturation studies suggest that C3G binding 
destabilizes the overall structure of rhodopsin.  Further, these effects were 
attributed to be the underlying mechanism for the observed increased 
regeneration rates.  In the case of Ce6, 19F NMR studies monitoring time-
dependent changes upon light-activation of two selectively-labeled sites in the 
CP domain showed modulation of conformational states of rhodopsin.   
e. Application of 19F NMR approaches to study dynamics of selectively labeled 
sites in rhodopsin was demonstrated for the first time.  A significant change in 
the flexibility of one of the sites, at residue Cys-316 was demonstrated upon 
binding to Ce6.  The 19F NMR results together with the 1H NMR studies (see 
b, above) collectively suggest that molecular mechanism by which Ce6 
binding inhibits Gt activation may be due to the faster conversion of light-
activated state to an opsin-like inactive state. 
f. NMR data acquired using α-ε-15N tryptophan labeled rhodopsin demonstrated 
that the structure of TM domain in rhodopsin is allosterically modulated upon 
binding to Ce6 and most likely induces conformation flexibility in this 
domain.   
II. The structural and functional similarity between orthosteric and allosteric ligand 
binding pockets was demonstrated. 
a. By docking allosteric modulators to active and inactive homology models 
of mGluRs, which are class C GPCRs, based on structures of rhodopsin, a 
class A GPCR, it was demonstrated that positive allosteric modulators 
(PAMs) and negative allosteric modulators (NAMs) of mGluRs 
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preferentially bind to class A-GPCR like active and inactive states of the 
receptor, respectively.   
b. 3,3`-difluoro-benzaldazine (DFB-3,3`), a positive allosteric modulator of 
mGluR5, was shown to interact with rhodopsin.  DFB-3,3` was predicted 
to bind at the same binding site as 11-cis retinal using molecular modeling 
studies.  The total amount of rhodopsin regenerated decreased after 
addition of DFB-3,3` in a concentration-dependent manner.  This supports 
the idea that both 11-cis retinal and DFB-3,3` may occupy the same 
binding pocket.   
III. A chemokine ligand was found to bind to rhodopsin, indicating rhodopsin has a 
capacity for allosteric modulation in the extracellular domain. 
a. An interaction between the chemokine ligand CXCL11 and rhodopsin was 
presented for the first time.  The interaction was predicted using machine 
learning approaches, and experimentally validated using chemotaxis 
assays. Binding of chemokine to rhodopsin inhibited Gt activation. 
b. From computational docking studies, we predicted CXCL11 to bind near 
the extracellular domain of rhodopsin.  Further, comparisons of the 
interaction of chemokine ligand with chemokine receptor and rhodopsin 
showed similar interaction, involving extracellular loop 2.  Previous 
studies on chemokine receptors indicated that the E2 loop by itself is 
capable of interacting with CXCL11 and inducing chemokine activity, 
confirming that molecular docking studies can be used to successfully 
predict ligand protein interaction sites in these receptors. 
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IV. We developed a suite of NMR spectroscopic tools applicable to membrane 
receptors in detergent micelles. 
a. We extended the 1D proton based ligand screening method previously 
demonstrated for soluble proteins, to membrane proteins, by combining it 
with a selective excitation scheme to overcome the constraints posed by 
detergent micelles.   
b. As the 1H-based approach (a) may sometimes lead to overlapping signals 
between protein(s) and ligand(s), we also developed a ligand-based 
screening method for ligands labeled with 19F. In this approach, the signal 
comes uniquely from the ligand as there is no 19F background in proteins.   
c. The above methods (a and b) were successfully applied to study the 
interactions of C3G and Ce6 with rhodopsin. We also showed that such 
approaches may be used as screening tools for receptor ligands. Both in 
vivo and in vitro based approaches were demonstrated as a proof of 
principle for a set of ligands labeled with 19F.  
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2.1. PREPARATION OF MATERIALS 
 
 
All operations involving rhodopsin were carried out under dim-red light illumination unless 
otherwise stated. Buffer designations are listed in Table 2.1 at the end of this chapter (pg. 57). 
 
2.1.1. Urea-washed ROS Membranes 
 
 
ROS membranes were prepared from frozen bovine retinae, purchased from W. A. Lawson Co. 
(Lincoln, NE) as described (Papermaster 1982). The thawed retinae were homogenized in two 
batches with each 15 ml of buffer A containing 30% sucrose by vortexing for 1 min. 
Centrifugation (4500 rpm, 6 min, SA600 rotor) yielded a supernatant and a pellet, which was 
suspended by vortexing in 15 ml buffer A, 30% sucrose. After centrifugation as above the 
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combined supernatants were slowly mixed with one volume of buffer A. The crude ROS were 
pelleted (10000 rpm, 10 min, SA600 rotor) and then homogenized using a manual homogenizer 
in a total volume of 40 ml buffer A, containing 15% sucrose. Two 20 ml fractions of the 
homogenate were underlayed with 10 ml of 0.64 M sucrose in buffer A utilizing a long needle. 
After spinning the samples (10 min, 10000 rpm, SA600 rotor), the pellet was suspended in a total 
volume of 20 ml 0.64 sucrose in buffer A by manual homogenization with a pestle and by 
passage through a No. 23 gauge needle. 4 sucrose gradient tubes were prepared in Beckman ultra 
clear centrifuge tubes in the cold room, as follows. 9 ml of 0.78 M sucrose in buffer A was 
underlayed slowly at the base of the tubes with 1 M sucrose, buffer A, then with 1.2 M sucrose in 
buffer A. The crude ROS were carefully overlayed on top of each gradient, centrifuged (25000 
rpm, 45 min, 4°C, SW28 rotor) and the 0.78M/1M interface was recovered by aspirating using a 
No. 18 needle. The ROS membranes were diluted to 50 ml with buffer A, pelleted (20000 rpm, 
30 min, rotor Ti45) and suspended in buffer A using the pestle and the No 23 needle to refine the 
vesicles. The suspension was centrifuged (30000 rpm, 4°C, 20 min, Ti45 rotor). The pellet was 
washed again with buffer A before suspended in buffer B and the vesicles refined as above to 
give a final volume of 25 ml each tube. The suspension was end-over-end mixed at 4°C for 1 
hour, followed by dilution with 2 volumes of buffer C and centrifugation (35000 rpm, 4°C, 45 
min, Ti45 rotor). The pellet was washed 3 times with 70 ml of buffer C by manual suspension as 
described above followed by pelleting at 35000 rpm for 30min. After the final wash the ROS 
were suspended in 15 ml of buffer D. This ROS suspension was stored in aliquots of 250μl at -
70°C after snap-freezing in liquid nitrogen. 
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2.1.2. Transducin 
 
 
Gt was purified from bovine ROS as described (Baehr, Morita et al. 1982). All steps were carried 
out on ice in the light. Each vial of 50 retinae was divided into 2 x 50 ml Falcon tubes. Each 
fraction was homogenized in 15 ml of buffer A containing 30% sucrose by vortexing for 1 min. 
After spinning at 4500 rpm for 6 min using an SA600 rotor, the supernatant was kept separately 
and the pellet resuspended by vortexing in 15 ml of buffer A containing 30% sucrose. After 
spinning as above, all supernatants were combined and slowly mixed with one volume of buffer 
A. The crude ROS were pelleted (10000 rpm, 10 min, SA600 rotor). The pellet was 
homogenized using a manual homogenizer in a total volume of 40 ml of buffer A containing 
15% sucrose. Two 20 ml fractions of the homogenate were underlayed with 10 ml of 0.64 M 
sucrose in buffer A utilizing a long needle. After spinning the samples (10 min, 10000 rpm, 
SA600 rotor), the pellet was resuspended in a total volume of 20 ml of buffer A containing 0.64 
sucrose solution by manual homogenization with a pestle and by passage through a No. 23 gauge 
needle. 4 sucrose gradient tubes were prepared in Beckman ultra clear centrifuge tubes in the 
cold room as follows: 9 ml of 0.78 M sucrose in buffer A was under-laid with 1 M sucrose in 
buffer A, then with 1.2 M sucrose. About 5 ml of crude ROS were carefully overlaid on the top 
of each gradient. The balanced tubes were centrifuged (25000 rpm, 45 min, 4oC, SW28 rotor). 
The 0.78M/1M interface was recovered by aspirating and diluted to 50 ml with buffer A. The 
ROS solution was centrifuged (20000 rpm, 30 min, rotor Ti45) and washed 4 times with buffer J, 
each resuspension followed by passage through a No. 23 needle. Gt(αβγ) was then extracted by 
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three further washes with buffer Fcontaining 100 μM GTP. This extract was applied to either a 
hexylagarose or a DE52 column. 
 A 6 ml (6 cm x 1.5 cm) hexyl agarose column (ICN) was equilibrated with buffer J. The 
GTP extractions were applied to this column at a flow rate of 0.3 ml/min. The column was then 
washed with buffer F containing 100 mM NaCl until reaching the pre-wash base-line of the 
equilibration (removal of GTP). At this point buffer F was supplemented with 300 mM NaCl and 
1 ml-fractions were collected. Fractions containing the 280 nm peak were pooled and dialyzed 
o/n against 1 l of buffer K. The protein was stored in 200 μl aliquots at -20oC. 
 As an alternative to purification on hexyl agarose, 50-100 ml of DE52 (a pre-swollen 
microgranular anion exchanger, Whatman) was end-over-end mixed o/n with 0.5 - 1 M of Tris 
pH 7.5 at 4oC. After allowing the slurry to settle, the supernatant was decanted to remove any 
fines. The resin was then washed with water by vacuum filtration to lower the salt concentration. 
The ion exchanger was re-suspended in buffer F (1:1) and poured into a 3x23 cm column (50 ml 
bed volume). The column was pre-equilibrated with 5-10 volumes of buffer F prior to 
application of the GTP extractions. The flow rate was 0.6 ml/min. GTP was removed with buffer 
F containing 100 mM NaCl and the G-protein was eluted with buffer F containing 500 mM 
NaCl. 
 
2.1.3. Expression of Rhodopsin in HEK293 Cells Grown in Suspension 
 
 
Cells stored in liquid nitrogen were thawed as quickly as possible by placing vials in a 37oC 
water bath after removal from liquid nitrogen. The cells were transferred to a 15 ml Falcon tube 
and slowly (over 2 min) 10 ml of buffer I medium was added to allow slow diffusion of the cryo-
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preservative DMSO from the cell. Cells were pelleted at 1K for 10 min, the supernatant was 
aspirated and 10 ml of fresh buffer I medium was added. The cells were resuspended and 
transferred to a 10 cm tissue culture dish and incubated at 37oC, 5% CO2 (Forma model #3956) 
in buffer G medium, supplemented with L-glutamine/ Penicillin/Streptomycin (buffer H 
medium) and 10% fetal bovine serum (buffer I medium). Buffer G medium was purchased as a 
powder mixture (Irvine Scientific). After dissolving, it was supplemented with 3.7g NaHCO3 per 
liter of media. Cells were maintained at about 90% confluence maximum to avoid damage to the 
cells by overgrowth. Cells were fed every three to four days, until ~80-90% confluence was 
reached. After approx. 3 days the confluent cells were split typically 1:5.  
After removal of the medium, plates are washed with 8ml buffer F. 4.5ml buffer F, 0.5ml 
10x trypsin (0.05%), 0.2% EDTA was sequentially added and the cells were left to detach from 
the plates. Cells were then transferred into the appropriate volume (20ml medium per plate) of 
buffer I media. The mixture was then added to new plates (20ml/plate). Cells were confluent 
after approx. 3 days for a 1:5 dilution. 
Suspension cultures were set up using 2-liter spinner flasks containing 500 ml media as 
depending on whether isotope and non-isotope labeled material was to be prepared. For non-
labeled material, cells were grown in buffer H medium, containing 10% fetal bovine serum. For 
isotope labeled material, media were in composition according to buffer G media formulation. 
However, since certain amino acids had to be omitted, the media were prepared from individual 
components. Thus, all solutions were prepared as 100x concentrated stock solutions, except 
glucose, NaCl, glutamine and the isotope labeled amino acid, which were added as solids. 
Deviations from the buffer G media formulation were as follows. 1. The glutamine concentration 
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was lowered by ½. The same amount was then added on day 5 or 6, together with the other 
additions described above. 2. The CaCl2 concentration was lowered to 50 mg/l (Eilers, Reeves et 
al. 1999). Isotope labeling also required the serum to be dialyzed to remove any amino acids. 
Thus, e.g. 500 ml fetal bovine serum was dialyzed 3-times against 10 l buffer J at 4oC with a 
tubing cut off of 1 kDa as described (Eilers, Reeves et al. 1999).  For both, labeled and unlabeled 
material, the media were supplemented with 0.1% Pluronic F-68, 50 μg/ml heparin.  Spinner 
flasks were inoculated using three-four 15 cm tissue-culture dishes confluent with cells (6-9 x 
107) per 500 ml of media and incubated at 37oC in a humidified incubator.  After 5-6 days, when 
the media turned yellow, the culture medium was further supplemented with 6 ml of 20% (w/v) 
glucose and 4 ml of 8% (w/v) NaHCO3, 5mM sodium butyrate. Cells were fed daily with glucose 
solution until the cells were harvested (usually on day 8). Cells were transferred to centrifuge 
vials equilibrated at 4oC and the spinner flask was rinsed with 2x50 ml of ice-cold buffer J and 
combined with the main culture. After centrifugation for 10 min at 4K, 4oC, in a Sorvall RC-3B 
centrifuge, the supernatant was immediately decanted and the cells kept on ice. 25 ml of ice-cold 
buffer J was added and the cells were resuspended. After transfer to a 50 ml Falcon tube, a 
further 25 ml was used to rinse the centrifuge pot and added to the Falcon tube. Cells were 
pelleted by centrifugation at 4oC. The wet-weight of the pellet was recorded and the cells 
resuspended in a final volume of 20 ml buffer J. 
 
 
2.1.4. Preparation of 11-cis Retinal 
 
 
Opsin produced in HEK293 cells required reconstition with 11-cis retinal. 11-cis-Retinal was a 
gift from Dr. Rosalie Crouch (University of South Carolina and the National Eye Institute of the 
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National Institutes of Health, U. S. Public Health Services). It was also prepared from all-trans 
retinal following a published procedure (Knowles and Priestley 1978). Approx. 100 mg all-trans 
retinal was dissolved in 50 ml ethanol at approx. 5 mM concentration and cooled to 4oC. This 
solution was irradiated with a 300 W >435nm light for 20-30 min. The resulting isomer mixture 
was dried under Argon in a water bath. The dry residue was dissolved in 10-20 ml hexane 
containing 6% ether. The solution was filtered through a 0.2 μm filter before injection in 4 ml 
batches into a Dynamax-60A (Si 83-121-C, 21.4mm x 300mm) silica column. Retinal isomers 
were separated in hexane containing 6% ether at a flow-rate of 8 ml/min. A separation profile is 
shown in Figure 2.1. The effluent was collected in the dark and evaporated to dryness under 
argon using a water bath. After dissolution of the residue in ethanol, the concentration of 11-cis 
retinal was determined by absorbance spectroscopy (see below, pg. 42). The extinction 
coefficient used for 11-cis retinal in ethanol at A379.5 was 24,940M-1cm-1 and for all-trans retinal 
in ethanol at A383 42,884M-1cm-1 (Knowles and Priestley 1978). 
 
 
2.1.5. Reconstitution of the Opsin Expressed in HEK293 Cells with 11-cis Retinal 
 
 
Cell pellets from a 500 ml culture were resuspended in 20 ml of buffer J containing benzamidine 
(0.005%) and PMSF (0.7 mM).  Cells harvested from plates were resuspended in 2ml buffer J 
per plate. 11-cis Retinal was added to give 5 μM concentration and the suspension was incubated 
for at least 1.5 hours.  The concentration of reconstituted mutant rhodopsin was estimated by 
UV/Vis absorbance difference spectrum analysis of an aliquot solubilized in buffer J containing 
1% DM.  Addition of 11-cis retinal was repeated until no further increase at A500 was observed 
by difference spectroscopy.   
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Figure 2.1. Preparation of 11-cis retinal. Shown is an HPLC profile of the isomer mixture 
produced by irradiation with >435nm light. Peaks are labeled with their respective isomers.  
 
 
2.1.6. Solubilization of Cell Pellets Containing Rhodopsin by Use of Detergents 
 
 
For solubilization in DM, the rhodopsin containing cells or ROS membranes were end-over-end 
mixed for 1 hour in buffer J containing 1% DM. The volumes used for solubilization depended 
on the rhodopsin source. ROS membranes were solubilized at a final rhodopsin concentration of 
1 mg/ml. HEK293 cells were solubilized at 10ml buffer/g wet pellet. Unsolubilized material was 
removed by centrifugation for 30 min at 4oC, 35,000 rpm, rotor 60Ti or 45Ti, Beckmann Ultra 
Centrifuge, or for volumes <1ml 10 min at 35,000 rpm, rotor TLA100.3. The supernatant was 
added to 1D4-Sepharose beads as described below in Section 2.1.7. 
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For solubilization in OG, rhodopsin was solubilized in buffer J containing 4% OG as 
described above for solubilization using DM.  
 
 
2.1.7. Affinity Chromatography of Rhodopsin Using 1D4-Sepharose 
 
 
2.1.7. (a) Preparation of 1D4-Sepharose 
 
 
CNBr-activated sepharose 4B was prepared from CNBr and sepharose 4B (Kumel, Daus et al. 
1979), based on the rapid reaction of cyangen halides with the hydroxyl groups of carbohydrates 
at high pH to form cyanate esters (Figure 2.2). The monoclonal anti-rhodopsin antibody 1D4 
(Oprian, Molday et al. 1987) was then coupled to CNBr-activated sepharose 4B via its amino 
groups (Oprian, Molday et al. 1987) with minor modifications.  
 
 
 
-H+ 
 
 
Figure 2.2: Activation of sepharose by CNBr and coupling of protein to the activated gel. 
This figure is taken from ref.(Kohn and Wilchek 1978). 
 
 
 
Prior to coupling, 1D4 was purified from a myeloma cell line provided by R.S. Molday 
(University of British Columbia) as follows. 1500 mg 1D4 antibody (stored at -20°C) were 
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thawed. 300 ml of Protein A-sepharose 4B were packed and equilibrated with 5 times the bed 
volume of buffer K. All flow rates were between 0.5-1.5 ml/min, unless otherwise stated. The 
sample was diluted with 5 times its original volume of buffer K. The sample was loaded, 
followed by washing with buffer K until a straight baseline at A280 was reached. The sample was 
eluted with approximately 300 ml of buffer L. Fractions of 4ml each were collected while 
monitoring A280. In order to store the column for future use, it was regenerated with 300ml buffer 
M at a flow rate of 0.5ml/min. The column was stored at 4°C after washing with 2-10 times the 
bed-volume of buffer N. Due to the poor stability of 1D4 at pH 3, the pH of the fractions was 
immediately after elution adjusted to pH 8.3 using 0.5 M NaHCO3 pH 10. Fractions containing 
1D4 sepharose were combined and used directly for coupling, as long as the concentration of 
1D4 was above 3 mg/ml. If the concentration was lower, the solution was first concentrated to up 
to 10 mg/ml before coupling. The concentration of antibody was determined using A280 (A280  = 
1.383 is equal to a concentration of 1mg/ml). Dialysis tubes (Spectrapor, 14 kD cut-off, but 
could be higher) were washed thoroughly with aqua dest. and filled with the 1D4 solutions. 
Dialysis was against 5-10 l of buffer O 4 hours to overnight. Dialysis buffer was subsequently 
changed at least 3 times. After dialysis, the concentration was determined using A280 as above. 
 The purified 1D4 antibody was coupled to CNBr sepharose as described below. First, 20 
ml CNBr-Sepharose was prepared. 100-200 mg of 1D4 antibody can be bound to this amount of 
CNBr-Sepharose. If 100 mg of 1D4 was coupled the capacity of the final product was typically 
1mg rhodopsin/ml of 1D4 sepharose. 500 μl acetonitrile was added per 1 g of BrCN (Sigma). 
The volume increased after dissolving the BrCN, so that the final concentration was 1g/ml. This 
stock solution could be stored at –20oC. 20 g of Sepharose 4B slurry (Sigma) was washed three 
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times with water in a filter funnel. 20 g of sepharose corresponds to 30 ml of slurry. Water was 
removed by vacuum and the sepharose was added to 30 ml of buffer P. While stirring vigorously 
with a regular stirring bar under the hood, 1 ml of BrCN-solution was added and stirred for 
exactly 2 min. The suspension was transferred quickly to the filter funnel that contained ice-cold 
water and was vacuum-filtered immediately. The beads were washed with 300 ml of ice-cold 
buffer Q followed by 500 ml 1 mM HCl. All the washes were carried out extremely rapidly, i.e. 
such that vacuum-filtering of 100 ml took less than 30 seconds. Thus prepared CNBr-sepharose 
could not be stored. Coupling to 1D4 had to follow immediately after preparation, ideally within 
2 min. If CNBr-sepharose was purchased from Pharmacia, 1g of the dry powder CNBr-sepharose 
was equivalent to approx. 3.5ml gel slurry. The dry CNBr sepharose was washed on a sintered 
glass filter with 500 ml of 1mM HCl. All subsequent steps were the same for commercially 
available or self-made CNBr sepharose. 
The coupling to 1D4 to CNBr sepharose was carried out at 3-10mg 1D4 per 1ml CNBr-
sepharose 4B. 20 ml slurry was added to the concentrated sample of 1D4 containing 100 mg 1D4 
in buffer O. Coupling was allowed to proceed by end-over-end mixing at until the supernatant 
after spinning down the beads for 5min contained less than 5% of the total protein (after 4-5 
hours at RT). The supernatant was discarded. A volume equal to that of the original supernatant 
of blocking agent (1M ethanolamine pH 8) was added. Blocking was allowed to proceed for 2 h 
at RT or overnight at 4oC. The beads were washed on a sintered glass filter 4 times with 
alternating solutions of buffer O and buffer R. Buffer J containing 0.05% NaN3 was added in 
equal volume as the beads. The coupled 1D4-sepharose was stored at 4°C. 
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The capacity of 1D4-Sepharose was determined as follows. 500μg ROS membranes were 
solubilized using DM as described in Section 2.1.6 above (pg. 36) and the exact concentration 
was determined spectroscopically (as described below, pg. 42). 200μl of 1D4-sepharose were 
added and rhodopsin was purified as described in Section 2.1.7 and 2.1.9 below. The capacity 
was calculated using the ratio between the rhodopsin purified and the amount of rhodopsin 
originally solubilized. Typically the capacity was 1 mg rhodopsin per 1 mg 1D4-sepharose if 100 
mg of 1D4 was coupled to 20 ml of CNBr-sepharose. A capacity of up to 1.7 mg/ml could be 
obtained if correspondingly larger amounts of 1D4 were used. 
 
 
2.1.7. (b) Binding of Solubilized Rhodopsin to 1D4-Sepharose 
 
 
After centrifugation of non-solubilized material (Section 2.1.6 above, pg. 36), the supernate was 
added to 1D4-Sepharose. The amount of beads necessary to bind quantitatively the rhodopsin 
present in the supernate could be calculated from the 1D4 sepharose binding capacity, usually 1 
mg of rhodopsin per ml settled beads. About 10% excess of 1D4-Sepharose over rhodopsin 
content was used.  After end-over-end mixing for at least 6 hours at 4oC, the suspension was 
packed into a column. For 10-15 mg of rhodopsin to be purified the dimensions of the column 
were 2.7 cm diameter x (2 to 3) cm. If smaller amounts were purified, i.e. 100-500 μg, Biorad 
disposable chromatographic columns were used. The packed beads were washed at RT with at 
least 50 column volumes of buffer J, containing 0.88% OG or 0.05% DM, for purification in OG 
or DM, respectively. This was followed by further washes with 10 bed volumes of buffer E, 
containing 0.88% OG or 0.05% DM, for purification in OG or DM, respectively. The flow rate 
was 0.5-1 ml/min.  
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2.1.8. 19F Derivatization of Rhodopsin Bound to 1D4-Sepharose using TET 
 
 
After the washing described in Section 2.1.7 (b) above, the total beads containing ~10 mg bound 
rhodopsin were resuspended in 40 ml of buffer E and 4-PDS was added from a 1 M stock 
solution in ethanol to give a final concentration of 1 mM.  After end-over-end mixing for 5 min 
at RT, excess reagent was removed by multiple washing with 40 ml of buffer E under slight 
Argon pressure.  A total of at least 35 times the column volume of buffer E was used.  Complete 
removal of 4-PDS was tested spectrophotometrically, by monitoring the absorption at 323nm 
upon addition of 1mM DTT. After a flat baseline was observed at 323nm, the beads were then 
resuspended in 30 ml of buffer E and TET (3 μl of 11.2 M) was added to give a final 
concentration of approximately 1 mM.  After end-over-end mixing for several hours at RT, 
excess reagent was removed as described above for 4-PDS removal.   
 
 
2.1.9. Elution of Rhodopsin from 1D4-Sepharose 
 
 
Unlabeled and TET labeled rhodopsin were eluted from 1D4-Sepharose using buffer E 
containing 70 μM epitope nonapeptide at a flow rate of 0.3-0.35 ml/min, the effluent being 
monitored by UV/Vis absorption spectroscopy.  Complete elution of the rhodopsin mutants 
usually required ~5 column volumes of elution buffer. The elutions where A280/A500 ratio’s 
within the range 1.6 – 2.2 were considered for further studies, ensuring proper folding of 
rhodopsin. 
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2.1.10. Concentration and Buffer Exchange of Rhodopsin for Solution NMR Analysis 
 
 
Fractions from 1D4-immunoaffinity chromatography containing >0.2 μM rhodopsin (A280/A500, 
1.6-1.8) were pooled and concentrated using the membrane filter Ultracel-30 (Amicon).  About 
6-10 mg amounts of rhodopsin were concentrated to final volumes of 0.05-0.1 ml. 
For analysis of rhodopsin by 19F NMR spectroscopy, after concentrating as above, the 
solvent was exchanged to buffer S by the addition of 1 ml buffer S, followed by membrane 
filtration to a volume below 0.1 ml as above.  This operation was repeated three times.  The final 
volume was then adjusted to 0.3 ml with buffer S.  TFA was added from a 50 mM stock solution 
(in D2O) to give a final concentration of 0.2 mM.  
For analysis of isotope labeled rhodopsin by heteronuclear and 1H NMR spectroscopy, 
after concentrating as above, the solvent was exchanged to buffer S by membrane filtration as 
described above. The final volume was adjusted to 0.3 ml with buffer S. 
 
 
2.2. SPECTROSCOPIC TECHNIQUES 
 
 
2.2.1. Absorbance Spectroscopy 
 
 
A Perkin–Elmer λ-25 spectrophotometer, equipped with a multiple water-jacketed cuvette holder 
was used to record absorption spectra. All spectra were measured at 20°C unless otherwise 
specified. All measurements were recorded in the 250nm to 650nm range, using a 10mm path 
length cell, bandwidth of 1nm, with a response time of 1s and scan speed of 960nm/min. 
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Rhodopsin concentrations were calculated using a molar extinction coefficient of the 500 
nm chromophore absorption of 40,600 M-1cm-1 (Wald and Brown 1953). A500 was determined 
either directly from absorbance spectra of pure rhodopsin solutions, or for solutions with a high 
absorbance background, i.e. solubilized membranes, by absorbance difference spectroscopy. 
First, the dark spectrum was recorded. The rhodopsin solution was illuminated (see below) and 
the spectrum was again recorded. The difference between the two spectra allowed estimation of 
A500 and the concentration of rhodopsin was calculated as above. 
For light-activating rhodopsin, the samples were illuminated with a 150-W fiber optic 
light (Fiber Lite A-200; Dolan-Jenner, Woburn, MA) equipped with a > 495 nm long-pass filter 
for 30 sec.  
 
 
2.2.2. NMR Spectroscopy 
 
 
All operations were carried out in the dark, unless otherwise stated. 19F NMR spectra were 
recorded on a Bruker 600MHz spectrometer using a 19F,1H,15N TXO 5mm triple gradient probe.  
Data acquisition and analysis was carried out using TopSpin Version 2.0 Software.  The sample 
was locked on deuterium.  The relaxation delay was 0.5 sec. Line broadening was 20 Hz.  An 
internal standard, TFA was used as control or reference in each case.  Acquisition time, number 
of scans averaged and specific parameters were as indicated in the text or legends.   
For the 19F dynamics study, longitudinal relaxation experiments were conducted using the 
Freeman-Hill method (Freeman and Hill 1971) with relaxation delays of 0.0, 0.05, 0.1, 0.15, 0.2, 
0.25, 0.3, 0.4, 0.5, and 0.6 s.  Transverse relaxation experiments were performed using a Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence (Carr and Purcell 1954; Meiboom and Gill 1958) 
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with a half duration of CPMG pulses of 0.3 ms.  Relaxation rates were determined by recording a 
series of spectra with the relaxation delays of 0.0, 1.2, 2.4, 3.6, and 4.8 ms (R2). All experiments 
were conducted with 1H decoupling during acquisition periods.  Both longitudinal and transverse 
relaxation rate constants were determined at 10, 15, 20, 25, 30, and 35°C. 
The 1D 1H selective excitation NMR spectra were recorded at a spectrometer 1H 
frequency of ~800 MHz at the Structural Biology Department, University of Pittsburgh using a 
Bruker spectrometer. The details of the acquisition of 1D selective excitation 1H NMR spectra 
are as follows. As the samples contained detergent micelles, a selective excitation scheme with 
sculpting, using a double pulse field gradient spin echo sequence (DPFGSE) as described 
previously (Hwang and Shaka 1995; Stott 1995) was used. Each spectrum was obtained after 
applying two hyperbolic secant shaped pulses of length 2.8ms and 1.9ms, following a 90o hard 
pulse of 9.9µs at 0.5db over a spectral width of 35ppm. A delay of 0.5sec between each scan was 
used. A total of 2048 scans were averaged to obtain the final spectrum except for pH titration 
experiments of C3G, where a total of 512 scans were recorded at each pH value. The total 
acquisition time was ~ 29min, 7min and 2.2min to acquire 2048, 512 and 160 scans, 
respectively. A line broadening of 0.3Hz or 1Hz was used to process the final spectra.  
1H-15N HSQC NMR spectra of α-ε-15N-tryptophan and α-15N-lysine labeled rhodopsin 
were obtained at a spectrometer frequency of ~900 MHz and ~800MHz Bruker spectrometer 
mentioned as above, respectively. Data acquisition and analysis was then carried out using 
Topspin Version 2.0 Software. Different pulse sequences were used as indicated in the text.  
The illumination of the NMR samples was carried out as explained above (refer to 
Section 2.2.1, pg. 43) by placing the light source ~1cm away from the NMR tube. 
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2.2.3.  Fluorescence Spectroscopy 
 
 
Tryptophan fluorescence of rhodopsin was recorded using a Varian Cary Eclipse instrument. In 
all experiments, the data acquisition parameters were similar to those described previously 
(Farrens and Khorana 1995): excitation and emission wavelengths were at 295nm and 330nm, 
with slit widths of 5nm and 10nm, respectively. Samples contained 0.25μM or 0.5μM (as 
indicated) of purified rhodopsin in 0.05% or 0.6% DM (as indicated) either in the absence or 
presence of additives and the fluorescence was measured in the dark and after illumination. The 
sample temperature was always kept at 20oC unless otherwise specified.  
 For thermal denaturation experiments, the temperature was raised to 55oC and changes in 
fluorescence were measured at this constant elevated temperature. 
For highly absorbing species, fluorescence values were corrected for absorbance, as 
described in specific analytical procedures, Section 2.4.5, below. 
 
2.3 MOLECULAR MODELING AND DOCKING STUDIES 
 
 
2.3.1. Homology Modeling 
 
 
All homology models were built using MODELLER software (Sali, Potterton et al. 1995; Fiser 
and Sali 2003). The generated models in each case were further evaluated using MOLPROBITY 
(Davis, Murray et al. 2004) for structural constraints.  
 The homology model of the chemokine receptor CXCR3 was generated based on the 
rhodopsin dark state crystal structure (PDB id: 1L9H) as a template. 
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A three-dimensional model of the Gt peptide (VLEDLKSCGLF) was built by homology 
modeling based on the NMR structure of the Gt C-terminal peptide IRENLKDSGLF (340-350) 
(PDB id: 1LVJ)(Koenig, Kontaxis et al. 2002) as the structural template.  
 
 
2.3.2.  Protein – Ligand Docking 
 
 
2.3.2. (a)  Docking with ArgusDock: All ligands were docked to inactive and active models of 
the respective receptors using ArgusLab software, version 4.0 (Thompson ArgusLab 4.0.1). 
Ligand pdb files were generated using JME Molecular Editor software 
(http://www.cambridgesoft.com/software/ChemDraw/). Hydrogen atoms were added to the 
ligand coordinate file prior to docking using ArgusLab. The docking between each receptor 
subtype and ligand was performed using the “Dock a ligand” option. All the residues of the 
receptor were defined to be part of the binding site i.e, cubic boxes measuring 151 × 123 × 145 
points for the inactive model and 111 x 151 x 151 for the active model were built to include the 
entire protein in each case, allowing no bias towards the binding pocket. A spacing of 0.4 Å 
between the grid points was used. Docking simulations were performed by selecting 
“ArgusDock” as the docking engine. “Dock” was chosen as the calculation type, “flexible” for 
the ligand and the AScore was used as the scoring function. The AScore function, with the 
parameters read from the AScore.prm file was used to calculate the binding energies of the 
resulting docked structures. This file contains the coefficients for each term in the scoring 
function. Structures were visualized and the best docked structure was chosen based on lowest 
energy and minimal solvent accessibility of the ligand, as follows. First, the top 150 unique poses 
were retrieved. Typically, 20% of these conformations were ligands docked to the surface of the 
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protein, highly water accessible.  These conformations were discarded manually. In at least ~2/3 
of the remaining structures, the ligand was bound in a pocket analogous to the retinal binding 
pocket. Those ligands that were only partially buried in the protein interior, with parts of the 
ligand facing the outside of the helical bundle, were also discarded. Only ligands with maximal 
burial in the protein interior were retained. This typically included a list of 50 structures. These 
structures were rank-ordered by minimum energy and the structure with the lowest energy was 
chosen as the predicted receptor-bound conformation of the ligand. 
 
 
2.3.2. (b)  Docking with AutoDock: Ligands were docked to  the receptors using the 
Lamarckian Genetic algorithm (LGA) provided by the AutoDock program, either version 3.0 or 
4.0 (Goodsell, Morris et al. 1996). Solvation parameters were added to the protein coordinate file 
with the “Addsol” option in AutoDock, and the ligand torsions were defined using the “Ligand 
torsions” menu option of AutoDock. The grid maps representing the protein were calculated 
using the “AutoGrid” option. A cubic box was built around the protein with 126 × 126 × 126 
points; a spacing of 0.403 Å between the grid points was used. The protein was centered on the 
geometric center prior to docking. Docking simulations were carried out with an initial 
population of 300 individuals, and a maximum number of 50,000,000 energy evaluations. Apart 
from this a maximum number of 27,000 generations, a translation step of 2 Å, a quarternion step 
of 50° and a torsion step of 50° were used as the docking parameters for obtaining the final 
docked structures. Resulting orientations that have less than or equal to 0.5 Å root mean square 
deviation were clustered. In addition to returning the docked structure, AutoDock also calculates 
an affinity constant for each ligand-receptor configuration. The best ligand-receptor structure 
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from the docked structures was chosen based on lowest energy and minimal solvent accessibility 
of the ligand, analogous to the procedure described above for ArgusLab, with the difference 
being that only the top 10 or 25 most favorably bound ligand structures were analyzed as 
mentioned in the text. 
 
2.3.3.  Protein – Protein or Protein – Peptide Docking  
 
 
A three-dimensional model of the Gt peptide (VLEDLKSCGLF) and crystal structure of 
chemokine ligand CXCL11 (PBD id: 1RJT)  were docked to the rhodopsin dark state crystal 
structure (PDB id: 1L9H:A)(Palczewski, Kumasaka et al. 2000) and/or the Meta II ANM model 
(Isin, Rader et al. 2006). The Docking was performed using the ClusPro docking software 
(Comeau, Gatchell et al. 2004). The ZDOCK algorithm along with the available default 
parameters were used in the docking procedure. From the set of returned favorable 
conformations, the top 2000 scoring structures were further filtered by analyzing the desolvation 
and electrostatic energies. The top 2 models were submitted to the FastContact analysis program 
(Camacho and Zhang 2005) to further analyze the binding energy of the conformations and to 
identify the residues which are at the interface between the two proteins in the docked complex 
that either stabilize/destabilize the complex. 
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2.4. ANALYTICAL PROCEDURES 
 
2.4.1. Protein Quantification 
 
 
Protein concentrations were determined using the Bradford assay. A calibration curve was 
obtained by mixing 0, 10, 20, 30, 40 and 50 μl of a 0.1 mg/ml bovine serum albumin stock 
solution with water such that the final volume was 100 μl. The sample solution was also adjusted 
to 100 μl at appropriate dilutions. The Bradford reagent (Biorad) was diluted 5 fold and 1 ml was 
added to each Eppendorf tube. After mixing and incubation for 5 min, the 595 nm absorbance 
was measured in a disposable plastic cuvette. The concentration was determined using the bovine 
serum albumin standard curve. 
 
 
2.4.2. Meta II Decay 
 
 
The rate of Meta II decay was measured, after illumination of the samples, by following the rate 
of fluorescence increase, which corresponds to the rate of retinal release (Farrens and Khorana 
1995), using a solution of 2-4 μg of the protein in 200 μl of buffer E containing 0.05% DM.  The 
samples were bleached at 20oC for 30 sec and the fluorescence increase was measured.  The 
excitation and emission wavelengths were 295 nm (slit width = 5 nm) and 330 nm (slit width = 
10 nm), respectively.  
 
2.4.3. Rhodopsin Regeneration  
 
 
Regeneration studies (n=2) were performed with samples containing a rhodopsin concentration 
of 0.5μM and either a C3G concentration of 1mM or DFB-3,3` concentration of 0.5 or 2.5μM. 
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All the samples used in the regeneration experiments contained a final DM concentration of 
0.6%. 11-cis retinal was added to rhodopsin from a 0.5mM stock in ethanol, prior to 
illumination, to obtain a final concentration of 0.5μM.  
For C3G studies, the changes in the A500 absorption upon illumination were monitored as 
a function of time.  
The increase in the A500 absorption upon addition of 11-cis retinal 1.5 hours after 
illumination was monitored to estimate the regeneration. 
The total amount of increase at 500nm for the samples in the absence and presence of 
additives was normalized to 100%.  
 
 
2.4.4. Transducin Activation 
 
 
2.4.4. (a) By Fluorescence Spectroscopy: Activation of Gt by rhodopsin was monitored using 
fluorescence spectroscopy (PTI fluorimeter) at 20 °C as described with minor modifications 
(Phillips and Cerione 1988; Fahmy and Sakmar 1993; Yang, Farrens et al. 1996). The excitation 
wavelength was 295 nm with a 2 nm slit width, and the emission wavelength was 340 nm with a 
12 nm slit width. Gt was added (final concentration of 250 nM) to buffer A containing 0.012% 
DM. The solution was stirred for 300 s to establish a baseline. Photobleached rhodopsin was then 
added to the mixture to a final concentration of 5 nM. Photobleaching was carried out using 
>495 nm light for 10 s. After an additional 600 s, GTPγS was added to the reaction mixture to a 
final concentration of 5 μM, and the increase in fluorescence was followed for an additional 
2000 s. To calculate the activation rates, the slopes of the initial fluorescence increase after 
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GTPγS addition were determined by linear regression through the data points covering the first 
60 s. 
 
 
2.4.4. (b) By [35S]GTPγS Filter Binding Assay: Binding of transducin to rhodopsin with and 
without chlorin e6 (Ce6) was monitored using a [35S]GTPγS filter binding assay previously 
established (Wessling-Resnick and Johnson 1987), with several modifications described below.  
Transducin (Gt) and urea-washed ROS membranes were prepared as described above (refer 
Section 2.1.1, pg 30) from dark adapted bovine retinas (W.A. Lawson and Co.) and were stored 
at -80oC prior to use. Gt activation studies were carried out in the absence and at varied 
concentrations of accessory ligands, stored as a 100mM stock solution in DMSO. Each reaction 
contained 1μM Gt, 50nM ROS or rhodopsin, 1nM [35S]GTPγS (1250Ci/mmol; American 
Radiolabeled Chemicals, Inc.), 499nM cold GTPγS and 1μM GDP.  Samples were illuminated 
with >495nm light for two minutes, then shaken at 250rpm until the reactions were stopped by 
filtering 25μl aliquots through nitrocellulose membranes using a Millipore vacuum manifold, 
washing 3 times with 5ml of ice-cold wash buffer (10mM Tris, pH 7.4, 100mM NaCl, 5mM 
MgCl2, 2mM DTT).  Washed membranes were dried on the manifold then placed in 5ml of 30% 
ScintiSafe LSC-cocktail (Fischer Scientific). Total [35S]GTPγS bound was measured using a 
Beckman LSC 6500 counter.  Reactions were performed in triplicates with control samples 
remaining in the dark.   
To determine the relative IC50 values of Ce6 in ROS and rhodopsin in DM micelles, 5nM 
of either ROS or rhodopsin in DM micelles were incubated with various concentrations of Ce6 
for 30min post-illumination (2min) then filtered as described above.  Final DMSO 
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concentrations for each reaction were 1% and radioligand concentrations were identical to that 
described above. The IC50 values were estimated by fitting the data using the sigmoidal dose-
response function of ligand binding provided by Sigmaplot. 
 
 
2.4.5. Binding of Small Molecules Monitored by Fluorescence Spectroscopy 
 
 
Binding of either C3G, Ce6 or as a control Chlorophyll-a (Chl-a) was quantified by measuring 
the fluorescence of 4μg of rhodopsin in 500μl of 2mM sodium phosphate pH 6, 0.05% β-
dodecyl-D-maltoside (DM) as described (Farrens and Khorana 1995). C3G, Ce6 or Chl-a was 
added prior to illumination from a 100mM DMSO stock solution or its dilutions, at the final 
concentrations indicated.  The different in total fluorescence between rhodopsin in the absence 
and presence of various concentrations of ligands was used to estimate the affinity of interaction. 
The binding affinities for the interaction were calculated with the one-site saturation ligand 
binding function using Sigmaplot 10.0 scientific graphing software.  
For the studies with Ce6 and Chl-a, the fluorescence measured at each concentration was 
corrected for the resulting inner filter effect, where the excitation light is being absorbed by the 
added ligand at the excitation wavelength and the emitted fluorescence from intrinsic tryptophan 
residues is reabsorbed by the added ligand at the emission wavelength, as follows. We corrected 
for the inner filter effect using the Parker method (Parker 1968; Birdsall, King et al. 1983). The 
function used for correcting the data is 
F(real) = (F(measured)*2.303*A)/(1-10
-A)  where A is the absorbance of the sample at 295nm 
(excitation) or 330nm (emission). F(real) and F(measured) are the corrected and observed fluorescence 
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values at each concentration of Ce6 or Chl-a measured (Birdsall, King et al. 1983). The same 
correction was applied to dark and light samples, as the absorbance spectra at the excitation and 
emission wavelengths used did not change. We also determined an empirical correction function 
experimentally by checking the fluorescence intensity decrease of solutions containing 2.5μM 
and 25μM concentrations of tryptophan giving the same fluorescence counts as rhodopsin 
samples in the dark and in the light, respectively, as a function of increasing concentrations of 
Ce6, covering a similar range as used for rhodopsin. (Note that we experimentally verified the 
absorbance of each sample to obtain the exact Ce6 concentration in solution in all experiments 
reported here, to ensure accuracy.) The decrease in fluorescence was fit to a linear equation 
which was used to extrapolate to the exact concentrations of Ce6 in each sample. The ratio 
between the original fluorescence counts of tryptophan solutions in the absence of Ce6 and the 
actually observed fluorescence counts in the presence of Ce6 were used to scale the rhodopsin 
fluorescence counts accordingly.  
  
 
2.4.6. Thermal Denaturation  
 
 
Thermal stability experiments (n=2) were performed at 50oC using 0.5μM of both rhodopsin and 
C3G. Samples were placed in the cuvette holder and the first spectrum was taken at 20oC. 
Subsequently, the temperature was raised to 50oC, and the corresponding spectra were recorded 
every 5 minutes. All experiments were carried out at the three different pH values of 4, 6 and 8. 
The data was analyzed by fitting the increase and decrease observed at 500 nm absorbance for 
regeneration studies and stability experiments, respectively, to a non-linear regression function 
using Sigmaplot 10.0 scientific graphing software. 
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2.4.7.  Calculating Binding Affinities from NMR Data 
 
 
All spectra were processed using Bruker using Bruker Topspin1.3 software and corrected for 
phase and baseline using identical parameters. The peaks in the spectra were manually selected 
by using the peak picking module in the Topspin software. 
C3G binding affinities were calculated from 1H NMR spectra essentially as described 
(Fielding, Rutherford et al. 2005) with the following modifications. The NMR spectra of 50μM 
rhodopsin in the absence and presence of 25, 50, 100 and 200 μM C3G were processed as 
described above. Changes in intensities of ligand peaks 2, 11 and 14 were quantified in 
comparison to the ligand alone peak. The peak intensity in each case was estimated using the 
most intense protein peak (number 13) as a reference, which was normalized to 1.0. We also 
analyzed chemical shift changes in protein signals, specifically in peaks numbered 3, 4, 7, 8, 9 
and 10 in Figure 3.6A.  
 Ce6 binding affinities were estimated from the changes in ligand signal intensities upon 
addition of various concentrations of rhodopsin in comparison to free ligand control. We 
estimated the dissociation constants of interaction between the ligands and rhodopsin as 
described previously (Shortridge, Hage et al. 2008). The dissociation constant is given by: 
[ ][ ]
][C
PLK FFD =  
LF, PF and C correspond to the concentration of free ligand, free protein and complex 
between protein-ligand, respectively. For estimating the fraction bound or the total concentration 
of complex formation, we assumed that the signal intensity observed after addition of rhodopsin 
was due to the free ligand species present in the solution. Therefore, the intensity of the bound 
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ligand (IB) peak was determined by subtracting the intensity of the observed ligand peak (IO) in 
the presence of rhodopsin from the intensity of the free ligand peak (IF): 
OFB III −=  
Binding constants were determined from the ratios of bound and free ligand 
concentrations quantified by integrating 1H signals. While this is not as accurate a way of 
determining binding constants in comparison to T2 relaxation based measurements which contain 
a weighted average of relaxation rates of the free and bound forms of a ligand at different 
concentrations, it is so far the only method that gives rise to signals in the 1H NMR spectrum in 
the presence of detergents. Relaxation based ligand binding approaches cannot be applied to 
membrane proteins because of the dynamic range problem, i.e. the suppression of protein signals 
as a result of high intensity of signals from detergent micelles, and the unfavorable relaxation 
properties of membrane proteins in large detergent micelles, which decay very fast. In addition to 
this, the protein does not give rise to distinct and equally intense peaks even in selectively 
isotope labeled samples, as they experience selective conformational exchange broadening. 
Thus, the binding affinities cannot be estimated using relaxation based and line broadening 
methods. 
The data obtained from the changes in ligand peak intensities were fitted using the non-
linear regression function (one site specific binding) in Graphpad Prism5.0 to estimate the KD. 
Errors were calculated from the fit for each peak analyzed.  
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Table 2.1: List of buffer compositions. 
 
A 70mM K2HPO4/KH2PO4 (pH 6.8), 1mM MgOAc, 5 mM β-mercaptoethanol, 0.1mM PMSF 
B in 50 mM Tris-HCl (pH 7.4), 5M urea, 5mM EDTA 
C 50mM Tris-HCl (pH 7.4) 
D 20mM Tris-HCl (pH 7.2), 2mM EDTA, 10% sucrose, 1mM β-mercaptoethanol, 0.1mM PMSF 
E 2mM Na2HPO4/NaH2PO4 (pH 6) 
F 5 mM Tris (pH 7.5), 5 mM MgOAc, 5 mM β-mercaptoethanol, 0.1 mM PMSF 
G Amino Acid Composition of DMEM (Irvine Scientific): 
Essential 
Amino Acid 
mg/
l 
Non-essential 
Amino Acid 
mg/l Vitamins  mg
/l 
Inorganic 
Salts and 
other 
mg/l 
Arginine 
* HCl 
84 Alanine None D-Ca 
pantothenate 
4 CaCl2 50 
Histidine 
* HCl * H2O 
42 Asparagine None Choline 
Chloride 
4 Fe(NO3)3 
* 9 H2O 
0.1 
Isoleucine  105 Aspartate None Folic Acid 4 MgSO4 97.7 
Leucine 105 Cystine* 2HCl 63 i-Inositol 7.2 KCl 400 
Lysine 
* HCl 
146 Glutamate None Niacinamide 4 NaCl 6400 
Methionine 30 Glutamine 584 Pyridoxal*HCl 4 NaH2PO4 
*H2O 
125 
Phenylalanine 66 Glycine 30 Riboflavin 0.4   
Threonine 95 Proline None Thiamine*HCl 4   
Tryptophan 
 
16 Serine 42   Phenol 
Red * Na+ 
15 
Valine 94 Tyrosine* 2 Na+
* 2 H2O 
104   Glucose 4500 
H buffer G plus 2 mM L-glutamine, 100 units/ml Penicillin, 100 units/ml streptomycin 
I buffer H plus 10% FBS 
J 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4 (pH 7.2) 
K 1.5M glycine, 3M NaCl 
L 0.1M citric acid, 0.15M NaCl (pH 3) 
M 6M guanidinium-HCl 
N 50mM Na2HPO4/NaH2PO4 (pH 7), 0.01% thimerosol 
O 0.25M NaHCO3, 0.5M NaCl (pH 8.3) 
P 3.3 M K3PO4 (pH of 11.9 at 10-fold dilution) 
Q 0.25 M NaH2PO4/Na2HPO4 (pH 6) 
R 0.1 M NaOAc, 0.5 M NaCl (pH 4) 
S 20 mM NaH2PO4/Na2HPO4, pH 6 in 10% D2O (Cambridge Isotopes, Andover, MA). 
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SUMMARY 
 
 
Recent studies indicated that anthocyanin compounds, in particular cyanidin-3-glucoside 
(C3G) (Matsumoto, Nakamura et al. 2003) and the chlorophyll derivative chlorin e6 
(Ce6) (Washington, Brooks et al. 2004; Isayama, Alexeev et al. 2006), modulate the 
function of the photoreceptor rhodopsin.  Using fluorescence spectroscopy, here we show 
that Ce6 and C3G directly interact with rhodopsin.  Further, the binding affinities of 
interactions were determined by a selective excitation 1H NMR approach, overcoming 
some of the limitations posed by using fluorescence spectroscopy for these compounds.  
Molecular docking studies indicate that the binding pocket for both ligands is located in 
the CP domain.  Further, 19F and 1H NMR experiments indicate that the binding of both, 
Ce6 and C3G, modulate the structure of the CP domain, which is a key functional region 
in rhodopsin,.  GTPγS binding assays indicate that binding of these compounds to 
rhodopsin exert differential effects on G protein binding to rhodopsin at the CP domain.  
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Ce6 strongly inhibits activation of Gt, the associated G protein for rhodopsin, while C3G 
only modestly alters its activation.  Thermal denaturation and stability studies using 
circular dichroism (CD), fluorescence and UV/Visible absorbance spectroscopy show 
that C3G exerts an overall destabilizing effect on rhodopsin structure. The results provide 
a molecular mechanism for the previous observation that C3G accelerates rhodopsin 
regeneration by 2 folds (Matsumoto, Nakamura et al. 2003): modulation of rhodopsin 
structure via long-range mediated structural effects enhances access to the retinal binding 
pocket. Ce6 binding to rhodopsin investigated by NMR spectroscopy of α-ε-15N-
tryptophan labeled samples show that ligand binding in the CP domain can allosterically 
modulate the TM domain.   
 
 
SIGNIFICANCE 
 
 
The studies presented here identify C3G and Ce6 as the first small organic molecules that 
bind to rhodopsin, other than 11-cis retinal. The results obtained clearly demonstrate the 
presence of a novel ligand binding pocket in the CP domain of rhodopsin.  The idea that 
binding of small molecules in this pocket may result in allosteric modulation of 
rhodopsin (either by accelerating regeneration or by inhibiting the G protein) is 
intriguing, since allosteric modulation is an emerging concept in the GPCR field.  
Previously, there were no known allosteric modulators for rhodopsin, and all known 
modulators for other GPCRs bind in either the TM or EC domains.  Moreover, as the CP 
binding pocket identified is relatively conserved in class A GPCRs, it is possible that 
ligands binding in this pocket could be developed into universal modulators of GPCR 
activity.  This could have potential for the medical and drug development communities 
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for developing therapeutics for such cancers where multiple GPCRs are involved in 
growth regulation (Gschwind, Prenzel et al. 2002; Lui, Thomas et al. 2003; Thomas, 
Bhola et al. 2006; Zhang, Bhola et al. 2007). 
 
 
INTRODUCTION 
 
 
Several lines of evidence suggest that rhodopsin in the presence of anthocyanins and 
porphyrin compounds show enhanced sensitivity to light of low intensities and of longer 
wavelengths (Matsumoto, Nakamura et al. 2003; Washington, Brooks et al. 2004).  
Rhodopsin, the prototypical class A GPCR, is a dim light photoreceptor in rod outer 
segments that has a covalently bound ligand, 11-cis retinal (a vitamin A derivative). On 
light-activation, 11-cis retinal isomerizes to all-trans retinal, resulting in a series of 
intermediate conformational states.  Of these, the Meta II state of rhodopsin is considered 
to be the active state of the protein and is an initiator of the visual signal transduction 
cascade.  Meta II activates two opposing signaling cascades, sensitization and 
desensitization.  In sensitization, Meta II binds and activates the G protein transducin 
(Gt), ultimately resulting in hyperpolarization of the cell. Although it is often presented in 
the literature that Gt interacts with rhodopsin only upon activation, compelling evidence 
for a dark-state rhodopsin-Gt complex has also been proposed. Previous studies by Fung 
et al., have shown that Gt cannot bind to pure phospholipid vesicles but binds well to 
phospholipid vesicles containing either dark state or light activated Meta II state of 
rhodopsin (Fung 1983; Fung and Nash 1983). In addition to this, a rhodopsin antagonist 
that blocks Gt binding to purified Meta II state in the absence of phospholipids was also 
shown to dissociate Gt from the ROS membranes in the dark (Hamm, Deretic et al. 
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1987). However, the binding affinity of Gt is greater for Meta II than for dark state 
rhodopsin. In desensitization, the binding of the protein arrestin, following the 
phosphorylation of the C-terminus of rhodopsin by rhodopsin kinase, down-regulates the 
signal (Chabre, Bigay et al. 1988; Farrens, Altenbach et al. 1996; Sokal, Pulvermuller et 
al. 2002; Janz and Farrens 2004).  Meta II gives rise to the opsin state (the apoprotein) 
through release of the all-trans retinal chromophore from the binding pocket, ultimately 
leading to the dissociation of protein and ligand to opsin and free retinal.  All the proteins 
involved signaling interact at the CP domain of rhodopsin.  
 
 
Evidence for anthocyanin interactions with rhodopsin:  Anthocyanins, plant pigments 
belonging to the large group of phenolic compounds, the flavonoids, are abundant in a 
diet rich in fruits and vegetables.  A large subset of anthocyanins are derivatives of the 
cyanidin backbone structure shown in Figure 3.1, where the 3,5,6,7,3’,4’ and 5’ positions 
(Figure 3.1A) are substituted to give the vast array of anthocyanin structures observed in 
nature (Veitch and Grayer 2008).  The variation in color is not only due to the different 
chemical substituents of the cyanidin backbone, but is also observed as a function of pH, 
solvent and co-pigments (Brouillard and Dubois 1977; Malien-Aubert, Dangles et al. 
2001).  The effect is based on the fact that anthocyanins interconvert between different 
species that exist in an equilibrium that is highly dependent on pH.  The different species 
of the cyanidin backbone are shown in Figure 3.1A-D. 
Anthocyanins exert potent antioxidant activity and are highly beneficial for 
human health, but like most nutrients, their target spectrum is broad (Lila 2004).  
However, one particularly consistent physiological function which eating fruits 
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containing high concentrations of anthocyanins is associated with, is vision.  
Enhancement of normal vision, protection from visual damage, and treatment of visual 
dysfunctions have all been investigated as potential application areas for anthocyanins 
(Muth, Laurent et al. 2000; Nakaishi, Matsumoto et al. 2000; Matsumoto, Inaba et al. 
2001; Matsumoto, Nakamura et al. 2003; Lila 2004).  British and French war pilots are 
said to have eaten berries before night flights for enhanced night vision, but this effect by 
anthocyanins as a general benefit is still a matter of debate as it appears to be strongly 
dependent on the individuals under study (Lee, Lee et al. 2005).  The specific example 
shown in Figure 3.1A is for cyanidin-3-glucoside, found in black currant extracts 
(Koeppen and Herrmann 1977).  Recently, it was observed that these compounds have 
functional effects on rhodopsin, the photoreceptor in rod cells; in rod outer segment 
preparations the rate of reaction of opsin with 11-cis retinal (referred to as regeneration) 
was enhanced (Matsumoto, Nakamura et al. 2003).  Because the retinal preparations 
contained many proteins of the visual signal transduction cascade, it was not known 
whether these effects on regeneration are mediated by direct binding of anthocyanins to 
rhodopsin. 
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Figure 3.1: Chemical structures of pH dependent equilibrium species of the 
cyanidin-3-glucoside. (A) Flavylium cation. (B) Quinoidal base example. (C) Carbinol 
pseudobase. (D) Chalcone. ‘R’ in the chemical structures of C3G represents the glucoside 
sidechain.  Numbering of C3G is indicated in 3.1A. 
 
 
Evidence for Ce6 interaction with rhodopsin:  The chlorophyll derivative Ce6 (Figure 
3.2) is believed to enhance sensitivity of rhodopsin to red light in deep-sea fish rhodopsin 
(Douglas, Partridge et al. 1999; Isayama, Alexeev et al. 2006).  Indeed, in vivo studies 
with salamander and mouse models have confirmed that Ce6 can effectively enhance 
vision in other animals as well (Washington 2007).  A decrease in the 500nm peak of a 
UV-Vis spectrum of salamander rhodopsin was observed by illuminating the sample at 
668nm, a wavelength at which Ce6 absorbs while rhodopsin essentially does not 
(Isayama, Alexeev et al. 2006).  Additionally, mice administered with Ce6, showed an 
two fold increase in electroretinogram b-wave amplitudes (the electrical signaling to 
brain upon a flash) as a response to red and blue light (Washington 2007).  It is so far not 
known whether Ce6 physically binds to rhodopsin, but it has been proposed that there 
may be an energy transfer between Ce6 and 11-cis-retinal (Isayama, Alexeev et al. 2006).  
 
 
 
65 
CHAPTER 3: CYTOPLASMIC ALLOSTERIC LIGANDS. 
 
 
 
 
Figure 3.2:  Chemical structure of Ce6. 
 
 
Although the evidence presented above suggests that there is a direct interaction 
between rhodopsin and these compounds, prior to this thesis it was not known 
experimentally if and where these compounds bind to rhodopsin and what the molecular 
determinants and consequences of binding are.  Here, we investigated these questions 
using bovine rhodopsin reconstituted in n-dodecyl-β-D-maltoside micelles as a model 
system.  Bovine rhodopsin is the best studied membrane receptor to date, providing the 
most thorough baseline on structure, dynamics and function of the receptor in the absence 
of these chromophores. We used a combination of computational and experimental 
approaches to test the hypothesis that rhodopsin is a direct target.  We further focused our 
efforts on C3G and Ce6 in particular, the ligands that showed the greatest effects in each 
case. Previous studies with rats and rabbits have shown that both anthocyanins and 
chlorin e6 localize to the retina and retinal pigment epithelium when administered either 
orally or intravenously (Haimovici, Ciulla et al. 2002; Matsumoto, Nakamura et al. 2006; 
Washington 2007). 
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3.1. CYANIDIN-3-GLUCOSIDE INTERACTION WITH 
RHODOPSIN 
 
 
3.1.1. Ligand Binding and Affinity Estimation 
 
 
As an initial step we tested the binding of C3G to rhodopsin using intrinsic rhodopsin 
tryptophan fluorescence.  Tryptophan fluorescence of rhodopsin in the absence of 
additives is largely, but not fully, quenched in the dark due to bound retinal (Figure 3.3A, 
black trace).  Upon light-activation, tryptophan fluorescence increases as a function of 
time, due to the retinal leaving the binding pocket (Farrens and Khorana 1995) (Figure 
3.3A, see arrow for point of illumination).  To quantify ligand binding, we first 
investigated C3G’s ability to quench rhodopsin tryptophan fluorescence, but then moved 
to using 1H NMR spectroscopy to obtain more detailed and quantitative data on ligand 
binding. 
 
 
3.1.1. (a) Fluorescence Spectroscopy Studies of C3G Binding to Rhodopsin:  As a 
first step, we investigated whether C3G binds and quenches rhodopsin fluorescence.  
Shown in Figure 3.3A are the fluorescence traces of rhodopsin in the absence and 
presence of varied concentrations of C3G.  A concentration-dependent quenching of 
fluorescence of rhodopsin was observed both in the dark and upon light-activation.  At 
750-fold excess C3G over rhodopsin, the signal was similar to background fluorescence 
of C3G solutions alone.  These studies suggest that C3G might bind to both dark and 
light-activated states of rhodopsin.  The differences in fluorescence in the dark and in the 
light with and without addition of C3G were used to estimate the fractions of free and 
bound conformations of rhodopsin.  This data was fitted using a non-linear regression 
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function to estimate binding affinity of interaction.  The affinity of interaction of C3G 
with rhodopsin was calculated as 90μM for the Meta II state and 450μM for the dark 
state.  
 
 
 
 
 
Figure 3.3:  Binding of C3G to rhodopsin in the dark and in the light as monitored 
by fluorescence spectroscopy.  The image is a courtesy of Kalyan Tirupula and Judith 
Klein-Seetharaman. (A) Fluorescence traces obtained at wavelengths for excitation of 
280nm and for emission of 330nm in the presence of increasing amounts of C3G.  (B) 
Absorption spectra of C3G alone at different pH conditions.  The figure shows the 
absorption spectrum of 5µM C3G at different pH values.  The predominant species of 
C3G observed at each pH is labeled in the spectrum (Levi, Scarminio et al. 2004).   
 
Because of the known equilibrium dependence of C3G on factors such as pH, we 
also measured the absorbance spectra of detergent containing solutions of C3G under 
different pH conditions.  The UV-Vis spectrum of C3G was measured at pH 3.0, 4.0, 5.0, 
6.0, 7.4 and 8.0.  Overall, the spectrum had four major absorption maxima (Figure 3.3B), 
corresponding to the different species of C3G (Figure 3.1).  Further, the distributions of 
these species varied with pH.  At least three different species are observed at pH 6.0, the 
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conditions at which the fluorescence spectra were obtained.  Thus, although fluorescence 
spectroscopy indicates that C3G binds to both dark and light-activated states of 
rhodopsin, it cannot differentiate between the different C3G species that may be 
responsible for binding to rhodopsin to different extents. Thus, the fluorescence studies 
can only give a qualitative indication of C3G binding to rhodopsin. They demonstrate 
that overall C3G binds with higher affinity to illuminated rhodopsin (including Meta II 
and opsin species) than the dark state. 
 
 
3.1.1. (b) Development of NMR Technique to Study Ligand Binding in Membrane 
Proteins using Selective Excitation 1H NMR:  As described in 3.1.1 (a), it is difficult to 
estimate binding affinities accurately based on fluorescence spectroscopy alone.  As the 
results obtained using these methods often need to be adjusted for inner filter effects, for 
the case of Ce6 (refer to section 3.2.1. (a)) and in some cases cannot differentiate between 
the different species present at equilibrium (Figure 3.1), as confirmed by absorbance 
spectroscopy above for C3G, we wanted to establish a method that would be able to 
overcome these limitations.  1H NMR spectroscopy may be the best suited method in this 
case because different structures will give rise to different chemical shifts, imparting 
specificity.  However, 1H NMR based methods to study ligand binding are constrained by 
the presence of background signals.  In the case of rhodopsin being a membrane protein, 
the detergent micelles required to keep the protein in solution interfere with detection of 
protein signals.  Moreover, as detergent concentrations are several orders of magnitude 
higher than the protein concentrations, the high signal intensity originating from the 
detergent leads to the suppression of signal intensities from the protein and also results in 
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overlapping of signals.  To overcome these problems, we proposed a solution that has 
extended the applicability of 1H NMR-based approaches to membrane proteins, described 
in more detail in Chapter 6.  The principle of the approach is briefly outlined here. 
Because detergent signals are only observed upfield of the water signal and many protein 
resonances of interest appear downfield of the water signal, we can focus on the latter 
region of the spectrum.  Using selective excitation sculpting (Hwang and Shaka 1995; 
Stott 1995) applied to full-length rhodopsin in detergent micelles using a hyperbolic 
secant shaped pulse centered around 10-12ppm, we have been able to observe the 1H 
chemical shifts from both backbone and side chain regions of rhodopsin, removing 
contributions of the detergent signals altogether.  Here, we extend this approach to study 
ligand binding to rhodopsin.  Selective excitation 1H spectra of C3G alone in 0.6% DM 
and Ce6 alone in 0.3% DM (Figure 3.4) show that many of the ligand resonances appear 
in the region downfield of the water signal and can therefore be observed simultaneously 
with protein resonances that typically show backbone and side chain NH resonances as 
well as aromatic side chain proton resonances in this region.  This establishes the 
selective 1H excitation approach as a suitable assay to study both C3G and Ce6 binding to 
rhodopsin. 
 
 
3.1.1. (c). pH Dependence of C3G Selective Excitation 1H  NMR Spectra in 
Detergent Micelles:  Because the equilibrium concentration between different C3G 
species is pH dependent we first recorded NMR spectra of C3G alone at different pH 
values (Figure 3.5).  Using chemical shift values reported in the literature (Kucharska and 
Jan 2002; McGhie, Rowan et al. 2006; Yawadio, Tanimori et al. 2007), we partially 
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assigned some of the resonances observed.  The most prominent resonances at pH 4 are 
the protons at   positions 4, 6’ and 2’ of the cyanidin rings (Figure 3.5A).  As the pH is 
raised, the 2’ and 6’ resonances show changes in chemical shift and their signal intensity 
increases significantly.  At pH 6, the 2’ resonance begins to show a shoulder, indicating 
formation of the quinoidal base with carbonyl formation probably at the neighbouring 5’ 
position (Figure 3.5C).  As the pH is raised further, the 2’ resonance splits into 4 distinct, 
but overlapping peaks that, at pH 8, combine into one sharp and highly intense signal 
(Figure 3.5E).  The increase in signal intensity is due to increased flexibility of the ring, 
first with disruption of the electron delocalization as the flavylium ion is lost, and 
ultimately, with chalcone formation in which the middle ring is replaced essentially by a 
flexible linker (Figure 3.1). 
 
 
 
 
 
 
 
Figure 3.4: One dimensional 1H NMR spectra of C3G (A) and Ce6 (B). The spectra 
were acquired using 50μM of each ligand at pH 6.0 with the selective excitation NMR 
approach.  
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Figure 3.5:  pH dependence of C3G monitored by selective excitation 1H NMR 
Spectroscopy.  One dimensional selective 1H excitation NMR spectra of C3G in 0.6% 
DM at pH (A) 4.0, (B) 5.0, (C) 6.0, (D) 7.4 and (E) 8.0.  
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3.1.1. (d). Selective Excitation 1H NMR Studies at pH 6 Confirm Binding of C3G to 
Rhodopsin:  The selective excitation 1H NMR spectra of C3G in the presence of 
rhodopsin at pH 6 are shown in Figures 3.6.  We have chosen pH 6 because of 
rhodopsin’s stability at this pH (Tirupula, Balem et al. 2009) and the presence of both 
quinoidal as well as chalcone forms (Figure 3.1, 3.3(B)).  The 1H NMR spectra of 50M 
dark-adapted rhodopsin in the presence of 50μM C3G in the chemical shift range 6.5ppm 
to 8.5ppm is shown in Figure 3.6A-C.  We sequentially numbered the major peaks 
observed arbitrarily from 1-24.  For reference, the C3G alone spectrum is shown in 
Figure 3.6D and the peak numbers are those corresponding to the respective peaks in the 
rhodopsin/C3G spectrum (Figure 3.6A,B).  
The 1H NMR spectrum of dark rhodopsin in the presence of C3G showed clear 
signals from ligand peaks at positions 2, 11, 14, 18 and 19 (Figure 3.6A, red dotted trace). 
However, the intensity of each signal was less as compared to that observed for 50μM 
C3G alone.  Some of the peaks from the ligand disappeared, namely the two peaks 
labeled with an ‘X’ and peaks 22, 24 (Figure 3.6D).  The decrease in signal intensity 
suggests binding of C3G to dark-state rhodopsin because the ligand experiences 
restriction in mobility.  The changes in ligand peaks at varying concentrations of C3G 
were used to estimate the affinity of the C3G-rhodopsin interaction (refer to Chapter 2, 
pg. 55).  The calculated KD values were 51+12μM, 100+45μM and 45+6μM for peaks 2, 
11 and 14, respectively. 
Next, we analyzed light-activated rhodopsin in the presence of C3G (Figure 3.6B) 
and compared the light-activated spectra in the presence and absence of C3G (Figure 
3.6C).  The C3G ligand peaks showed differences when comparing the states bound to 
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dark and light-activated rhodopsin (Figure 3.6B).  A decrease in intensity for the peaks at 
positions 2, 11, 18 and 22 was observed after activation (Figure 3.6B, red trace) as 
compared to dark state (Figure 3.6B, black trace).  In contrast, ligand peaks 14, 23 
exhibited no changes.  The differences between ligand peaks bound to dark and light-
activated rhodopsin can be seen when comparing Figure 3.6A and Figure 3.6C. In 
particular, ligand peak 11, arising mostly from chalcone and quinoidal base  species of 
C3G showed differential effects as compared to dark-adapted rhodposin. In the dark , an 
overall decrease in signal intensity was observed in comparison to the ligand alone 
control. Upon light-activation, the signal corresponding to the quinoidal base (refer to 
Section 3.1.1. (c)), drastically decreased in intensity, indicating a preferential binding of 
this species to lightactivated rhodopsin. This finding suggests that the quinoidal base has 
a higher affinity of interaction for the light-activated state, further validating the results 
obtained from the docking studies (see above, Section 3.1.2. (a)). 
In addition to the major peaks 2, 11, 14 and 18, there are significant changes in 
peaks 19, 22 and 24.  For example, while peaks 22, 24 were absent in the dark-state 
spectrum, they are clearly visible in the light-activated spectrum.  These results suggest 
that C3G binds not only to the rhodopsin dark state, but also its light-activated, Meta II, 
state.  The binding of C3G to Meta II exerts different effects on ligand signals as 
compared to binding to the dark state. This indicates that different C3G species and/or the 
same species bind with different orientations to the rhodopsin dark and light-activated 
states. 
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Figure 3.6:  Monitoring binding of C3G to dark and light-activated rhodopsin with 
and without C3G.  One dimensional selective excitation 1H NMR spectra of (A) 
rhodopsin in the absence (black solid line) and presence of C3G (red dotted line).  (B) 
Rhodopsin with C3G in the dark (black solid line) and upon light-activation (red dotted 
line).  (C) Illuminated rhodopsin in the absence and presence of C3G (red dotted line).  
(D) C3G alone in phosphate buffer and 0.6% DM.  NMR samples contained 50μM of 
rhodopsin in 20mM sodium phosphate buffer (pH 6.0), 0.6% DM and 10%D2O.  C3G 
was added from a stock solution of 10mM in DMSO, yielding a final DMSO 
concentration of 0.5% (v/v) in NMR samples containing C3G.  
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3.1.2. Location of C3G Binding on Rhodopsin 
 
 
3.1.2. (a) Docking of Different Isoforms of C3G to Dark-state, Opsin and ANM 
Conformations of Rhodopsin:  The absorbance and NMR spectroscopic results 
described above (section 3.1.1 (a), (b) and (d)) confirm that different species of C3G exist 
at equilibrium concentrations depending on the pH of the solvent used and indicate that 
these species bind differentially to dark- and light-activated states of rhodopsin.  To better 
understand these effects and to see where and how the different cyanidin species bind to 
rhodopsin, we performed computational docking studies using Autodock 4.0 (Morris, 
Goodsell et al. 1998).  First, the ligands shown in Figure 3.1 were docked to the dark-
state rhodopsin crystal structure (Okada, Fujiyoshi et al. 2002).  These ligands were 
found to dock mostly at the CP side of rhodopsin for all species (Figure 3.7), but the 
conformation, orientation, and predicted binding affinity differed for the various species.  
Out of the four cyanidin species docked, the chalcone structure exhibited 6 out of 25 
conformations bound in the CP domain. 
The top ranked structure had an energy of -8.44 kcal*mol-1, the most favorable 
energy as compared to the other three species (Table 3.1).  The quinoidal form was the 
next most favorable structure with a predicted binding energy of -7.69 kcal*mol-1. 2 
conformations were bound at the CP interface.  The ligand binding site was essentially 
identical for the quinoidal and chalcone species (Figure 3.7 B and D) and similar binding 
energies were observed (Table 3.1).  In all cases, the top ranked or most energetically 
favorable structure showed C3G bound at the CP surface.   
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Figure 3.7:  Docking of various isoforms of C3G to rhodopsin.  Docking of C3G 
chemical structures:  (A) Flavylium cation, (B) quinoidal base example, (C) carbinol 
pseudobase, (D) chalcone, and (E) cyanidin-3-glucoside (C3G) to dark state rhodopsin. 
The dark state of rhodopsin (pdb id 1l9h (Okada, Fujiyoshi et al. 2002)) is shown in 
cartoon representation.  The helices in the rhodopsin structure are colored from blue to 
red, with helix 1 being blue and helix 7 being red.  The ligand C3G in (A), (B), (C), and 
(D) is rendered as spheres and in (E) is a surface representation.  The ligand is colored 
lime green for the cyanidin moiety and orange for the glucoside moiety.  
 
 
To examine potential changes in binding to different conformations of rhodopsin, 
we docked all four ligand species also to the ANM generated active model with all-trans 
retinal (Isin, Rader et al. 2006) and to the opsin state crystal structure without any 
chromophore (Christopher J R Illingworth 2008).  The binding energies are shown in 
Table 3.4.  The quinoidal species was bound with the most favorable energy and highest 
number of conformations (4/25) followed by chalcone (3/25).  These results are the 
reverse of the preferences observed for the dark state of rhodopsin described above.  In 
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contrast, neither of these two species was favorably bound to the opsin state.  Instead, the 
carbinol pseudobase (Figure 3.1 C) was bound to the opsin state with the highest energy, 
namely -8.38 kcal*mol-1.  Recall that the carbinol pseudobase is predicted to bind with 
least energy to the dark and Meta II states (Table 3.1).  These results confirm 
theoretically the experimental observations from NMR spectroscopy that C3G exerts 
differential effects for different C3G species and for different conformations of 
rhodopsin.  Because the equilibrium between the C3G species is pH dependent, this 
would suggest that the nature of C3G binding to rhodopsin is dependent on pH.  
Overall the CP binding site was the most prominent binding site observed in the 
docked structures (Figure 3.7).  Further analysis of predicted binding energies (Table 3.1) 
also provides an explanation for the differences in the ligand peaks observed in the dark 
and upon illumination.  At pH 6.0, both chalcone and quinoidal forms are present in 
equilibrium as established by absorbance spectroscopy (see section 3.1.1 (a)).  The 
chalcone form was found to bind with high energy to dark state rhodopsin.  In contrast, 
the quinoidal species exhibited the highest binding energy when docked to the light-
activated ANM model of rhodopsin, supporting the differential effects of binding of 
different C3G species to dark and light-activated rhodopsin measured by 1H NMR 
(Figure 3.6).  Because pH affects the equilibrium of the different species as mentioned 
above, these findings imply that binding is pH dependent.  
 
3.1.2. (b) Changes in CP Domain upon C3G Binding Monitored by 1H NMR 
Spectroscopy: To investigate the effect of C3G binding on the CP domain, one-
dimensional selective excitation 1H NMR spectra without and with C3G were recorded, 
as these spectra give rise to signals preferentially from flexible residues in proteins. In 
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rhodopsin, these would be the CP residues (refer to Chapter 6).  As the C-terminus is the 
most flexible region in rhodopsin, we measured the NMR spectra of a peptide 
corresponding to the last nine amino acid residues corresponding to the C-terminus of 
rhodopsin (Figure 3.35D). The majority of the signals in the the 1H NMR spectra 
recorded in the dark for 50μM rhodopsin in the absence of any additives were found at 
identical chemical shift values as those observed in the 9-mer peptide. In particular, the 
signals at positions 1, 3, 4, 7, 8, 12 and 13 are proposed to originate from the C-terminus 
residues of rhodopsin (compare Figure 3.6A and Figure 3.35). In the presence of 50μM 
C3G, the spectrum resulted in an upfield shift of the peaks at positions 3, 4, 7, 8, 9 and 10 
(Figure 3.6A. red dotted trace). Especially, the signals at position 3, 4, 7 and 8 overlapped 
with C-terminus signals in the dark, validating the predicted CP binding domain. Upon 
illumination, in the presence of C3G no further shift in the peaks at positions 3, 4, 7, and 
8 was observed. However, an overall decrease in the peak intensities arising from the 
flexible residues of rhodopsin, along with chemical shift changes at peak positions 6 and 
17 was observed (for more detailed comparisons pls. refer to section 3.2.4 (a)).  These 
results indicate that the binding of C3G to rhodopsin may be at the CP domain.  
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Table 3.1:  Predicted binding energies for dark state (Okada, Fujiyoshi et al. 2002), 
ANM generated activated model (Isin, Rader et al. 2006), and opsin state (Christopher J 
R Illingworth 2008) of rhodopsin with different species of cyanidin-3-glucoside as shown 
in Figure 3.1.  The top 25 most highly ranked structures were considered.  For the 
proposed primary binding site in the center of the CP side of the helical bundle, we also 
provide its rankings amongst the top ranked structures.  Note that for each of the four 
conformations of C3G, the structure with the lowest energy is found in the CP binding 
pocket, with the exception of the ANM computational model of the activated state, where 
it was the second highest rank (and also other highly ranked structures). 
 
 
Binding Energy (kcal*mol-1) 
(Conformations docked) 
 
Flavylium Quinoidal Carbinol Pseudobase Chalcone 
1L9H 
(Okada, Fujiyoshi et al. 2002) 
 
-7.14 
(2) 
 
 
-7.69 
(1,3) 
 
 
-7.40 
(1) 
 
 
-8.44 
(1,3,5,6,13,19) 
 
ANM 
(Isin, Rader et al. 2006) 
 
-5.34 
(7,20) 
 
 
-6.92 
(2,5,12,19) 
 
 
-5.03 
(17) 
 
 
-5.71 
(4,5,8) 
 
OPSIN 
(Christopher J R Illingworth 
2008) 
did not dock
 
-6.12 
(11) 
 
 
-8.38 
(1) 
 
 
-5.21 
(14) 
 
 
 
 
3.1.3. Effects of C3G Binding on Rhodopsin Function 
 
 
3.1.3. (a) C3G Slightly Inhibits G Protein Activation:  The proposed CP binding site is 
also the site of interaction of rhodopsin with its G protein transducin (Gt). We therefore 
investigated if C3G binding affects rhodopsin activity in terms of Gt activation.  Upon 
light incidence rhodopsin catalyzes GDP to GTP exchange of Gt.  The GTP-bound Gt is 
quantified in vitro by [35S]GTPγS filter binding assays (refer to Chapter 2, pg. 52).  The 
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activation of Gt by rhodopsin is measured as the increase in GTP-bound Gt.  When tested 
at low concentrations of C3G, such as a 10-fold excess over rhodopsin concentration, the 
decrease in Gt activation was not significant and was within the error range observed in 
the absence and presence of C3G.  We then tested Gt activation at the highest 
concentration possible, 1mM C3G, corresponding to a 200,000-fold excess over 
rhodopsin concentration.  The ratio of radioactivity counts for light-activated over dark-
adapted rhodopsin was 2.2+0.3 (n = 4) and 1.5+0.1 (n = 4) in the absence and presence of 
1mM C3G, respectively.  Thus, there is a 58% decrease in Gt activation in the presence of 
these high concentrations of C3G.  Thus, it was not possible to completely inhibit Gt 
activation, even at such high concentrations. 
 
 
3.1.3. (b) C3G Enhances Regeneration of Purified Rhodopsin in Detergent Micelles:  
Previous studies had shown that regeneration of rhodopsin in rod outer segment 
membranes was accelerated in the presence of cyanidin compounds from black currant 
such as C3G (Matsumoto, Nakamura et al. 2003).  However, it was not clear whether 
C3G targets rhodopsin directly or acts in an indirect manner through other proteins 
present (Matsumoto, Nakamura et al. 2003).  To investigate if C3G also enhances 
rhodopsin regeneration in the absence of any other proteins, the rates of regeneration 
were measured for purified rhodopsin reconstituted in detergent micelles.  The increase in 
500nm absorbance by addition of 11-cis retinal after light-activation was followed by 
UV/Visible spectroscopy (Figure 3.8).  The normalized change in absorbance at 500nm 
of 0.5μM rhodopsin at pH 6 in the presence of 0.5μM 11-cis retinal after illumination in 
the absence (filled circles) and presence of C3G (open circles) is shown in Figure 3.19 A.  
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The corresponding regeneration rates for rhodopsin in the absence and presence of C3G 
at pH 6 are 0.072±0.009 min-1 and 0.119±0.008 min-1, respectively.  In the presence of 
two-fold excess (1μM) C3G over rhodopsin, the rate of regeneration was increased by 
1.65-fold as compared to rhodopsin alone (Figure 3.8 A).  Furthermore, the presence of 
C3G decreased the total amount of rhodopsin regenerated by 9±2% to a total of 81±1% 
efficiency as compared to rhodopsin alone at pH 6, which could be regenerated with 
89±3% efficiency (Figure 3.8 C).  Thus, we find that the effect of C3G on regeneration of 
rhodopsin in detergent micelles is two-fold – an increase in the rate, but a decrease in the 
extent of regeneration.  The effects are observed at relatively low concentrations of C3G 
(1 μM), supporting the notion that the affinity of rhodopsin for C3G after light-activation 
is likely higher than that for the dark state, which is estimated at 50-100μM at pH 6 (refer 
section 3.1.1 (d)).  
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Figure 3.8: Regeneration studies of rhodopsin at different pH conditions.  
Regeneration of rhodopsin in the absence (filled circles) and presence (open circles) of 
C3G at (A) pH 6 and (B) pH 8.  Shown in panel (C) are the difference spectra 
(regenerated rhodopsin dark minus light) of regenerated rhodopsin (0.5μM) in the 
presence and absence of C3G (1μM) at pH 4 (intermediate gray), 6 (black), and 8 (light 
gray).  For the samples in A and B, the total amount of increase at 500nm at pH 6 and 8 
both in the presence and absence of C3G was normalized to 100%.  All samples 
contained a final DM concentration of 0.6%.  The plots were generated using Sigmaplot 
10.0 scientific graphing software. 
 
 
3.1.4. Effects of C3G Binding on Rhodopsin Structure and Dynamics 
 
 
3.1.4. (a) Changes in Rhodopsin Structure upon C3G Binding Monitored by 1H 
NMR Spectroscopy:  Having shown that rhodopsin binding alters C3G ligand 
resonances, we then studied if C3G binding affects rhodopsin structure and dynamics.  
To this effect, the one dimensional 1H NMR spectra without and with C3G were analyzed 
from a protein peak perspective.  The 1H NMR spectra recorded in the dark for 50μM 
rhodopsin in the absence and presence of 50μM C3G (Figure 3.6 A), showed clear 
changes in protein peaks, in addition to the changes in ligand peaks described above: 
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Binding of C3G to rhodopsin resulted in the upfield shift of the peaks at positions 3, 4, 7, 
8, 9 and 10 (Figure 3.6A).  For clarity, an expanded region of the spectrum, indicated by 
the box in Figure 3.6A, is shown in Figure 3.9A.  We used the upfield chemical shift 
changes in these protein signals upon titrating rhodopsin in the dark with varying 
concentrations of C3G to estimate the binding affinities.  However, even though all peaks 
resulted in curves that reached saturation within the concentration range used, large 
variations in both KD and Bmax values prevented reliable estimates (data not shown).  
Upon illumination, an overall decrease in peak intensities was observed as 
compared to rhodopsin with C3G in the dark (Figure 3.6B, 3.9B), indicating a restriction 
in mobility at these positions.  Further, a shift in the peaks at positions 6 and 17 was 
observed, indicating a structural change upon illumination (Figure 3.6B and 3.9B, red 
dotted trace).  Furthermore, we observed changes in protein signals upon illumination 
without and with C3G in the range 9.7ppm to 10.0ppm, which are shown in Figure 3.10.  
Two signals corresponding to aromatic residues at 9.96ppm and 9.90ppm were observed 
upon light-activation.  None of these peaks were observed in the dark, both in the absence 
and presence of C3G. 
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Figure 3.9: One dimensional selective excitation 1H NMR spectra of the expanded 
regions represented in a box in 3.6A, B and C. For the legends of (A), (B) and (C), 
refer to Figure 3.6. 
 
 
In addition to these signals, the NMR spectra in the presence of C3G gave rise to 
an additional peak at 9.8ppm (Figure 3.10, black trace).  These signals were absent in the 
dark, both in the absence and presence of 50μM C3G.  When we titrated different 
concentrations of C3G (25μM, 50μM, 100μM and 200μM, data not shown), we found 
that the signal at 9.8ppm only appears at higher concentrations of C3G, at 100μM C3G 
concentration and above.  In addition to chemical shift changes, we also observed 
changes in the dynamics of protein peaks when comparing the binding of C3G to dark 
and light-activated rhodopsin.  The overlay of the 1D 1H NMR spectra of the illuminated 
samples of rhodopsin without (Figure 3.6C, black solid trace) and with C3G (Figure 
3.6C, red dotted line), reveals that binding of C3G restricts the mobility of some of the 
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residues, as indicated by decrease in peak intensities at peak positions represented as ‘+’ 
in Figure 3.6C. These results confirm binding of C3G to rhodopsin and suggest that 
binding modulates the structure and dynamics in both the dark and light-activated states 
of rhodopsin.  
 
 
 
 
 
Figure 3.10:  One dimensional selective excitation 1H NMR spectra of the aromatic 
amino acid side chain region of rhodopsin.  The spectra for rhodopsin in the presence 
and absence of C3G upon light-activation are colored in black and orange, respectively.  
The spectra for rhodopsin in the dark both without and with C3G displayed no peaks in 
this region and are therefore not shown in this figure. 
 
 
3.1.4. (b): C3G Binding Destabilizes Secondary and Tertiary Structure of 
Rhodopsin:  To corroborate the findings from NMR spectroscopy that C3G alters the 
structure of rhodopsin, we used fluorescence and UV Absorbance spectroscopy to 
monitor the effects of C3G on rhodopsin structure and stability.  As a first step we 
monitored the thermal stability of rhodopsin at 55°C in the absence and presence of C3G 
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using fluorescence.  Initially, the samples were kept at 20oC for 5min, and then the 
temperature was raised to 55oC.  Following this an increase in fluorescence was observed 
as a function of time.  This is due to the leaving of the 11-cis retinal from the binding 
pocket as a result of disruption of the retinal-protein interactions at elevated temperatures.  
Shown in Figure 3.11A are the fluorescence traces of rhodopsin in the absence and 
presence of C3G at pH 6.0.  The maximal fluorescence of rhodopsin in the presence of 10 
fold excess C3G over rhodopsin was quenched, similar to observed before (Figure 3.3A).  
However, such a decrease in maximal fluorescence will not affect the thermal decay 
rates.  The thermal decay rate of rhodopsin in the presence of C3G was accelerated ~ 2-
fold as compared to rhodopsin alone with t1/2 values 73±6 min and 111±11 min, 
respectively.  
 To further characterize the observed effects, we measured the stability of the 
retinal-protein interaction using UV/Vis spectroscopy.  A decrease in 500nm peak with a 
concomitant increase in 380nm peak is followed over time as a result of thermal decay.  
These changes in 500nm peak at pH 6.0 in the absence and presence of 10 fold excess 
C3G are shown in Figure 3.11B.  This data was fitted to an exponential decay function to 
estimate the decay rates.  The decay rates for rhodopsin without and with C3G were 
0.025min-1 and 0.066min-1, with a t1/2 of 27.77min and 10.54min, respectively.  The rate 
of decay in the presence of C3G was accelerated approximately by 3 folds as compared 
to rhodopsin.  Collectively the studies from fluorescence and UV/Vis spectroscopy 
stability studies indicate that C3G binding changes in the overall structure of rhodopsin. 
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Figure 3.11:  Changes in secondary and tertiary structure of rhodopsin in the 
absence (black) and presence of C3G (gray) probed by spectroscopy techniques.  (A) 
Stability of rhodopsin at 55°C measured by fluorescence spectroscopy.  (B) Retinal-
protein interactions probed by UV spectroscopy at 50°C.  
 
 
3.1.5. Discussion 
 
 
Our goal of the studies described in this section was to investigate whether C3G interacts 
directly with rhodopsin, and if so, what the mechanisms are by which anthocyanins aid in 
regenerating rhodopsin as was first reported by Matsumoto et al. (Matsumoto, Nakamura 
et al. 2003) and confirmed here in a purified system in detergent micelles (Figure 3.8).  
First, we investigated the binding of C3G to rhodopsin using fluorescence spectroscopy.   
The results obtained indicated that C3G physically binds to rhodopsin both in the dark 
and after light-activation, but with higher affinity to the light-activated states.  However, 
referring to C3G as a molecular entity is inaccurate because it consists of multiple species 
that are at equilibrium with each other (Figure 3.1). The relative distributions of the 
species depend on the pH. We confirmed the pH dependency of the equilibrium species 
of C3G using UV/Vis spectroscopy (Figure 3.3).  Based on earlier studies (Levi, 
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Scarminio et al. 2004) we identified a predominant flavylium cation at lower pH (~3), 
chalcone and anhydrobase (quinoidal) conformations at slightly acidic and neutral pH (6 
and 7.4) and an ionized anhydrobase at basic pH from our spectra.  Thus, while the 
fluorescence studies reported here suggest that C3G physically binds to rhodopsin, it 
being a bulk biophysical technique cannot be expected to differentiate between the 
species.  To investigate binding taking the pH depend species distribution into account, 
we next investigated binding using 1H NMR spectroscopy. This was possible because the 
different species gave rise to differential 1H NMR spectra.  This laid the ground for 
investigation of C3G binding to rhodopsin.  To do so, we developed an NMR based C3G 
binding assay using the selective excitation sculpting scheme (Hwang and Shaka 1995; 
Stott 1995).  The 1H NMR spectra of C3G at pH 4.0 – pH 8.0 (Figure 3.5), suggested that 
our approach is suitable.  Detailed analysis of the 1H NMR spectra recorded in the dark 
and in the light, with and without C3G clearly indicated that both the ligand and 
rhodopsin peaks are modulated in an activation-state dependent manner.  These findings 
showed that studies of ligand binding to membrane proteins by 1H NMR spectroscopy are 
possible for membrane proteins such as rhodopsin using selective excitation.  The 
selective excitation scheme (Hwang and Shaka 1995; Stott 1995) we used to record these 
1H NMR spectra tends to highlight flexible regions in the protein because of the extended 
length of the experiment and the fast relaxation of immobilized rhodopsin resonances in 
the large detergent micelle environment.  In particular, there is overlap between the peaks 
observed and those reported previously for the C-terminus of rhodopsin (Werner, Richter 
et al. 2008), implying that many of the resonances arise from flexible regions of the 
protein, such as the CP loops and the C-terminus.  We find that both rhodopsin and C3G 
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ligand structure and dynamics are modulated in the C3G-rhodopsin complex, both in the 
dark and upon light-activation. 
Although NMR spectroscopy is not the best method to quantify ligand binding 
affinities, as they can be associated with high error margins and uncertainties on the 
binding stoichiometry (Fielding, Rutherford et al. 2005), we estimated the affinity using 
intensity changes in the ligand peaks with increasing amounts of ligand added to constant 
rhodopsin concentrations as described (Shortridge, Hage et al. 2008).  We obtained 
values on the order of 50-100μM indicating moderate to weak binding of C3G to dark-
state rhodopsin at pH 6.  The affinity is comparable to, for example, ANS binding to 
proteins (Latypov, Liu et al. 2008), a ligand that binds with relatively broad specificity to 
molten globule-like states of proteins.  Thus, the anthocyanin ligand investigated here is 
certainly not a high-affinity ligand that can compare in affinity to retinal ligands.  
It is also not likely that C3G will only bind to rhodopsin, given the broad 
spectrum of physiological effects that anthocyanins display (Lila 2004).  However, all of 
our binding curves show saturation, indicating that binding to rhodopsin is to a specific 
site (or sites).  C3G is also a specific ligand in terms of its structure, because a relatively 
small change in chemical structure at the 3’ position (Figure 3.1A) from –H to –OH 
resulted in loss of the enhancement of rhodopsin regeneration (Matsumoto, Nakamura et 
al. 2003).  Furthermore, the mode of binding is conformation-specific.  Upon light-
activation of rhodopsin, both protein peaks and ligand peaks exhibited changes.  The 
binding of C3G to light-activated rhodopsin resulted in decreased chemical shift 
intensities of protein peaks as compared to rhodopsin alone (Figure 3.6C, labeled ‘+’), 
suggesting that the binding affinity might be higher as compared to dark state of 
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rhodopsin.  The analysis of peak 11 indicates that only one of the populations of the 
ligand is affected after light-activation, suggesting a preference of this ligand 
conformation for light-activated rhodopsin.  Thus, it appears that both structural changes 
in the protein upon light-activation and changes in the binding constant alter C3G binding 
to rhodopsin in the light.  
To complement the NMR data, we performed computational docking studies of 
different species of C3G to different states of rhodopsin (rhodopsin, Meta-II and opsin) 
for predicting the binding sites and modes of binding.  The CP binding site was the most 
prominent of the docked structures (Figure 3.7).  This finding fits well with the NMR 
results, especially since most of the signal observed probably arises from the flexible 
regions of rhodopsin including the flexible CP domain.  Analysis of predicted binding 
energies (Table 3.1) also provides an explanation for the differences in the ligand peaks 
observed in the dark and upon illumination.  At pH 6.0, both chalcone and quinoidal 
forms are present in equilibrium as established by absorbance spectroscopy.  The 
chalcone form was found to bind with high energy to dark state rhodopsin.  In contrast, 
the quinoidal species exhibited the highest binding energy when docked to the light-
activated ANM model of rhodopsin, supporting the differential effects of binding of 
different C3G species to dark and light-activated rhodopsin measured by 1H NMR 
(Figure 3.6B).  Because pH affects the equilibrium of the different species, these findings 
imply that binding is pH dependent.  
Having shown that C3G physically interacts with rhodopsin, we repeated the 
regeneration assay with just rhodopsin in DM micelles and C3G to confirm that it is a 
direct rhodopsin binding effect and not mediated by other signaling proteins.  We found 
91 
CHAPTER 3: CYTOPLASMIC ALLOSTERIC LIGANDS. 
 
that regeneration is enhanced to similar degree as was found by Matsumoto et al. 
(Matsumoto, Nakamura et al. 2003), clarifying that these effects are not mediated by any 
other components than rhodopsin and C3G alone. As discussed above, C3G binds to 
dark-state rhodopsin with apparent KD values ranging form 50 to 100 μM depending on 
which C3G peak in 1H NMR spectra was chosen for analysis.  It was also clear that C3G 
binds to the Meta II and opsin states based on changes in the 1H NMR spectrum, 
probably with affinities higher than the dark-state.  Due to the instability of the light-
activated state, we have so far been unable to determine the actual KD value upon 
illumination.  Comparison of the 1H NMR spectra of rhodopsin 0.5 and 1.5 hours post-
illumination clearly indicated that C3G still remained associated with the opsin state as 
there is no change observed in the ligand peaks as compared to Meta II state.  Further, 
some of the 1H peaks in the presence of C3G also exhibited restriction in mobility both in 
the Meta II and opsin states.  In light of these NMR results, the regeneration studies 
obtained prove that the effects of C3G on regeneration are a direct result of the binding of 
C3G and modulating the structure of rhodopsin upon illumination.  
While previously only an effect on the rate of regeneration was reported 
(Matsumoto, Nakamura et al. 2003), we here find that the presence of C3G not only 
changes the rate, but also the extent of regeneration.  C3G decreased the total amount of 
rhodopsin regenerated by ~10% as compared to rhodopsin alone at pH 6 (Figure 3.8C).  
This relatively small, but significant, difference was not noted earlier (Matsumoto, 
Nakamura et al. 2003) probably because the rhodopsin concentrations were not kept 
constant across different experiments as the samples were from opsin membranes.  The 
data were thus normalized to 100% rhodopsin levels.  Our system with pure components 
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of rhodopsin and anthocyanin allowed us to quantify more precisely the rhodopsin 
concentrations before and after regeneration from which the extent and rate of 
regeneration can be obtained with high accuracy. 
As anthocyanins undergo reversible modifications at different pH, and binding to 
rhodopsin was observed to be pH dependent (see section 3.1.1), we also performed 
regeneration studies at pH 4.0 and 8.0.  At both low and high pH values rhodopsin is 
destabilized and the extent of regeneration is dramatically decreased (~20% and ~30% of 
rhodopsin is regenerated at pH 4 and 8, as compared to ~90% at pH 6).  C3G does not 
further decrease or increase the extent or rate of regeneration at these extreme pH values.  
Next, we investigated whether C3G binding alters rhodopsin function at a further 
downstream level.  After light-activation, rhodopsin binds and activates the G protein, 
transducin (Gt).  We therefore performed functional assays with rhodopsin and Gt in the 
presence of 1mM concentrations of C3G.  At this high of a concentration, which even for 
the low estimate of a KD for the dark state (50μM) would amount for 95% receptor 
occupancy, 42% of Gt activity remains.  This relatively modest decrease in Gt activation 
at such elevated concentrations of C3G argues that the C3G effects on Gt activation are 
comparatively small.  
After having ruled out an effect of C3G on activity as the cause for the enhanced 
regeneration rates, we studied the stability of secondary and tertiary structures of 
rhodopsin at pH 6.0 to understand the mechanism underlying the regeneration effects.  
Thermal denaturation at constant elevated temperature (55oC) showed that in the 
presence of C3G there is a faster thermal decay rate in fluorescence spectra.  This 
indicates an overall destabilizing effect on rhodopsin structure.  Further, we also 
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investigated the effects of C3G interaction on rhodopsin chromophore stability in the 
dark, by measuring the rate of retinal leaving from the rhodopsin binding pocket at 50oC 
by UV/Visible spectroscopy at pH 6.0.  The decay rate of rhodopsin in the presence of 
C3G was drastically accelerated.  This clearly demonstrates that the retinal-protein 
interactions are destabilized by the presence of C3G. 
Collectively, these studies suggest that C3G binds directly and enhances the 
regeneration of rhodopsin.  Furthermore, loss of flexibility in residues giving rise to 1H 
resonances in NMR spectra of illuminated rhodopsin in presence of C3G along with a 
shift in the C3G peaks as observed in NMR studies hint at a higher affinity of some 
species of C3G over others for binding to illuminated rhodopsin (Meta II and opsin 
states).  Additionally, computational docking studies supplement the experimental 
observations and predict that C3G preferably binds in the CP side of rhodopsin.  One 
explanation for the increased rates of regeneration could be that the binding of C3G in the 
CP side results in destabilization of the rhodopsin structure upon light-activation.  Such 
destabilization in the overall structure of rhodopsin might lead to easier access to retinal 
binding site, thus allowing the 11-cis retinal to interact faster with rhodopsin. 
 
 
3.1.6. Conclusions 
 
 
In summary, our results confirm that there is increase in the rate of regeneration of 
rhodopsin, while the G protein activation is only slightly affected if at all. Especially at 
the low concentrations used for the regeneration assay, we could not detect any changes 
in Gt activation.  Thermal denaturation experiments suggest that there may be a structural 
effect of C3G binding on rhodopsin.  Further, UV absorbance spectra also confirm that 
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the retinal-protein interactions are altered by C3G.  This suggests that the mechanisms of 
C3G enhancement of rhodopsin regeneration may be based on changes in rhodopsin 
structure upon light-activation, enhancing access to the retinal binding pocket.  The 
studies presented here aid in understanding the mechanism of action of anthocyanins on 
rhodopsin.  The knowledge gained here could be useful in developing small molecule 
drugs that enhance or correct normal or weakened vision. 
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3.2. CHLORIN E6 INTERACTION WITH RHODOPSIN 
 
 
3.2.1. Ligand Binding Studies 
 
 
In analogy to the studies described above for C3G, we conducted fluorescence and NMR 
spectroscopic measurements to investigate if Ce6 also binds to rhodopsin. As a first step, 
we performed fluorescence assays based on intrinsic tryptophan fluorescence of 
rhodopsin. To obtain more quantitative and detailed information, we then measured 1H 
NMR spectra using the methodology developed above for C3G.  
 
 
3.2.1. (a) Fluorescence Spectroscopy Studies of Ce6 Binding to Rhodopsin:  Selected 
tryptophan fluorescence traces in the dark and upon light-activation in the presence of 
increasing quantities of Ce6 are shown in Figure 3.12A, colored traces.  The fluorescence 
is quenched in the dark, indicating binding of Ce6 to dark-state rhodopsin.  At 25-fold 
excess Ce6 to rhodopsin, the signal is close to background fluorescence of Ce6 solutions 
alone.  Upon light-activation, the maximal fluorescence signal obtained after Meta II 
decay is quenched, in a concentration-dependent fashion, showing that light-activated and 
subsequent opsin species also bind Ce6.  The Meta II-decay half-lives are not changed 
(Table 3.2), indicating that the residual increase in fluorescence is due to Ce6-free 
rhodopsin.  Thus, the differences in fluorescence in the dark and in the light can be used 
to calculate the fractions of free and bound conformations.  This is shown in Figure 
3.12B for light-activated rhodopsin (circles) before (black trace) and after (red trace) 
correction for Ce6 absorbance using the Parker equation (refer to Chapter 2, pg. 53).  We 
also recorded identical buffer solutions containing free tryptophan as a control (Figure 
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3.12B, triangles, black trace) and corrected the results with the Parker method (Figure 
3.12B, triangles, red trace).  While the Parker correction was able to recover some of the 
original fluorescence counts, there was still a significant linear decrease in fluorescence 
with increasing Ce6 concentrations.  It is likely that this is due to some unspecific 
interaction between tryptophan and Ce6 that probably would not occur with rhodopsin.  
Nonetheless, to err on the conservative side, we also corrected the rhodopsin fluorescence 
for the observed decrease in free tryptophan fluorescence.  We calculate for the Parker 
corrected affinities:  0.82±0.06μM (light), 2.6±0.2 μM (dark); for the tryptophan 
corrected affinity in the light 0.79±0.03μM.  The dark affinity could not be calculated for 
the tryptophan correction because the fluorescence counts were too low so that correction 
introduced a large variation in the counts.  Because the light-affinity is almost identical 
between the Parker and tryptophan corrected affinities, we assume that the dark affinity 
would be similar for both types of corrections as well.  It is important to note that due to 
the quenching of rhodopsin tryptophan fluorescence by Ce6, regardless of the presence of 
absence of retinal, we can no longer use fluorescence spectroscopy to assess the decay of 
Meta II to opsin and free retinal for the Ce6-bound rhodopsin. 
To rule out the possibility that crowding of the relatively hydrophobic Ce6 into 
the DM micelle alone, rather than specific binding, would result in a similar degree of 
tryptophan fluorescence quenching, we used chlorophyll-a (Chl-a) as a control.  Chl-a is 
identical in structure to Ce6 except for the presence of Mg2+ and a phytol chain, the 
highly hydrophobic tetramethylhexadecenol substitution at a carboxyl side chain.  
Ideally, we would have used pheophytin-a (Pheo-a) instead of Chl-a, as this would be 
lacking Mg2+ and more similar to Ce6; however, due to the chemical instability of Pheo-a 
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in solution we used Chl-a as a control, as the critical structural difference is the presence 
of the phytol chain, carried by both Chl-a and Pheo-a.  The phytol substitution makes the 
molecule significantly more hydrophobic than Ce6, and crowding into the micelle would 
be expected to be enhanced.  In titrations of fluorescence quenching with increasing 
amounts of Chl-a, identical to the experiments described above for Ce6, we find that 
there is no quenching of dark-state rhodopsin tryptophan fluorescence at any 
concentration tested (Figure 3.13). 
 
 
Table 3.2:  Meta II decay half-lives of rhodopsin in the absence and presence of additives 
(chlorophyll-a and Ce6) at various concentrations indicated.  All samples contained a 
rhodopsin concentration of 0.5μM. 
 
 
Chl-a 
Concentration Half-life 
Ce6 
Concentration 
Meta II decay  
Half-life 
0μM 13.8833 0.0μM 13.51 ± 0.3 
0.2μM 13.8 0.5μM 12.86 ± 0.76 
0.4μM 13.16794 1.0μM 12.47 ± 0.75 
1.77μM 10.42296 1.8μM 12.28 ± 0.78 
3.19μM 8.734177 2.4μM 11.57 ± 2.81 
7.08μM 6.818182 7.93μM Cannot be estimated with accuracy 
 
 
 
This indicates that Chl-a does not bind to dark-state rhodopsin at physiological 
concentrations and that partitioned Chl-a in the micelle is not able to quench tryptophan 
fluorescence of rhodopsin in the dark.  In contrast, there is some quenching of tryptophan 
fluorescence of light-activated rhodopsin.  The degree of quenching is low compared to 
Ce6, and we calculate an apparent binding affinity of 5.0+0.3μM.  This result rules out 
the possibility that unspecific partitioning of Ce6 into the micelle results in the high 
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degree of rhodopsin tryptophan quenching observed with Ce6 and confirms the validity 
of the use of fluorescence spectroscopy as a Ce6 binding assay.  Note, that Chl-a does 
slightly affect the Meta II half-live (Table 3.2) and at increasing Chl-a concentrations, 
Meta II is increasingly destabilized.  
 
 
 
 
 
Figure 3.12:  Binding of Ce6 to rhodopsin in the dark and in the light as determined 
by fluorescence spectroscopy. (A) Fluorescence traces obtained at wavelengths for 
excitation of 280nm and for emission of 330nm in the presence of increasing amounts of 
Ce6. (B) Decrease in the difference in fluorescence counts between rhodopsin kept in the 
dark and 1.5 hours after light-activation (circles) and free N-acetyl tryptophan (triangles) 
as a function of Ce6 concentration.  The N-acetyl tryptophan concentration was 25μM 
and the rhodopsin concentration was 0.5μM.  The uncorrected fluorescence counts are 
shown in each case in black, after Parker correction in red and after correcting for the 
linear decrease observed in the tryptophan fluorescence that could not be corrected for 
with the Parker equation in green.  All plots were created using SigmaPlot scientific 
graphing software.  
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Figure 3.13:  Plots of the relative populations of bound and free states in the dark (filled 
symbols) and in the light (open symbols) for chlorin e6 (circles) and chlorophyll-a 
(triangles).  A rhodopsin concentration of 0.5μM was used to obtain each data point. 
 
 
Finally, in order to also rule out the possibility that the oxygen species released as 
a result of illumination of Ce6 into the buffer is not the reason for the effects observed for 
rhodopsin in the presence of Ce6, we measured the Meta II decay using fluorescence 
spectroscopy by addition of dark and illuminated Ce6.  The fluorescence traces of 
rhodopsin upon light-activation of rhodopsin in the presence of activated and dark Ce6 
are shown in Figure 3.14.  The results indicated no significant effects on Meta II decay 
rates and the quenching effects (Figure 3.14). 
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Figure 3.14:  Effects of illuminated Ce6 on dark and light-activated rhodopsin. 
Fluorescence traces of rhodopsin in the presence of dark Chlorophyll-a (green circles), 
illuminated Chlorophyll-a (black circles), dark Ce6 (yellow circles) and illuminated Ce6 
(red circles).  A rhodopsin concentration of 0.5μM was used to record each fluorescence 
trace.  A ‘*’ represents that the sample is illuminated.  
 
 
Overall, we find that rhodopsin tryptophan fluorescence is strongly quenched by 
Ce6, especially in the light.  Control experiments with non-illuminated Ce6 and with 
separately illuminated Ce6 confirm that these effects do not require Ce6 excitation.  
Thus, it is unlikely that the Ce6 effects described in this paper are indirect effects, such as 
through reactive oxygen species formation mediated by the presence of Ce6, after 
excitation.  Furthermore, we show that these effects are consequences of Ce6 binding to 
rhodopsin by comparing tryptophan fluorescence quenching by Ce6 with that by Chl-a, 
which is more hydrophobic than Ce6 and would result in stronger unspecific interactions 
with rhodopsin, being recruited into the detergent micelles.  The results described above 
confirm that Ce6 binding is specific, as Chl-a results in a much lower degree of 
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fluorescence quenching, even lower than that observed for Ce6 binding to dark-adapted 
rhodopsin.  Chl-a does have an effect on rhodopsin, namely on Meta II half-life (Table 
3.2).  This result is not unexpected, as the Meta II half-life is highly dependent on the 
relative lipid and detergent environment (Mitchell, Straume et al. 1992; Brown 1994; 
Szundi, Lewis et al. 2005). 
 
 
3.2.1. (b) Application of Selective Excitation 1H NMR for Studying Ce6 Binding to 
Rhodopsin:  As described above (Section 3.1.1. (b)) and in more detail in Chapter 6, 
below, the selective excitation 1H NMR approach allows us to investigate the binding of 
Ce6 (analogous to C3G described above) to rhodopsin. The selective excitation 1H NMR 
spectra of Ce6 in the absence and presence of various concentrations of rhodopsin in the 
chemical shift range 8.9ppm to 10ppm is shown in Figure 3.15.  The 1H NMR spectra of 
50μM Ce6 in the absence of rhodopsin gave rise to three chemical shift signals at 9.72, 
9.58 and 9.00ppm.  For convenience, we will refer to these peaks as peak1 (9.72ppm), 
peak2 (9.58ppm) and peak3 (9.00ppm), respectively.  
The 1H NMR spectrum of Ce6 acquired in the dark in the presence of 10μM 
(Figure 3.15, red trace), 25μM (Figure 3.15, blue trace) and 50μM (Figure 3.15, magenta 
trace) showed clear signals from ligand peaks.  The intensity of each signal was less as 
compared to that observed in the NMR spectrum of 50μM Ce6 alone (Figure 3.15, black 
trace), indicating restriction in mobility of the ligand resonances in a concentration 
dependent manner.  This decrease in signal intensity suggests binding of Ce6 to dark-
state rhodopsin.  The change exhibited in the ligand peaks at varying concentrations of 
rhodopsin was used to estimate the affinity of the Ce6-rhodopsin interaction in the dark.  
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The binding curves for the dark state are shown in Figure 3.16 A.  The KD values were 
estimated based on ligand peaks 1, 2 and 3 were 16+7μM, 16+9μM and 25+3μM, 
respectively. 
 
 
 
 
 
Figure 3.15:  Overlay of the selective excitation 1H NMR spectra of 50μM C3G in 
the absence and presence of 10μM, 25μM and 50μM rhodopsin in the dark. 
 
 
We also acquired selective excitation 1H NMR spectra immediately at t=0 and 
t=30 minutes after light-activation to monitor the binding of Ce6 to Meta II and Opsin 
states.  We compared 1H NMR spectra of Ce6 at various concentrations of rhodopsin 
acquired immediately after light-activation in the absence and presence of Ce6.  A 
complete disappearance of the ligand peaks was observed.  Even at the lowest 
concentration (10μM) of rhodopsin tested, Ce6 ligand peak signals were absent.  This 
clearly suggests that the Ce6 binds to the Meta II state of rhodopsin with much higher 
affinity than what was observed for the dark state.  However, at this time we have not yet 
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estimated the binding affinity of this interaction.  In order to determine affinities in this 
case one has to acquire data points below the 5:1 ligand:protein ratios. To obtain this 
data, we will need to increase the concentration of ligand at least by 2-3 fold to get good 
signal to noise levels. Nonetheless, it is clear from the studies obtained above that Ce6 
binds to Meta II and preferably with higher affinity than observed for dark state. 
Finally, we also monitored the interaction of Ce6 with the opsin state.  The 
comparison of the 1H NMR spectra acquired in the absence and presence of rhodopsin 30 
min after light-activation, gave rise to detectable ligand peak resonances.  As explained 
for dark state rhodopsin above, a decrease in the intensity of peaks 1, 2 and 3 upon 
addition of rhodopsin protein as compared to free ligand peak intensities can be used to 
estimate binding affinities (Figure 3.16B).  We estimated an affinity of 7.6 ± 2.4, 10.9 ± 
2.3 and 5.6 ± 6.4 based on ligand peak 1, 2 and 3, respectively. 
The data obtained suggests that Ce6 binds to dark, activated Meta II and also 
opsin states of rhodopsin, albeit with different affinities.  Though it was not possible to 
obtain an estimation of the interaction between Ce6 and Meta II, it appears that the 
affinity of this interaction is higher than the dark and opsin states, consistent with our 
results obtained from fluorescence spectroscopy.  However, the affinities obtained from 
NMR spectroscopy are lower for the dark state (16±8µM) as compared to fluorescence 
studies (2.6±0.2μM). This is likely due to an over-estimation of quenching that was not 
fully corrected for by the Parker method. 
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Figure 3.16: The binding curves for the ligands peaks in the (A) dark and (B) 1.5 
hours post illumination.  Peak 1, 2 and 3 are labeled using red circles, blue squares and 
green diamonds colors respectively. 
 
 
3.2.2. Location of Ce6 Binding on Rhodopsin 
 
 
3.2.2. (a) Ce6 is Predicted to Bind to Rhodopsin at the CP domain:  To better 
understand the molecular details of Ce6 binding to rhodopsin, we conducted 
computational docking studies of Ce6 in comparison to two other putative ligands 
(methylene blue and tetra-porphobenzine) studied previously (Washington, Brooks et al. 
2004) as well as Pheo-a as a control (see above section 3.2.1 (a)).  All four ligands were 
docked to the dark-state bovine rhodopsin crystal structure (Palczewski, Kumasaka et al. 
2000) using the Autodock software (Goodsell, Morris et al. 1996).  In each case, the best 
scoring 10 conformations were considered for analysis, and for Ce6, methylene blue and 
tetra-porphobenzine more than 80% of these docked in near identical locations.  In 
contrast, Pheo-a was observed in variable regions.  Ce6 bound with the most favorable 
energy of the four ligands docked.  Of these ligands, Ce6 also showed the most effective 
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response of bovine rhodopsin to red light excitation (Washington, Brooks et al. 2004).  
Thus, our ligand docking results are validated by the available experimental data.  The 
location of Ce6 docking is in the center of the CP domain in all of the top ten most 
highly-ranked conformations of Ce6, methylene blue and tetra-porphobenzine (Figure 
3.17A, Table 3.3).  In contrast, Pheo-a is predicted to bind to the TM helices at sites 
facing the outside of the helical bundle, dominated by hydrophobic interactions (Figure 
3.18).  The lack of a single highly-ranked binding site also suggests that the affinity of 
Pheo-a would be low.  This confirms the results obtained by fluorescence spectroscopy 
(Figure 3.13).  
Ce6 and Pheo-a were also docked to our recently developed model of the Meta II 
state (Isin, Rader et al. 2006).  Ce6 again docked only in the CP domain, but with 
differences in the details of the interactions and the orientation of Ce6 as compared to the 
dark-state (compare Figure 3.17 A,C with Figure 3.17 B,D).  Pheo-a again docked only to 
the hydrophobic TM outside of the helical bundle, but also displayed some differences 
between dark and light-activated models (Figure 3.18).  The analysis of the 5Å binding 
pocket residues of Ce6 (Figure 3.17 B,D, Table 3.3) revealed that most of the binding 
pocket residues in the dark and light-activated models overlapped, namely Lys-67, Arg-
69, Thr-70, Pro-71, Glu-134, Arg-135, Val-138, Ala-246, Ala-247, Val-250, Asn-310, 
Gln-312, Ser-334, Thr-335, Thr-336, Gln-344, Val-345, Ala-346 and Pro-347. Some of 
these residues are known to be important for Gt binding and activation, and include the 
highly conserved Glu-134 and Arg-135 of the D/ERY motif, indicating an overlap in the 
binding interfaces (see below).  
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Figure 3.17:  Docking studies of Ce6 to different states of rhodopsin.  Docking of Ce6 
to (A) dark state rhodopsin (PDB identification 1L9H) (Okada, Fujiyoshi et al. 2002) 
with 11-cis retinal and (B) model of the Meta II state of rhodopsin with all-trans retinal 
(Isin, Rader et al. 2006).  11-cis Retinal and all-trans retinal are colored blue and Ce6 is 
colored in red.  All ligands are rendered space filling.  The residues within 5Å of the 
docked Ce6 are shown for (C) dark state rhodopsin and (D) Meta II state rhodopsin.  
Images were generated using VMD (Humphrey, Dalke et al. 1996) and PyMol 
(http://www.pymol.org) software.  
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There are some residues that differentiate the dark and light-activated models: 
Phe-148, Gly-149 and Glu-150 were unique to the dark state (Table 3.3, labeled ‘•’) and 
Leu-68, Leu-72, Asn-73, Lys-141, Thr-243 were unique to the light-activated model 
(Table 3.3, labeled ‘°’).  The results obtained support the experimentally observed 
differences in affinity of Ce6 for dark and light-activated states of rhodopsin (Figure 
3.13, filled and open circles) and suggest that binding of Ce6 may affect the structure and 
dynamics of the CP domain.  Further, these predictions also suggest that Ce6 binding at 
the CP domain might impact Gt binding to rhodopsin. 
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Figure 3.18:  Pheophytin-a docking to dark, X-ray crystal structure (pdbid:1L9H 
(Palczewski, Kumasaka et al. 2000)) and ANM activated model (Isin, Rader et al. 
2006) of rhodopsin.  The chemical structure of pheophytin-a, demetallated chlorophyll-a 
derivative is shown in (A).  The different positions at which the top 10 ligand 
conformations were found to dock are shown for dark (B), (C) and ANM activated model 
(D), (E), and (F).  The binding energies and number of ligand conformations docked in B, 
C, D, E and F are -15.10 (6/10), -13.24 (4/10), -13.77 (6/10), -13.75 (3/10), and -9.51 
(1/10) Kcal/mol, respectively. 
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Table 3.3.  List of amino acids within 5Å of Ce6 in bovine rhodopsin and respective 
amino acids.  For comparison, the amino acids within 5Å of the Gt C-terminal high 
affinity peptide docked to the rhodopsin crystal structure and the model of the Meta II 
state (Figure 3.8) are listed, as well as those amino acids within 5Å of the Gt C-terminal 
peptide bound in the opsin crystal structure (Scheerer, Park et al. 2008).  Finally, we are 
also reporting the high connectivity residues in the CP domain (Christopher J R 
Illingworth 2008).  These are residues that are likely to be involved in interactions with 
ligands.  The cutoff range is represented in percentage, with higher percentages being 
more likely interacting residues.  The labels, ‘•’ and ‘°‘, indicate that these residues are 
part of the binding pocket in either only the dark (•) or only the light-activated Meta II 
model (°).  The labels, ‘*’ and ‘-‘, indicate if the amino acid is or is not part of the 
binding pocket, respectively.  
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Lys-67 * - - Glu-150• * - - 
Lue-68° * - 80% Thr-243° *° * - 
Arg-69 * - - Ala-246 * * - 
Thr-70 * - 70% Glu-247 * - - 
Pro-71 * - 70% Val-250 * * - 
Leu-72°  * * 80% Asn-310 - * 70% 
Asn-73° * * 70% Gln-312 * * 70% 
Glu-134 * - 70% Ser-334 - - - 
Arg-135 *• * 70% Thr-335 * - - 
Val-138 * * - Thr-336 * - - 
Lys-141° * * - Gln-344 *° - - 
Arg-147 * - - Val-345 *° - - 
Phe-148
•
 * - - Ala-346 * - - 
Gly-149
•
 * - - Pro-347 * - - 
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3.2.2. (b) 19F NMR Studies of Rhodopsin Labeled at Positions Cysteine 140 and 316 
in the CP domain:  To further corroborate the CP ligand binding site, we investigated 
rhodopsin labeled with NMR probes specifically introduced via cysteine chemistry into 
the CP domain. Rhodopsin has a total of ten cysteines, four of which are not reactive 
(Cys110 and Cys187 are engaged in a disulfide bond and Cys322 and Cys323 are 
palmitoylated). Two of the remaining cysteines are located in the EC domain, four in the 
TM and two in the CP domain (Figure 3.19).  Out of all ten cysteines, only Cys-140 and 
Cys-316 are accessible in the dark or inactive form.  Both of these cysteines are located 
in the CP domain (Figure 3.19).  To enable 19F NMR spectroscopy, we introduced, 
through a disulfide linkage, the trifluoroethylthio- CF3-CH2-S- (TET-) group to the 
cysteine residues (Cys-140 and Cys-316) of interest as previously reported (Klein-
Seetharaman, Getmanova et al. 1999; Loewen, Klein-Seetharaman et al. 2001). 
To study the effects of Ce6 binding on CP domain, we recorded dark and light 19F 
NMR spectra of rhodopsin in the absence and presence of Ce6 (Figure 3.20).  In the 
absence of Ce6, this gave rise to two distinct peaks at -65.0ppm and -65.4ppm (10.5ppm 
and 10.1ppm using TFE as internal reference) in the dark (Figure 3.20B and C, black 
solid trace), similar to those reported previously of 10.6ppm and 10.0ppm in reference to 
TFA (Klein-Seetharaman, Getmanova et al. 1999).  Upon light-activation, these two 
peaks shifted to their Meta II positions (Figure 3.19C, red trace).  Meta II peaks decayed 
to form opsin and gave rise to a broad peak with a maximum at -65.80ppm.  
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Figure 3.19:  Secondary structure model of rhodopsin showing the positions of 
cysteines.  All the cysteines in rhodopsin are enclosed in blue circles.  The cysteines at 
positions 140 and 316 are indicated by an arrow and labeled in blue. 
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Figure 3.20: 19F NMR spectra of Ce6 binding to the CP surface of dark and light 
state rhodopsin. (A) Scheme of attaching the 19F label.  Two samples of 7 mg of 
rhodopsin 19F derivatized at positions Cys-140 and Cys-316 in a volume of 350μl DM 
micelles in NMR buffer (Methods) were investigated by NMR spectroscopy.  The 
rhodopsin concentration was 0.5mM and the DM concentration was 7.4%.  The two 
samples were identical and only differed in the presence or absence of Ce6. (B) Dark 
rhodopsin in the absence (solid trace) and presence (dotted trace) of Ce6.  Overlay of 
rhodopsin in the dark and immediately after light-activation (with in 2 mins) in the 
absence (C) and presence (D) of 8.25 fold excess Ce6, at a final Ce6 concentration of 
4.0mM.  Each spectrum was acquired within 2 minutes on a 600MHz Bruker instrument, 
at 20oC.  Each Spectrum is an average of 105 scans. A line broadening of 10Hz was used.  
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In the presence of Ce6, small but significant shifts of 0.2ppm were observed in 
both Cys-140 and Cys-316 peaks in the dark (Figure 3.20B, dotted trace).  Upon light-
activation, the peaks did not shift to the positions of Meta II peaks observed in the 
absence of Ce6 (Figure 3.19D).  Instead, the peaks shifted directly to a peak at -65.94ppm 
(identical for Cys-316 and Cys-140).  This chemical shift is similar, but not identical to 
the one of the opsin peak in the absence of Ce6, which is observed at -65.80ppm.  These 
19F NMR studies indicate that Ce6 binds in the CP face of rhodopsin.  
 
 
3.2.3. Effects of Ce6 Binding on Rhodopsin Function 
 
 
3.2.3. (a) Ce6 Interferes with Gt Binding to Rhodopsin:  The functional role of Meta II 
rhodopsin is to activate Gt and initiate signaling.  The observed differences in 19F NMR 
spectra in the presence and absence of Ce6 as well as the docking results suggest that Ce6 
may interfere with Gt activation.  To test this hypothesis we measured the activation of Gt 
by light-activated rhodopsin using a [35S]GTPγS filter binding assay in the absence and 
presence of Ce6.  Gt activation was inhibited in a concentration-dependent manner 
(Figure 3.21).  IC50 values of 65nM - 150nM were obtained for 5nM rhodopsin and 1μM 
Gt in DM micelles and ROS membranes (Figure 3.22A).  A time course of light-
dependent activation of Gt by rhodopsin in bovine ROS was measured in the presence 
and absence of a 25-fold excess Ce6 (Figure 3.22B).  At 120 seconds post-illumination a 
sample free of Ce6 displayed near saturation in activation, whereas an identical sample 
containing 25-fold excess Ce6 displayed no activation as compared to dark controls 
(Figure 3.22B).  These studies suggest that Ce6 interferes with Gt binding to rhodopsin 
and the effect is similar in ROS and rhodopsin in DM micelles. 
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Figure 3.21:  Gt activation in ROS by the [35S]GTPγS filter binding assay.  The 
relative ratio of light versus dark radioligand counts is plotted against the Ce6 
concentration in nM.  Gt activation is inhibited by the presence of Ce6.  The rhodopsin 
concentration used was 0.25μM. Data was fitted with the exponential decay function. 
 
 
3.2.3. (b) Modulation of Gt Peptide Binding to Rhodopsin in the Presence of Ce6:  
Further support for an interference of Ce6 with Gt binding came from studies with a high 
affinity analog of the Gt C-terminal peptide corresponding to the sequence 
VLEDLKSCGLF.  This peptide quenches rhodopsin tryptophan fluorescence only upon 
light-activation, as described (Kisselev, Meyer et al. 1999; Arimoto, Kisselev et al. 2001).  
However, unlike Ce6, the Gt peptide is not able to quench fluorescence fully, and even at 
a 1500-fold excess of the peptide, 25% of the fluorescence remains (Figure 3.23).  A 
similar level of quenched fluorescence is achieved with Ce6 with a 5-fold excess (Figure 
3.12 and Figure 3.23).  In the presence of both, a 5-fold excess Ce6 and 1500-fold excess 
Gt peptide fluorescence quenching is greater than in the presence of either compound 
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alone, consistent with the interpretation that Ce6 may largely displace the Gt peptide from 
rhodopsin, while the Ce6-free fraction is occupied by Gt.  
 
 
 
 
 
Figure 3.22:  Concentration-dependent inhibition of Gt activation by Ce6. (A) 
Decrease in Gt activation monitored with 5nM ROS (open circles) and 5nM rhodopsin in 
DM micelles (closed circles).  All reactions were incubated for 30 minutes following 
illumination (2 minutes) and stopped by filtering through nitrocellulose membranes as 
described in Supplementary Methods. (B) Time course of Gt activation with illuminated 
rhodopsin in the absence (filled circles) and presence of a 25-fold excess of Ce6 (open 
circles) over rhodopsin concentration.  The rhodopsin concentration used was 0.25μM.  
The data in (A) was fitted with the sigmoidal dose-response non-linear regression 
function and using the exponential growth function for (B). 
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Figure 3.23:  Modulation of Gt peptide binding to rhodopsin in the presence of Ce6.  
The effect of Ce6 on Gt peptide VLEDLKSCGLF binding to rhodopsin was determined 
by fluorescence spectroscopy.  The rhodopsin concentration used was 0.25μM.  Data was 
fitted using the exponential growth function. 
 
 
3.2.3. (c) Docking Studies of C-terminal Gt Peptide to Rhodopsin:  The most likely 
explanation for the effects of Ce6 on Gt peptide binding (Figure 3.23) is an overlap 
between the binding sites.  To help understand these effects we docked the Gt peptide to 
both dark (PDBID: 1L9H:A) (Palczewski, Kumasaka et al. 2000) and light-activated 
rhodopsin (Isin, Rader et al. 2006) models using ClusPro software (Comeau, Gatchell et 
al. 2004).  In each case, the top 10 best scoring conformations were considered for 
analysis, and 90% of the time they were docked in the CP domain of rhodopsin (Figure 
3.24).  The electrostatic and desolvation energies of both the dark and light-activated 
models of the peptide-rhodopsin complexes were estimated using FastContact analysis 
(Camacho and Zhang 2005).  The electrostatic energy of peptide binding to the light-
activated model was estimated at -14.1kcal/mol, as compared to -6.7kcal/mol for binding 
to dark-state rhodopsin.  This result is validated by the experimentally known fact that the 
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peptide essentially does not bind to dark-state rhodopsin.  The desolvation free energies 
calculated for the binding of peptide to dark and light state rhodopsin models was 
+1.1kcal/mol and -1.7kcal/mol, respectively, also supporting that the peptide binds better 
to the light-activated structure of rhodopsin.  Shown in Table 3.3 are the amino acids 
predicted to be within 5Å of the peptide docked to dark and light-activated structures as 
compared to the respective binding pocket of Ce6.  The predicted peptide binding pocket 
residues are in agreement with previously published data of the Gt C-terminal peptide 
(IRENLKDSGLF) (Filipek, Krzysko et al. 2004) and the recent  crystal structure of opsin 
bound to the peptide (Scheerer, Park et al. 2008).  We observe substantial overlap 
between the predicted Ce6 and Meta II binding pockets, and experimentally-observed 
peptide binding pockets in opsin (26 and 10 out of 28 residues, respectively).  
 
 
 
 
 
Figure 3.24:  Docking of C-terminal peptide to rhodopsin.  Docking of Gt C-terminal 
peptide IRENLKDSGLF to (A) Dark state and (B) ANM activated model of rhodopsin. 
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3.2.4. Effects of Ce6 Binding on Rhodopsin Structure and Dynamics 
 
 
3.2.4. (a) Time Dependent Conformational Changes in the CP domain in the Dark 
and upon Light-activation using 19F Labeled Rhodopsin at Cys-140 and Cys-316:  
To study the effects of Ce6 binding on rhodopsin structure and dynamics, we extended 
the 19F NMR spectroscopy discussed in section 3.2.2. (b) to record time dependent 
changes of rhodopsin upon light-activation in the absence and presence of Ce6.  
As described above (section 3.2.2. (b)), in the dark, the 19F labels attached to sites 
Cys-140 and Cys-316 results in two peaks at -65.0ppm and -65.4ppm (Figure 3.25A).  
Upon illumination, these two peaks shifted to form light-activated rhodopsin, Meta II.  
The Meta II peaks decreased with concomitant increase of the opsin peak with an 
estimated half-life of 12.2 minutes for the Cys-140 and 15.7 minutes for the Cys-316 
peak.  These half-lives fit well with the Meta II decay of rhodopsin recorded in the 
presence of 10% DM using fluorescence spectroscopy (Figure 3.26).  
In the presence of Ce6, in the dark we also saw two signals corresponding to Cys-
140 and Cys-316 peaks (Figure 3.25B, black trace).  However, upon light-activation, the 
peaks did not shift to the positions of Meta II peaks observed in the absence of Ce6 
(Figure 3.25, red traces in A and B).  Instead the peaks shifted directly to a peak at -
65.94ppm (identical for Cys-316 and Cys-140).  This chemical shift is similar, but not 
identical to the one of the opsin peak in the absence of Ce6, which is observed at -
65.80ppm.  Furthermore, the opsin peak is clearly visible only after 30 minutes in the 
absence of Ce6 (Figure 3.25A, orange trace), while it is instantly observed after 
illumination in the presence of Ce6 (Figure 3.25B, orange trace).  This raises the question 
of whether the chemical shift difference of 0.14ppm represents an opsin-like structure or 
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corresponds to actually retinal-free opsin protein.  The former would assume that Meta II 
is indeed formed in the presence of Ce6 but has a different conformation in the CP 
domain from Ce6-free Meta II.  The latter would suggest that retinal leaves the binding 
pocket in less than 2min, the time it takes to record the first NMR spectrum after 
illumination.  This question can be answered with absorbance spectroscopy.  UV/Visible 
absorption spectra will show a 440nm peak after addition of 1% HCl (v/v) if the retinal is 
still bound to Lys296. Indeed, we find a 440nm peak even in the presence of Ce6 
immediately after illumination, but not 1.5 hours after illumination, essentially identical 
to what is observed with rhodopsin in the absence of Ce6 (data not shown).  This result 
suggests that the 19F NMR peak at -65.94ppm observed immediately after illumination in 
the presence of Ce6 arises from an altered Meta II state, rather than opsin.  The 
subsequent transition to opsin is essentially NMR-silent because the chemical shift values 
are very close and the peaks are very broad.  
 Interestingly, the gradual formation of the opsin state in the absence of Ce6 
triggers the release of free 19F label from the two cysteines, resulting in a decrease of the 
opsin peak and an increase in free label peak at -68.96ppm (Figure 3.27C).  In the 
presence of Ce6, the decay of the opsin peak was slower (Figure 3.27A) and free label 
peak formation was minimal (Figure 3.27B), a very striking difference to what is 
observed in the absence of Ce6.  We conclude from these 19F NMR studies that Ce6 
affects the local environment of both cysteines in the CP face of rhodopsin.  Further, 
binding results in modulation of conformational states of rhodopsin upon light-activation.
120 
CHAPTER 3: CYTOPLASMIC ALLOSTERIC LIGANDS. 
 
 
 
 
 
 
 
Figure 3.25:  Time dependent changes in the CP domain of rhodopsin upon light-
activation.  Overlay of one dimensional 19F NMR traces as a function of time in the dark 
and upon light-activation in the absence (A) and presence (B) of Ce6.  Cysteine residues 
at positions 140 and 316 in rhodopsin were labeled by trifluoroethylthio (TET) groups as 
described previously (Klein-Seetharaman, Getmanova et al. 1999).  A total of 7mg of 
rhodopsin in 20 mM sodium phosphate buffer with 9% n-dodecyl-β-D-maltoside (DM) 
and 10% D2O at pH 6.0 was used for each sample.   
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Figure 3.26:  Comparison of the decay of Meta II peaks of Cys-140 and Cys-316 
measured by NMR spectroscopy with Meta II decay kinetics obtained using 
fluorescence spectroscopy.  The Meta II decay plot of rhodopsin at 10% DM obtained 
by fluorescence is shown as black circles and those from NMR spectroscopy as (red and 
green circles.  Peak 1 and 2 correspond to the Meta II peaks of Cys-140 and Cys316 
peaks after light-activation.  The calculated decay rates for rhodopsin (fluorescence), 
peak 1 and peak 2 are 0.0454, 0.0566 and 0.0385 min-1, respectively.  A rhodopsin 
concentration of 0.5μM and 0.5mM was used to record fluorescence and NMR spectra, 
respectively.  The results obtained from these two independent methods are in good 
agreement. 
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Figure 3.27:  Decay of rhodopsin after light-activation and free label formation in 
the absence and presence of Ce6. (A) Decay of the broad peak around -66ppm (-
65.80ppm and -65.94ppm for rhodopsin (blue line in (C)) and rhodopsin plus Ce6 (red 
line in (C), respectively) in the absence (filled circles) and presence (open circles) of 8.5 
fold excess Ce6.  The decay rate of opsin in the presence of Ce6 was decreased by a 
factor of 2. (B) Plot of the formation of the free label peak (its position in the spectrum is 
indicated in (C)) in the absence (filled circles) and presence (open circles) of Ce6.  Less 
than 20% of the 19F label appeared as free label after 16 hours.  Data were fitted using the 
exponential decay function for (A) and linear function for (B). (C) Overlay of one-
dimensional 19F NMR spectra of rhodopsin 3 hours after illumination in the absence (blue 
line) and presence of Ce6 (red line).  
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3.2.4. (b) Development of NMR Methodology to Study Membrane Protein 
Dynamics by 19F NMR Methyl Relaxation:  The studies described in section 3.2.4 (a) 
strongly suggest the possibility of changed dynamics in the CP region upon binding to 
Ce6.  Solution NMR relaxation techniques have been very useful to measure and 
characterize motions occurring in biological molecules on different time scales ranging 
from fast to slow internal motions.  While this technique has proven successful for many 
soluble proteins, its application to membrane proteins is limited.  This is due to 
constraints such as size of the molecule, detergent environment; and suppression of signal 
intensities due to large detergent peaks.  19F NMR spectroscopy has been found 
especially useful for studying the conformational changes in rhodopsin (Klein-
Seetharaman, Getmanova et al. 1999; Loewen, Klein-Seetharaman et al. 2001).  As 
explained in section 3.2.2. (b), in the 19F NNR strategy we follow conformational 
changes associated with residues specifically labeled at desired positions (Gerig 1989; 
Klein-Seetharaman, Getmanova et al. 1999; Loewen, Klein-Seetharaman et al. 2001; 
Klein-Seetharaman 2002).  Furthermore, fluorine atoms are very sensitive to changes in 
the local environment and the overall mobility of molecule itself (Gerig 1989).  Here, we 
developed a 19F NMR spectroscopic approach to study the conformational dynamics in 
rhodopsin in the presence and absence of Ce6. This is the first application of 
quantification of 19F-methyl dynamics to a membrane protein. 
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Figure 3.28:  19F NMR relaxation rates of Cys-140 and Cys-316 in rhodopsin. (a) R2 
values and (b) R1 values determined at various temperatures.  The values are plotted for 
Cys-140 (filled circles) and Cys-316 (open cicles).   
 
 
Longitudinal (R2) and transverse (R1) relaxation rates of 19F methyl groups 
attached to two cysteine sites in the CP surface of rhodopsin, at positions Cys-140 and 
Cys-316, were recorded on a Bruker 600MHz instrument (Figure 3.28).  For the details 
on labeling at these sites please refer to section 3.2.2 (b).  The accessible cysteines in 
rhodopsin Cys-140 and Cys-316 contain the label –S-CH2-CF3.  R1 and R2 rates were 
determined as a function of temperature in the range from 10 to 35°C, with an interval of 
5°C.  The R2 values of both Cys-140 and Cys-316 exhibit almost linear Arrhenius plots 
(Figure 3.28A), indicating that they are predominantly determined by a single correlation 
time.  Such linear dependence indicates that there are no conformational changes in the 
protein over the temperature range tested.  Further comparison of the R2 rates for Cys-
140 and Cys-316 at different temperatures suggests that Cys-316 has shorter R2 values 
compared to Cys-140.   The calculated R2 rates for Cys-140 and Cys-316 measured at 
125 
CHAPTER 3: CYTOPLASMIC ALLOSTERIC LIGANDS. 
 
25°C are 334 ± 3 s-1, and 183 ± 3 s-1, respectively.  This indicates that that Cys-140 might 
be less flexible compared to Cys-316 (Figure 3.28A).  In contrast to the R2 values, the R1 
values of both Cys-140 and Cys-316 display non-linear Arrhenius plots (Figure 3.28B).  
This suggests that R1 values might be influenced by internal motions of the label, in 
addition to overall molecular rotation of the molecule.  The studies presented here 
support that 19F methyl relaxation, especially R2 measurements, can be applied to study 
dynamics of large protein systems at high magnetic fields in detergent micelles. 
 
 
Table 3.4:  Fluoromethyl relaxation rates at 25°C in the absence and presence of 
Ce6.  
 
 
rate Without Ce6 With Ce6 
(s-1) Cys-140 Cys-316 Cys-140 Cys-316 
R2 334 (2.5) 183 (3.3) 349 (2.1) 232 (6.3) 
R1 3.31 (0.03) 2.90 (0.04) 3.27 (0.06) 3.57 (0.03) 
 
 
3.2.4. (c) Application of 19F Dynamics Method to Rhodopsin-Ce6 Interaction:  
Shown in Figure 3.29 are the longitudinal and transverse relaxation values of 19F labeled 
rhodopsin with and without Ce6.  The dynamics of the CP domain upon Ce6 binding 
were monitored using the Cys-140 and Cys-316 positions in the CP domain as discussed 
above.  The R1 and R2 measurements were recorded at 10, 15, 20, 25, and 30°C.  In the 
presence of Ce6, the transverse (R1) and longitudinal (R2) relaxation values of Cys-316 
were higher at the different temperatures tested.  In contrast, the relaxation values of Cys-
140 in the absence and presence of Ce6 exhibited similar values at the different 
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temperatures tested.  The only exception was the longitudinal relaxation value acquired at 
30°C, which was higher in the presence of Ce6.  The comparison of the R1 and R2 values 
at 25°C for both the cysteines are listed in Table 3.4.  Overall, these results suggest a 
significant change in the flexibility of the residue Cys-316 upon binding to Ce6.  The 
observation that Cys-140 remains unchanged upon binding to Ce6, while more significant 
changes are observed in the flexibility of Cys-316 suggests that the CP binding site of 
Ce6 is closer to helix 8 than CP loop 2.  
 
 
 
 
 
Figure 3.29:  Comparison of 19F NMR longitudinal and transverse relaxation rates 
of Cys-140 and Cys-316 in rhodopsin in the absence and presence of Ce6.  The 
overlay of (A) R2 and (B) R1 values at various temperatures for Cys-140 (filled symbols) 
and Cys-316 (open symbols) without (circles) and with Ce6 (triangles). 
 
 
3.2.4. (d) Conformational Changes in the EC and TM Domain induced by Ce6 
Binding Probed by NMR Spectroscopy of α,ε-15N- Tryptophan Labeled Rhodopsin:  
Structural communication between the TM and the CP domain is well established for 
GPCRs. Upon light-activation, the changes due to the dissociation of the retinal in the 
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TM are communicated to the CP domain where a hydrophobic interface becomes 
exposed that allows other signaling proteins to bind.  In this case, a signal initiated at the 
interface between the TM domain and EC domain of rhodopsin is translated effectively to 
the CP domain.  Here, we propose that the reverse could also be true - binding of a ligand 
at the CP site of rhodopsin may affect the conformation of the TM and perhaps the EC 
parts of the protein. To test whether the overall structures of the TM and EC domains of 
rhodopsin are changed upon Ce6 binding at the CP domain, we followed the behavior of 
tryptophan residues (Klein-Seetharaman, Yanamala et al. 2004; Werner, Lehner et al. 
2007).  There are several reasons behind selecting tryptophan residues for performing this 
experiment:  (a) tryptophans are completely absent in the CP domain, (b) tryptophan 
residues are few in number (there are a total of five tryptophan residues in rhodopsin) and 
thus result in a less-crowded NMR spectrum, and (c) out of the five tryptophans present 
in rhodopsin, Trp-35 is in the EC domain, and the tryptophans in the TM domain are 
fairly distributed among different helices (Figure 3.30). As the 1H,15N resonances from 
all five backbone NH groups of tryptophans have been assigned recently (Werner, Lehner 
et al. 2007), we can identify which helices are predominantly affected by Ce6.  Further, 
Trp-126, Trp-161 and Trp-265 were shown to play an important role in the activation of 
rhodopsin (Lin and Sakmar 1996; Borhan, Souto et al. 2000).  In particular, Trp-265 is 
the highly conserved in GPCRs and participates in the ligand binding interactions. 
 To monitor if Ce6 binding at the CP domain exerts allosteric effects on EC and 
TM domains, we measured 1H-15N heteronuclear single quantum correlation (HSQC) 
NMR spectra of α-ε-15N-labeled tryptophan rhodopsin at 37°C.  In general, the 1H-15N 
HSQC spectrum contains chemical shifts originating from protons (HN) that are directly 
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connected to nitrogen in the protein backbone or side chains. For example, the HSQC 
spectrum also contains peaks from NH2 group protons of Lys, Asn, Gln, Trp and His.  
For the α-ε-15N -Tryptophan labeled rhodopsin sample, this spectrum should result in five 
backbone and five side chain signals in the range 7.0 - 9.0ppm and 10.0 – 12.0ppm, 
respectively.  An overlay of the conventional HSQC spectra of α-ε-15N-tryptophan 
labeled rhodopsin in the absence and presence of 10-fold excess Ce6 is shown in Figure 
3.31.  In the absence of Ce6 (Figure 3.31, black trace), the HSQC spectrum gave rise to 
five distinct peaks in the range ~10.0 – 11.5ppm corresponding to the expected five 
indole side chain signals.  The intensity of all the side chain signals was similar, except 
for the signal at ~10.6ppm.  This peak was unambiguously assigned previously to Trp-
175.  Additionally, we observed approximately twelve peaks instead of five signals in the 
range of 6.5 - 9.0ppm corresponding to the backbone nitrogen atoms.  A recent study 
combining both solid and solution state NMR, resulted in the assignment of signals in the 
backbone region corresponding to the five tryptophans (Werner, Lehner et al. 2007).  
Apart from these five assigned signals, all other signals have been attributed to be 
originating from the natural abundance of the amino groups from the flexible C-terminus 
residues (Werner, Lehner et al. 2007; Werner, Richter et al. 2008), while heterogeneity of 
tryptophan conformations has been proposed as an alternative explanation (Klein-
Seetharaman, Yanamala et al. 2004). Based on Werner et al (Werner, Lehner et al. 2007), 
the signals observed at 7.2, 7.7, 8.2, 8.3, and 8.7ppm were assigned to Trp-161, Trp-35, 
Trp-265, Trp-175 and Trp-126, respectively (Figure 3.30 and 3.31).   
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Figure 3.30:  Secondary structure model of rhodopsin indicating all the tryptophan 
residues.  The tryptophan residues in rhodopsin are labeled and circled in blue.  The 5Å 
predicted Ce6 binding pocket residues in rhodopsin are highlighted in bold and colored in 
red.  The disulphide bond between C110 and C187 is represented by a dotted line. 
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Figure 3.31:  One dimensional NMR spectra of 15N-α-ε-tryptophan labeled 
rhodopsin.  The NMR spectra in the absence and presence of 10-fold excess Ce6 are 
colored in black and red traces respectively.  The signals from the side chains and 
backbones are labeled clearly.  The chemical shift changes in the backbone upon addition 
of Ce6 are indicated by green arrows and labeled in red and the blue arrows indicate the 
changes in the tryptophan side chains regions. 
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 In the presence of Ce6, the overall spectrum looked similar to rhodopsin alone, 
except for the following changes.  Two out of the five indole side chain signals were 
shifted in the presence of Ce6 as compared to rhodopsin alone (Figure 3.31, blue arrows).  
A shift of +0.11, +0.06 and +0.03ppm for the peaks at 11.4, 11.1 and 10.6ppm in the side 
chain regions were observed.  So far, we cannot attribute these changes to specific 
tryptophans as there is no assignment yet for this region.  Only two of the signals in the 
backbone region were found to be shifted in the presence of Ce6.  The peaks 
corresponding to Trp-126 and Trp-161 were shifted by +0.07 and +0.11ppm. Further, an 
increase in the intensity of Trp-161 peak was observed in the backbone region, 
suggesting that Trp-161 might be experiencing increased flexibility in the presence of 
Ce6.  These studies clearly suggest that binding of Ce6 at CP domain induces changes in 
the TM region, in particular Trp-126 on helix 3 and Trp-161 on helix 4 located near the 
11-cis retinal ligand binding pocket, but towards the CP domain.  Further, these studies 
support the hypothesis that there may be an alteration in conformational flexibility in this 
region, which may be important for 11-cis retinal binding and thus in relaying the TM/EC 
signal back to the CP domain after activation. 
 
 
3.2.4 (e) NMR Analysis of α-15N-lysine Labeled Rhodopsin in the Dark and upon 
Light-activation:  To focus on amino acids mainly located at the CP side of the protein, 
we measured NMR spectroscopy of 50μM α-15N-lysine labeled rhodopsin in the absence 
and presence of Ce6  (Klein-Seetharaman, Reeves et al. 2002).  Rhodopsin contains a 
total of eleven lysine residues (Figure 3.32, circled in magenta).  Almost all of these 
residues are located in the CP surface of rhodopsin, except for two lysines, Lys-296 in the 
132 
CHAPTER 3: CYTOPLASMIC ALLOSTERIC LIGANDS. 
 
TM domain and Lys-16 in the EC domain.  Lys-296 is an important lysine residue as it 
serves as the attachment site of 11-cis-retinal.  NMR studies suggest that each of the 
lysines in rhodopsin has a different mobility and experiences different chemical 
environments (Klein-Seetharaman, Reeves et al. 2002).  To investigate if the mobility of 
these residues has been restricted upon binding of Ce6, we followed the changes in the 
chemical shifts that arise from 15N-labeled lysine residues in the 2D-1H-15N-HSQC 
spectrum (Klein-Seetharaman, Reeves et al. 2002). 
 In the absence of Ce6, the 2D HSQC spectrum recorded at +25°C in the dark gave 
rise to three signals (Figure 3.33, black line).  The intensity of the signals observed varied 
greatly with a sharp, highly intense peak at ~8.4ppm, a moderately intense peak at 
~7.93ppm and another moderately to less intense peak at ~8.30ppm.  Previous studies 
have shown that the signal at 8.4ppm corresponds to Lys-339, located in the flexible C-
terminus region of rhodopsin (Figure 3.32) (Klein-Seetharaman, Reeves et al. 2002). 
After 1.5hours post light-activation, the 2D HSQC spectrum resulted in the disappearance 
of the peak at ~8.30ppm (Figure 3.33, indicated by a black arrow).  However, no change 
in signals at ~8.4ppm and ~7.93ppm was observed.  Further, the spectrum gave rise to 
three new less intense peaks at 8.53ppm, 8.1ppm and 8.06ppm (Figure 3.33, indicated by 
red arrows). 
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Figure 3.32:  Secondary structure model of rhodopsin showing all the lysine residue 
positions.  Lys-296 that participates as the direct attachment site for 11-cis retinal is 
shown in filled red circle.  All other lysine positions are labeled and colored in red 
circles.  The predicted binding pocket residues are highlighted in bold and colored in 
blue. 
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Figure 3.33:  Two dimensional HSQC spectra of α-15N-lysine labeled rhodopsin.  
HSQC spectra (A) in the dark (black traces) and (B) 1.5 hours after light-activation (red 
traces) recorded at +25°C on a 800MHz Bruker NMR spectrometer. A rhodopsin 
concentration of 50μM was used. The sample was illuminated with >495nm light for 
30sec.  The signals that either disappear or appear upon light-activation are indicated by 
black and red arrows, respectively.  The signal corresponding to Lys-339 in the C-
terminus is labeled.  
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 Shown in Figure 3.34 is the comparison of the 2D HSQC spectra of 50μM α-15N-
lysine labeled rhodopsin in the presence of 50μM (1X) and 0.5mM (10X) Ce6 recorded 
in the dark and 1.5 hours post illumination.  In the dark, addition of Ce6 resulted in the 
complete disappearance of the signal at ~8.3ppm (Figure 3.33, indicated by black arrow).  
In addition, in the presence of already a 1-fold excess of Ce6 over rhodopsin, a signal at 
~8.53ppm started appearing.  These changes occurring in the presence of Ce6 in the dark 
were only found after light-activation in the absence of Ce6 (compare Figure 3.33, red 
arrows and Figure 3.34A, black arrow).  The overall spectrum showed a similar profile as 
compared to that of light-activated rhodopsin in the absence of Ce6 (Figure 3.33, red 
spectrum), with the exception of the peaks at 8.1ppm and 8.06ppm.  However, in the 
presence of a 10-fold excess Ce6, the peak at 8.53ppm was absent and an overall 
decrease in the broadness of the spectrum was observed (compare Figure 3.34A and B, 
black spectra).  
 Upon light-activation, in the presence of 50μM Ce6 (Figure 3.34A, red spectrum), 
the overall spectrum in comparison to the rhodopsin alone sample was similar with the 
exception of the following changes.  Instead of two distinct peaks at 8.1ppm and 
8.06ppm, a broad peak around ~8.05ppm was observed (indicated by red arrow).  
Additionally the peak at ~8.53ppm decreased in intensity compared to dark state 
rhodopsin with Ce6 (Figure 3.34A, black trace) and in the absence of Ce6 upon light-
activation (Figure 3.33, red trace).  Also, the Lys-339 peak at ~8.4ppm became less 
broad.  In the presence of a 10-fold excess of Ce6, the signal at 8.07ppm that was seen in 
both 0X and 1X Ce6 samples was no longer observed (compare 3.33, red trace and 
Figure 3.34A and B, red traces).  Further, in comparison to the two distinct peaks in the 
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absence and one broad peak in the presence of 1X Ce6, a single distinct peak at ~8.07 
was observed (compare Figure 3.33, 3.34A and B, red arrows).  The results obtained 
clearly indicate that the mobility of some of the lysine residues is restricted in the 
presence of Ce6.  
 
 
 
 
 
Figure 3.34:  Comparison of conventional HSQC spectra of α-15N-lysine labeled 
rhodopsin in the presence Ce6.  HSQC spectra of 50μM α-15N-lysine labeled rhodopsin 
with (A) 50μM Ce6 and (B) 0.5mM Ce6.  The spectra were recorded in the dark (colored 
black) and after 1.5 hours light-activation (colored red) at +25°C on 800MHz Bruker 
Spectrophotometer.  A rhodopsin concentration of 50μM was used in each experiment.  
The sample was illuminated with >495nm light for 30sec.  The changes in the dark and 
upon light-activation as compared to rhodopsin alone are colored in black and red arrows, 
respectively. 
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3.2.4. (f) Monitoring Structural Changes in Rhodopsin upon Ce6 Binding using 
Selective Excitation 1H NMR Spectroscopy:  Further evidence for the changes in 
structure and dynamics in rhodopsin came from recording one dimensional 1H NMR 
spectra of unlabeled rhodopsin without and with Ce6.  Shown in Figure 3.35 is the 
selective exciation 1H NMR spectra recorded in the range 7.3 – 8.7ppm for 50μM 
rhodopsin in the absence and presence of Ce6.  The peaks observed were sequentially 
numbered from 1-10 for convenience in each case.  Comparison of the spectra in the dark 
and upon light-activation in the absence of Ce6 showed an overall decrease in the peak 
intensities (Figure 3.35A).  A signal at peak position 1 appears upon light-activation 
increases in intensity in a time dependent manner.  The intensity of the peak at position 6 
increases in a time dependent manner after light-activation (Figure 3.35A, black trace 
with others). Additionally the peak at position 9 decreases in intensity after 0.5 and 1 
hours light-activated rhodopsin (Figure 3.35A, red and blue traces) and disappears 
completely in the 3 hour post illumination spectra (Figure 3.35A, magenta trace).  These 
studies suggest that the time dependent changes observed at peak positions 6 and 9 
correspond to the changes associated with structural transition from dark to opsin state.  
Further, the peaks at positions 2, 3, 7, 9, and 10 originated from the C-terminus residues 
of rhodopsin (Figure 3.35D, indicated as ‘*’).  This supports the idea that the signals in 
selective excitation 1H NMR spectra come from flexible residues in the proteins (refer to 
Section 6.1.1 for more details).  These observations suggest that the majority of the 
signals observed in selective excitation spectra might be from the CP residues, as this 
domain is the most flexible as compared to all the other domains in rhodopsin.  
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Figure 3.35: Monitoring binding of Ce6 to dark-adapted and light-activated 
rhodopsin.  Overlay of one dimensional selective excitation 1H NMR spectra in the dark 
and at different time points after light-activation of (A) rhodopsin (B) rhodopsin with 
10μM Ce6 and (C) rhodopsin with 50μM Ce6. (D) 1mM C-terminal peptide 
corresponding to the  last nine amino acids of rhodopsin in phosphate buffer and 0.3% 
DM.  In A, B, and C the NMR traces corresponding to the dark, 0.5, 1 and 3 hours after 
light-activation are colored in black, red, blue and magenta, respectively.  NMR samples 
contained 50μM of rhodopsin in 20mM sodium phosphate buffer (pH 6.0), 0.3% DM and 
10% D2O. 
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In the dark, titration of 10μM, 50μM, 400μM and 1mM concentration of Ce6 to 
50μΜ rhodopsin resulted in changes at peak positions 9 and 10.  Shown in Figure 3.36 is 
the overlay of the chemical shift region of rhodopsin for these two peaks in the absence 
and in the presence of various concentrations of Ce6.  The peaks at position 9 and 10 
gradually shifted upfield and downfield, respectively (Figure 3.36).  Except for this 
change, we did not observe any changes in the other positions for dark state rhodopsin.  
 
 
 
 
 
Figure 3.36: One dimensional selective excitation 1H NMR spectra of dark 
rhodopsin without and at various concentrations of Ce6.  The 1H NMR spectra of 
dark state rhodopsin in the absence (black trace) and in the presence of 10μM (red trace), 
50μM (blue trace), 400μM (green trace), 1mM Ce6 (magenta trace) in the chemical shift 
range 7.4ppm to 250μM 7.55ppm is shown.  These peaks correspond to the positions 9 
and 10 in Figure 3.35. 
 
 
Shown in Figure 3.37 are the spectral changes of rhodopsin immediately recorded 
within 2mins after light-activation and after 1.5 hours post light-activation in the absence 
and presence of Ce6.  Immediately upon illumination and after 1.5 hours light-activation 
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(representative of Meta II and opsin state, respectively), an increase in the peak at 
position 5 with a decrease at position 4 was observed in a concentration-dependent 
manner (Figure 3.37A, B).  In the absence of Ce6, this was only observed after complete 
decay of Meta II to opsin state, which happens with a half-life on the order of ~10-13 
minutes.  Further, a decrease in the broadness of the peak at position 6 was also observed, 
indicating changes in the mobility of these residues upon illumination (Figure 3.37).  
These results suggest that addition of various concentrations of Ce6 modulates the 
structure of rhodopsin resulting in faster transition towards the opsin like state.  
Additionally, these studies also suggest that the Ce6 bound light-activated state might 
exhibit different conformational flexibility as compared to Meta II and opsin states. 
Furthermore, we also observed changes in protein signals upon illumination 
without and with Ce6 in the range 9.8ppm to 10.1ppm, which are highlighted in Figure 
3.38.  Two signals corresponding to aromatic residues at 9.98ppm and 9.90ppm were 
observed upon light-activation.  None of these peaks were observed in the dark both in 
the absence and presence of Ce6.  Upon titrating Ce6, the signal at 9.90ppm disappeared 
completely, with the exception of the 10μM Ce6 sample.  When we titrated different 
concentrations of Ce6 (10μM, 50μM, 100μM), we found that the signal at 9.98ppm 
shifted downfield in a concentration dependent manner.  In contrast, this signal 
completely disappeared upon addition of 400μM and 1mM Ce6.  These results clearly 
confirm binding of Ce6 to rhodopsin and suggest that binding modulates the structure and 
dynamics in both the dark and light-activated states of rhodopsin.  
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Figure 3.37:  Change in the selective excitation 1H NMR spectra of Meta II and 
Opsin state of rhodopsin in the absence and at various concentrations of Ce6.  For 
the legends of (A), and (B), refer to Figure 3.36. 
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Figure 3.38:  One dimensional selective excitation 1H NMR spectra of the aromatic 
amino acid side chain region of rhodopsin with and without Ce6.  The spectra for 
rhodopsin in the absence (black) and presence of 10μM (orange), 50μM (red), 100μM 
(blue), 400μM (green) and 1mM  (magenta) Ce6 upon light-activation.  The spectra for 
rhodopsin in the dark both without and with Ce6 displayed no peaks in this region and are 
therefore not shown in this figure. 
 
 
3.2.5. Discussion 
 
 
First, we developed a Ce6 binding assay based on fluorescence spectroscopy where we 
found that rhodopsin tryptophan fluorescence is strongly quenched by Ce6, especially in 
the light.  Control experiments with non-illuminated Ce6 and with separately illuminated 
Ce6 confirm that these effects do not require Ce6 excitation (Figure 3.14).  Thus, it is 
unlikely that the Ce6 effects described in this thesis are indirect effects, such as through 
reactive oxygen species formation mediated by the presence of Ce6.  Consistent with this 
interpretation is also the fact that we observe similar fluorescence quenching in de-
143 
CHAPTER 3: CYTOPLASMIC ALLOSTERIC LIGANDS. 
 
oxygenated solutions (data not shown).  Furthermore, we show that these effects are 
consequences of Ce6 binding to rhodopsin:  Ce6 is essentially a degradation product of 
Chl-a, being demetallated and lacking the hydrophobic phytol chain.  To assess the 
specificity of Ce6 binding to rhodopsin, we therefore compared tryptophan fluorescence 
quenching by Ce6 with that by Chl-a, which is more hydrophobic than Ce6 and would 
result in stronger unspecific interactions with rhodopsin, being recruited into the 
detergent micelles.  The results confirm that Ce6 binding is specific, as Chl-a results in a 
much lower degree of fluorescence quenching, even lower than that observed for Ce6 
binding to dark-adapted rhodopsin.  Chl-a does have an effect on rhodopsin, namely on 
its Meta II half-lives (Table 3.2).  This is not uncommon, for example the Meta II half-
life is highly dependent on its lipid and detergent environment (Mitchell, Straume et al. 
1992; Brown 1994; Szundi, Lewis et al. 2005). 
 Further, the ligand binding studies were also confirmed using the selective 
excitation 1H NMR approach explained in section 3.1.1. (b).  We estimated the affinity  
of Ce6 interaction based on intensity changes in the ligand peaks with increasing amounts 
of rhodopsin added to a constant ligand concentration.  The lowest affinities values for 
the dark and opsin state of rhodopsin obtained are ~16+7μM and 8+3μM, respectively 
indicating moderate binding of Ce6.  However, we were not able to estimate the affinity 
of interaction between light-activated Meta II state and Ce6, due to the instability of the 
activated state.  The spectra obtained in the Meta II state qualitatively indicate a higher 
affinity of interaction for this state as compared to the other two states. 
19F NMR spectroscopy of rhodopsin carrying 19F labels in the CP domain, at 
positions Cys-316 and Cys-140, confirms the binding of Ce6 to rhodopsin, as distinct 
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changes in the NMR spectra are observed for both dark and light-adapted rhodopsin 
samples in the presence and absence of Ce6. 19F NMR further suggests that there are 
significant alterations in rhodopsin conformational preferences in the presence of Ce6, 
especially upon light-activation.  Ce6 binding changes the conformation of Meta II in the 
CP domain quite drastically, as the two resolved peaks for Cys-316 and Cys-140 in the 
Meta II state are shifted to a single, broad peak.  The chemical shift of this peak is 
similar, but not identical to that of a peak observed in the absence of Ce6, attributed to 
opsin.  Absorbance spectroscopy suggests that retinal is still bound to this species.  The 
peak does not decay to form free 19F label when Ce6 is present, contrary to what is 
observed in the absence of Ce6.  If we assume that the formation of free 19F label is due 
to nucleophilic attack of the trifluoroethyl-cysteine disulfide bond by amino acids in the 
protein, this suggests that Ce6 binding stabilizes rhodopsin, presumably preventing the 
motions required for such an attack.  
Computational modeling studies predict a binding pocket for Ce6 at the CP center 
of the helical bundle.  We propose that this binding pocket overlaps to a great extent with 
that of the G protein, based on fluorescence spectroscopic and computational modeling 
studies of the binding of a peptide representing a high-affinity analogue of the C-terminus 
of Gt  (Kisselev, Meyer et al. 1999; Arimoto, Kisselev et al. 2001).  Analysis of the recent 
Gt peptide bound opsin crystal structure (Scheerer, Park et al. 2008) also overlaps 
between Gt and the predicted Ce6 binding pockets (Table 3.3).  Consistent with the 
computational analysis, we find experimentally that Ce6 inhibits the activation of the 
heterotrimeric G protein in [35S]GTPγS filter binding assays.  The predicted CP binding 
site provides a plausible explanation for the observed effects of Ce6 binding on rhodopsin 
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conformation and G protein activation – it is located at the “heart of the action,” where 
the largest conformational changes are observed after light-activation (Janz and Farrens 
2004; Oldham and Hamm 2008), and where critical residues are exposed to interact with 
Gt (Janz and Farrens 2004; Oldham and Hamm 2008).  In agreement with this key role, 
some of the residues in this pocket are highly conserved.  For example, Glu-134 and Arg-
135 are the residues of the D/ERY motif, which is conserved close to 100% in Class A 
GPCRs (Sakmar 2002).  
The finding of a CP Ce6 binding pocket in rhodopsin fits well with recent 
independent predictions of small molecule binding pockets for rhodopsin based on 
analysis of high connectivity of residues in proteins (Christopher J R Illingworth 2008).  
Connectivity of a residue refers to the number of its neighboring contacts within a 
distance of 5.5Å where high connectivity residues were scored using the K-means 
algorithm (Christopher J R Illingworth 2008).  In addition to the retinal binding pocket, 
this method identified a total of 34 residues in the CP domain as likely binding sites when 
searching for residues containing atoms with a local connectivity within 70% of the 
maximal energy value for the protein.  Nine residues are part of both peptide and Ce6 5Å 
binding pockets (Table 3.3). 
 
After, showing that Ce6 physically binds to rhodopsin and interferes with Gt 
activation, we then investigated if Ce6 binding alters rhodopsin structure and dynamics.  
Several lines of evidence (refer sections 3.2.2, 3.2.3), suggest Ce6 binds at the CP domain 
of rhodopsin.  As traditional NMR relaxation measurements pose many constraints for 
membrane proteins (see section 3.1.1 (b)), a 19F based relaxation technique was 
developed to measure transverse and longitudinal relaxation values.  In the absence of 
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Ce6, the estimated R2 values indicated that Cys-316 on perpendicular helix 8 is more 
flexible as compared to Cys-140 on helix 3.  In the presence of Ce6, the conformational 
flexibility of Cys-316 was found to be decreased.  In contrast to this, binding of Ce6 to 
rhodopsin did not affect Cys-140 relaxation values.  They almost remained identical 
except at elevated temperatures.  The fact that only one of the cysteines exhibits changes 
upon binding to Ce6 validates the existence of the CP binding domain.   
In addition to monitoring the local effects induced by Ce6 binding we also 
investigated whether Ce6 binding at the CP domain has allosteric effects on the other 
domains of bovine rhodopsin.  To do so, we recorded 1H-15N-HSQC spectra of α-ε-15N-
tryptophan labeled rhodopsin in the presence and absence of Ce6 in the dark.  
Comparison of the HSQC spectra indicated chemical shift changes both in the backbone 
and side chain signals.  The backbone signals corresponding to Trp-126 and Trp-161 
were found to be modulated in the presence of Ce6, already in the dark.  Trp-126 and 
Trp-161 are located in the TM domain in helix 3 and helix 4, respectively.  Though, they 
are in the middle of these helices, they are close to the CP side as compared to other three 
tryptophan residues in rhodopsin.  Along with Trp-265, which participates in direct 
interaction with the retinal, Trp-126 and Trp-161 play a major role in rhodopsin 
activation (Lin and Sakmar 1996; Borhan, Souto et al. 2000).  These results together with 
the changes in dynamics observed above, clearly indicate that Ce6 binding to rhodopsin 
alters the conformational flexibility of rhodopsin.  This, in turn, could lead to altered 
signal transfer rates for interconversion between different conformational states.  This 
conclusion may explain the results obtained from 19F NMR (Figure 3.29) and Gt 
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activation studies (Figure 3.22B) where faster conversion to the opsin state provides a 
plausible interpretation of the results.  
To better understand the effects of Ce6 binding on the mobility of the C-terminal 
residues and the CP domain in general, we analyzed 2D 1H-15N-HSQC spectra of α-15N-
lysine labeled rhodopsin in the presence and absence of Ce6 before and after light-
activation.  The spectrum recorded in the dark without Ce6 at 25°C gave rise to three 
peaks with varying intensities as opposed to eleven equally intense peaks.  The variability 
in the intensity may be attributed to conformational exchange broadening where residues 
interchange between multiple conformations on the order of μs – ms timescales (Klein-
Seetharaman, Getmanova et al. 1999; Klein-Seetharaman 2002; Klein-Seetharaman, 
Reeves et al. 2002; Klein-Seetharaman, Yanamala et al. 2004).  Complete disappearance 
of one of the signals and appearance of three new signals upon light-activation, indicates 
changed mobility of these residues after 11-cis retinal leaves the protein.  No change in 
the two intense peaks at 8.4ppm and 7.93ppm was observed, suggesting that these 
residues still remain flexible upon light-activation.  However, in the dark, upon addition 
of Ce6, the HSQC spectrum was similar in appearance to that obtained for light-activated 
rhodopsin. In the presence of Ce6, the signal at ~8.3ppm completely disappeared and a 
new peak at ~8.53ppm was observed, which was only seen after light-activation in the 
absence of Ce6.  This suggests that Ce6 binding modulates the structure of dark state 
rhodopsin towards an opsin like state.  Upon light-activation, formation of a broad peak 
around ~8.06ppm, instead of two distinct peaks at 8.1ppm and 8.05ppm in the absence of 
Ce6 was observed, suggesting that the opsin state structure and dynamics upon binding to 
Ce6 might not be identical to opsin state without Ce6.  This observation was further 
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supported by the evidence from the studies in the presence of 10-fold excess Ce6 over 
rhodopsin.  A distinct peak at ~8.08ppm was observed, as compared to a broad peak in 
the presence of 1X Ce6 and two distinct peaks without Ce6.  Numerous lysine residues 
are in close proximity to the predicted Ce6 binding pocket residues. In particular, Lys-67 
is predicted to participate directly in the binding of Ce6.  Although we have not yet 
assigned the signals other than Lys-339, the results qualitatively indicate that the 
structure and dynamics of the CP domain is modulated in the presence of Ce6.  
Additionally, these results indicate that the overall structure of rhodopsin might be 
experiencing restriction in mobility upon binding to Ce6, as evidenced by the decrease in 
the broadness of the peaks.  As the Lys-339 signal did not result in any changes upon 
either light-activation or addition of Ce6, this can be interpreted in two ways 1) it does 
not participate in binding as predicted, where as the dynamics of other residues in C-
terminus are affected and 2) that C-terminus does not participate completely in Ce6 
binding to rhodopsin. 
Further evidence for the changes in the structure and dynamics of rhodopsin 
comes from the selective excitation 1H NMR spectra.  The  1H NMR spectra recorded 
without and upon addition of Ce6 at various concentrations clearly indicated changes in 
peaks at positions 3, 5, 6, 7, 9 and 10.  Specifically, the peaks at positions 3, 7, 9, and 10 
directly originated from the C-terminus of rhodopsin (compare with Figure 3.35A, B, C 
with D).  Comparison of the dark-adapted and light-activated states of rhodopsin in the 
absence of Ce6, clearly indicated these changes are time-dependent and arise as a result 
of transition from the Meta II state to opsin.  Binding of Ce6 to rhodopsin was found to 
accelerate these changes, suggesting that Ce6 induces changes in the conformational 
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flexibility of rhodopsin.  Such conformational flexibility can be further attributed to the 
accelerated signal transfer from 11-cis binding site to the CP face.  This might further 
serve as an explanation for the inhibition of Gt studies described above, as less time in the 
activated state would lead to decreased Gt activation.  These studies along with the α-15N-
lysine labeled rhodopsin studies clearly indicate that the structure and dynamics of the 
rhodopsin in the CP face and also in the C-terminus are modulated. 
 
 
3.2.6. Conclusions 
 
 
Chlorophyll-derivatives have been proposed to act as photosensitizers in dragon-fish 
(Douglas, Partridge et al. 1999) and Ce6 was found to be an effective photosensitizer in 
retinas from model organisms salamander, cow and mouse (Washington, Brooks et al. 
2004; Isayama, Alexeev et al. 2006; Washington 2007).  Here, we show that these effects 
are mediated by direct interaction of Ce6 with rhodopsin.  We identify a novel binding 
pocket in the CP domain and show that binding modulates rhodopsin structure, dynamics 
and function.  This makes Ce6 the first allosteric small organic molecule modulator of 
rhodopsin.  The interaction inhibits Gt activation of bovine rhodopsin, an effect that may 
prove general for other GPCRs because of the high conservation of predicted CP binding 
site residues for the GPCR family. 
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SUMMARY 
 
 
For metabotropic glutamate receptors (mGluRs), allosteric ligands are particularly 
promising drug targets because of their modulatory effects – enhancing or suppressing 
the response of mGluRs to glutamate (see section 1.1).  While glutamate, the endogenous 
ligand for these receptors, binds in the EC domain, the allosteric ligand binding pocket is 
localized in the TM region. Many allosteric ligands have been identified for mGluRs 
including positive, negative and neutral modulators, but the mechanisms by which the 
modulations occur are not known. The binding of ligands for which allosteric effects on 
mGluRs are experimentally known was studied by docking to computationally generated 
models of different mGluR subtypes based on structures of rhodopsin. The results 
indicate that the allosteric ligand binding pockets of mGluRs are overlapping with the 
retinal binding pocket of rhodopsin, and that ligands have strong preferences for the 
active and inactive states depending on their modulatory nature. These findings strongly 
support the hypothesis that mGluR allosteric modulation occurs via stabilization of 
different conformations analogous to those identified in rhodopsin where they are 
induced by photochemical isomerization of the retinal ligand – despite the extensive 
differences in sequences between mGluRs and rhodopsin. To further test this hypothesis, 
we also investigated if rhodopsin can accommodate the allosteric mGluR ligand, 3,3`-
difluorobenzaldazine, in its TM binding pocket normally occupied by 11-cis or all-trans 
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retinal. We find that the regeneration of rhodopsin with 11-cis retinal in the presence of 
3,3`-difluorobenzaldazine is decreased, in a concentration-dependent manner. This 
suggests that binding of 3,3`-difluorobenzaldazine competes with 11-cis retinal for 
binding, but with a lower affinity. 
 
SIGNIFICANCE 
 
 
We show in this chapter that positive and negative mGluR modulators can be 
distinguished by their higher affinities for the active and inactive conformations of the 
receptors, respectively. These conformations are based on rhodopsin structures. This 
versatility in accomodating allosteric and endogenous ligands for different members of 
the GPCR family is very intriguing and suggests that the structural determinants for 
active and inactive functional states may be conserved across the GPCR family. Thus, in 
future, we may be able to create a generic prediction algorithm. Being able to predict 
whether a given allosteric ligand will act as a negative, positive or neutral modulator 
would be highly beneficial in designing new drugs targeted at these receptors and GPCRs 
in general.  
 
 
INTRODUCTION 
 
 
In this chapter, we describe the binding of allosteric ligands to class C GPCRs, where the 
allosteric binding site is located in the TM domain, similar to most of the endogenous 
ligand binding sites in class A GPCRs. In particular, we investigated allosteric ligand 
binding to metabotropic glutamate receptors (mGluRs). mGluRs which are representative 
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members of class C GPCR. mGluRs bind to glutamate, an amino acid that functions as 
the major excitatory neurotransmitter in the brain. Thus, mGluRs perform numerous 
functions in the central and peripheral nervous systems and are involved in learning, 
memory, anxiety, and the perception of pain. Small changes in the chemical structures of 
allosteric ligands were shown to switch their modulatory effects. To understand the 
mechanism of action of allosteric modulators, we investigated their preferences for 
different receptor structures of mGluRs.  Towards this goal, we generated computational 
models of the TM regions of different mGluR subtypes in two different conformations 
based on active and inactive models of rhodopsin. We then docked ligands with known 
allosteric effects to the modeled mGluR structures using ArgusLab (Thompson ArgusLab 
4.0.1) and Autodock (Goodsell, Morris et al. 1996) softwares. To test, if the TM binding 
pocket of rhodopsin can accommodate allosteric ligands of other GPCR members, we 
tested for binding of the mGluR5 ligand 3,3`-difluorobenzaldazine to rhodopsin. 
 
 
4.1. MODELING OF STRUCTURE AND BINDING SITE OF 
ALLOSTERIC MODULATORS OF METABOTROPIC 
GLUTAMATE RECEPTORS 
 
 
4.1.1. Structure Prediction of mGluR Subtypes by Homology Modeling 
 
 
As explained above (see chapter 1, pg. 11), in humans, there are a total of eight subtypes 
of mGluRs. These subtypes are divided into three groups based on their pharmacological 
and signaling properties. Because there is no structural information available for the TM 
regions of mGluRs, we generated homology models of mGluRs based on rhodopsin. As a 
first step, an alignment of the seven-TM helices of rat and human mGluR1, mGluR2, 
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mGluR4, mGluR5 and mGluR7 with respect to the TM helices of bovine rhodopsin 
(Protein Data Bank code 1f88 (Palczewski, Kumasaka et al. 2000)) was generated using 
ClustalW (Thompson, Higgins et al. 1994). The alignment was manually validated by 
comparison with the alignment proposed in previous molecular modeling studies of 
mGluRs (Malherbe, Kew et al. 2002; Malherbe, Kratochwil et al. 2003; Malherbe, 
Kratochwil et al. 2003). Sequences were obtained from SWISS-PROT: mGluR1 
(P23385(rat), Q13255(human)), mGluR2 (Q14416), mGluR4 (Q14833), mGluR5 
(P31424(rat), P41594(human)) and mGluR7 (Q14831). The sequence of bovine 
rhodopsin was read directly from the rhodopsin crystal structure (Palczewski, Kumasaka 
et al. 2000).  
Using the generated sequence alignment, three-dimensional models of the 
different mGluR subtypes were built by homology modeling using the MODELLER 
software (Sali, Potterton et al. 1995; Marti-Renom, Stuart et al. 2000). The crystal 
structure of dark, inactive bovine rhodopsin with pdb id 1f88 (Palczewski, Kumasaka et 
al. 2000) and the ANM generated model of the activated state of rhodopsin (Isin, Rader et 
al. 2006) were used as the structural templates for generating the inactive and active 
models of mGluRs, respectively. All models were evaluated using PROCHECK 
(Laskowski, MacArthur et al. 1993), MOLPROBITY (Davis, Murray et al. 2004) and 
WHAT-IF (Vriend 1990).  
 
 
4.1.2. List of Ligand Abbreviations used in this Study 
 
 
CPCCOEt, cyclopropan[b]chromen-1a-carboxylate; DFB, difluorobenzaldazine; 
fenobam, N-(3-chlorophenyl)-N'-(4,5-dihydrol-1-methyl-4-oxo-1-H-imidazole-2-yl)-
155 
CHAPTER 4: TRANSMEMBRANE (ALLOSTERIC) LIGANDS 
 
 
urea; MPEP, 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine; R214127, 1-(3,4-
dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenyl-1-ethanone; Ro01-6128, 
diphenylacetyl-carbamic acid ethyl ester; Ro67-4853, (9H-xanthene-9-carbonyl)-
carbamic acid butyl ester; Ro67-7476, (S)-2-(4-fluoro-phenyl)-1-(toluene-4-sulphonyl)-
pyrrolidine; SIB1757, 6-methyl-2-(phenylazo)-3-pyrindol; SIB1893, ([phenylazo]-3-
pyrindole)-2-methyl-6-(2-phenylethenyl)pyridine; MTEP, 3-[(2-methyl-1,3-thiazol-4-
yl)ethynyl]pyridine; YM298198, (6-([(2-methoxyethyl)amino]methyl)-N-methyl-N-
neopentylthiaolo[3,2-a]benzoimidazole-2-carboxamide; EM-TBPC – 1-ethyl-2-methyl-
6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)- 1,6-dihydro-pyrimidine-5-carbonitrile; 
PTBE, (1-(2-hydroxy-3-propyl-4,4-[4-(2H-tetrazol-5-
yl)phenoxy]butoxyphenyl)ethanone); NPS2390,  2-quinoxaline-carboxamide-N-
adamantan-1-yl; CPPHA, N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)methyl]phenyl)-2-hydroxybenzamide; 5MPEP, 5-methyl-6-(phenylethynyl)-pyridine;  
MPEPy, 3-Methoxy-5-pyridin-2-ylethynylpyridine; PHCCC, N-phenyl-7-
(hydroxylimino)cyclopropa[b]chromen-1a-carboxamide; AMN082, N,N'-
Dibenzhydrylethane-1,2-diamine dihydrochloride. 
 
 
4.1.3. Identification and Analysis of the Ligand Binding Pocket  
 
 
A total of 24 ligands were identified that bind to three mGluR subtypes, the Class I 
mGluRs mGluR1 and mGluR5, the Class II mGluR, mGluR2 and the Class III mGluRs, 
mGluR4 and mGluR7. The structures of the ligands are shown in Figure 4.1. Receptor 
modulation was reported in human and in rat receptors (for references, see Table 4.3) and 
docking was performed with homology models of the mGluR of the respective species. 
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We compared the results from two different docking programs, ArgusLab and AutoDock. 
Of the rank-ordered list of bound ligand conformations, we have chosen in each case the 
ligand conformation where the ligand was most buried and had minimum energy in 
comparison to all other conformations in the same binding pocket. In some cases, ligands 
were predicted not to bind, but this was only the case for one of the two programs. If a 
ligand did not dock in AutoDock, it did dock in ArgusLab, and vice versa, so that for all 
ligands binding could be examined. The unbiased searching of the whole receptor with 
each of the modulators studied revealed that all of the ligands preferentially bound in a 
region similar to that of retinal in rhodopsin (Figure 4.2), in the TM domain including 
helices 3, 5-7 near the interface with the EC domain, especially EC loop 2. The binding 
pocket was similar for all ligands docked to all receptors, and is exemplary described in 
more detail for mGluR5, below. 
In order to compare the residues in contact with different ligands, we analyzed the 
residues predicted to be located within 5Å distance from the docked ligand. The results 
obtained with ArgusLab are listed in Table 4.1 and are shown in Figure 4.3 for mGluR5 
in the active and inactive conformations. To demonstrate the similarities and differences 
between positive and negative modulators, we compared specifically the negative 
modulator MPEP with the positive modulator DFB-3,3`. Analysis of the binding pocket 
residues in the mGluR5 subtype revealed that Trp-784 was in closest proximity to both 
docked ligands and in both conformations, active and inactive. Trp-784 is highly 
conserved in all mGluRs and in class A GPCRs in general. This tryptophan corresponds 
to Trp-265 in rhodopsin. In addition to Trp-784, residues Arg-647, Tyr-658, Leu-743 and 
Phe-787 were found to be part of the binding pocket regardless of the type of modulator 
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and conformation of the receptor. In addition, Cys-732, Val-788, Met-801 and Ser-804 
are found frequently in the binding pockets. In contrast, Ser-657, Leu-785, Cys-781 and 
Thr-734 were found to be unique for the positive modulator DFB-3,3` (Figure 4.3C,D; 
Table 4.1) and were not found in the binding pocket of the negative modulator MPEP. 
Conversely, Arg-726 and Val-805 were unique to the binding pocket of MPEP (Figure 
4.3A,B; Table 4.1). 
 
 
 
 
 
Figure 4.1: The structures of the ligands studied. (A) EM-TBPC (B) Ro67-7476 (C) 
Ro01-6128 (D) Ro67-4853 (E) R214127 (F) triazafluorenone (G) CPCCOEt (H) 
YM298198 (I) MPEP (J) SIB-1757 (K) SIB-1893 (L) Fenobam (M) MTEP (N) DFB-
derivatives. The positions of the fluorine atoms are indicated for DFB-2,2’ and DFB-4,4’. 
DFB-3,3’ is shown. (O) PTEB (P) NPS2390 (Q) CPPHA (R) 5MPEP (S) MPEPy (T) 
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PHCCC (U) AMN082 . For definition of ligand names see abbreviations list above. 
Images were created using ArgusLab software (Thompson ArgusLab 4.0.1). 
 
4.1.4. Validation of the Ligand Binding Pocket with Experimental Data 
 
 
Site-directed mutagenesis to identify residues in mGluR5 that are critical for ligand 
binding have been reported in the literature (Malherbe, Kratochwil et al. 2003; 
Muhlemann, Ward et al. 2006). Table 4.1 summarizes the comparison between these 
experimentally identified ligand binding pocket residues and those predicted by our 
docking studies with ArgusLab. The results for AutoDock are not shown because the 
overlap between the predicted binding pockets and those experimentally determined was 
significantly less. The previous experimental studies with mGluR5 have shown that 
residues Pro-654, Tyr-658, Leu-743, Thr-780, Trp-784, Phe-787, Tyr-791 and Ala-809 
are crucial for binding of the negative modulator MPEP (Malherbe, Kratochwil et al. 
2003). Our prediction of MPEP binding to both active and inactive mGluR5 models 
predicted all of the above residues to be within 5Å of the ligand, except Ala-809, Thr-780 
and Tyr-791 (colored in red in Table 4.1). Additionally there are several residues that are 
predicted to be important for MPEP binding but that have not yet been experimentally 
verified (colored green in Table 4.1). For the binding of the positive modulator DFB-3,3`, 
it was concluded from site-directed mutagenesis that Met-801, Ser-657 and Thr-780 are 
critical for binding and modulatory function (Muhlemann, Ward et al. 2006). There was 
also evidence that Pro-654, Ser-657, Leu-743 and Asn-733 may contribute more weakly 
to DFB-3,3` binding. All of these residues are predicted to be part of the DFB-3,3` 
binding pocket in the inactive model, but Ser-657 and Thr-780 are not present in the 
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active model. In addition, we predict several residues to be part of the binding pockets 
that have not been investigated previously (shown in green in Table 4.1). Thus, the 
comparison of the predicted ligand binding pockets in mGluR5 inactive and active 
models with the available experimental site directed mutagenesis data strongly validates 
our models. In addition, we generated testable hypotheses on important residues 
previously not investigated, and provide evidence that there may be differences in the 
roles of the amino acids in the binding pocket depending on the conformation of the 
receptor. 
 
 
 
 
Figure 4.2: Cartoon representation of the mGluR5 receptor (A) active and (B) 
inactive models docked with negative modulator MPEP. MPEP is colored in dark blue 
and is rendered in spheres.  MPEP refers to 2-methyl-6-(phenylethynyl)-pyridine. Images 
were created using Pymol Software (http://www.pymol.org). 
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Table 4.1: Residues within 5Å distance from the MPEP and DFB-3,3` ligands in active and inactive models of mGluR5 in 
comparison to the experimental results published. Residues colored in red – were not predicted in our docking, green- additional 
residues predicted and black – residues correctly predicted. 
  
MPEP 
Data 
(Malherbe, 
Kratochwil 
et al. 2003) 
mGluR5/MPEP
Active Model 
mGluR5/MPEP 
Inactive Model 
DFB-3,3` 
Data 
(Muhlema
nn, Ward 
et al. 2006) 
mGluR5/DFB-3,3` 
Active Model 
mGluR5/DFB-3,3` 
Inactive Model 
TM3 
Arg-647, 
Pro-654, 
Tyr-658 
Arg-647, Ile-650 
, Tyr-658 
Arg-647, Ile-650, 
Pro-654, Tyr-658 
Arg-647, 
Pro-654,  
Ser-657, 
Tyr-658 
Arg-647, Pro-654, 
Tyr-658 
Arg-647, Pro-654, Ser-
657, Tyr-658 
EC2 Asn-733 
Arg-726, Glu-
727, Ile-731, 
Cys-732, Asn-
733, Asn-736 
Ile-731, Cys-732, 
Asn-733 Asn-733 
Arg-726, Ile-731, 
Cys-732, Asn-733 
Cys-732, Asn-733, Thr-
734,  Asn-736 
TM5 Leu-743 
Leu-737, Leu-
743, Pro-742 Pro-742, Leu-743 Leu-743 
 
Leu-737, Gly-738, 
Leu-743, Gly-744, 
Pro-742 Leu-743  
TM6 
 
Thr-780, 
Trp-784, 
Phe-787, 
Val-788, 
Tyr-791 
Trp-784, Phe-
787,Val-788 Trp-784, Phe-787 
Thr-780, 
Trp-784, 
Phe-787, 
Val-788, 
Tyr-791 
Trp-784, Phe-787, 
Val-788 
Thr-780, Trp-784, Phe-
787, Cys-781, Leu-785, 
Val-788, Tyr-791 
TM7 
Met-801, 
Ala-809 
Met-801, Cys-
802, Ser-804, 
Val-805 
Thr-800, Met-801, 
Cys-802, Ser-804, 
Val-805 Met-801 
Thr-800, Met-801, 
Cys-802, Ser-804  Met-801, Ser-804 
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4.1.5. Analysis of Binding Energies 
 
 
The above in-depth analysis of the mGluR5 binding pocket suggests that there may be significant 
differences between the interactions made by negative and positive modulators with mGluRs 
depending on the conformation state of the receptor. To test if there is a general trend that 
distinguishes the action of positive and negative modulators on the receptors, we quantified the 
overall binding energies for the 24 different ligands with known modulatory nature (positive 
versus negative). Note that the absolute predicted binding energies from computational studies 
are not expected to be meaningful due to current limitations in docking methodology and are 
rarely consistent with experimentally determined affinities. In fact, the actual values are 
generally dependent on the docking program and scoring function used. We therefore only 
compared the relative difference between the binding energies of ligands docked to active vs 
inactive models.  Table 4.3 shows the binding energies of the ligand-protein complexes 
calculated by ArgusLab and AutoDock and Figure 4.4 plots the difference between the 
respective energies for active and inactive conformations. Where the energies for the active and 
inactive conformations were very similar, the docking was repeated three times to estimate the 
error on the predictions (indicated in Table 4.3 and Figure 4.4). In general, the results obtained 
with ArgusLab were less variable between repeated runs than those obtained with AutoDock. A 
total of 9 ligands were experimentally shown to act as positive modulators of specific subtypes, 
14 ligands were negative modulators and one ligand was neutral. In general, the positive 
modulators bound with more favorable energy to the model of the active mGluR conformation 
based on the rhodopsin ANM model (Isin, Rader et al. 2006), while the negative modulators 
bound with more favorable energy to the model of the inactive mGluR conformation based on 
the rhodopsin inactive, dark-state (Palczewski, Kumasaka et al. 2000). The neutral ligand, 
162 
CHAPTER 4: TRANSMEMBRANE (ALLOSTERIC) LIGANDS 
 
 
5MPEP, showed relatively little differences between the energies of the inactive and the active 
models, but was consistently better docked to the active model using both programs. ArgusLab 
predicted 12 of the 14 (86%) negative modulators to bind with more favorable energy to the 
inactive model and 8/9 (89%) positive modulators to the active model, while the numbers for 
AutoDock were less correlated: 10/14 (71%) and 7/9 (78%). There were also more incidences in 
which AutoDock was not able to predict binding for the ligands. Five of the predictions for 
negative modulators and one positive modulator obtained with AutoDock were near or beyond 
the accuracy limit of AutoDock as judged by the error obtained when multiple independent 
docking experiments were carried out. In contrast, in the case of ArgusLab only one difference 
between docking to active and inactive models was within the noise level. We conclude that the 
relative difference between the binding energies of the docked ligands for the active and inactive 
models is highly predictive of the nature of the modulator, positive or negative. Positive 
modulators in most cases appear to prefer the active conformation over the inactive conformation 
and negative modulators vice versa. 
 
4.1.6. Specificity of Ligands to Different mGluR Subtypes 
 
The studies described above suggested that the relative difference between the active and 
inactive protein – ligand complexes is highly predictive of the modulatory nature of allosteric 
ligands. Next, we tested if the docking is able to predict the specificity of binding of allosteric 
modulators to different mGluR subtypes. We docked the allosteric negative modulators 
EMTBPC, MPEP, DFB-4,4` to mGluR subtypes 1 – 8 using AutoDock 3.0 docking software 
(Morris, Goddsell et al. 1998). Table 4.2 shows the predicted binding energies of interaction of 
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the selected ligands with both active and inactive models of the different mGluR models. Those 
ligands that were not predicted to bind to a particular mGluR subtype are represented with a ‘-‘ 
in the table. The comparison of the docking of EM-TBPC to different mGluR subtypes showed 
high specificity to mGluR1 in congruence with experimental data (Malherbe, Kratochwil et al. 
2003). It also is predicted to interact with mGluR subtype 5, albeit with less energy. Apart from 
these two subtypes, EM-TBPC did not bind to other mGluR subtypes. Similarly, MPEP and 
DFB-4,4`, experimentally confirmed mGluR5-specific  negative modulators (Malherbe, 
Kratochwil et al. 2003; O'Brien, Lemaire et al. 2003), were predicted to bind to mGluR5 with the 
highest energy as compared to other receptors. These studies clearly indicate that the interaction 
of the different allosteric modulators to mGluRs is subtype specific.  
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Table 4.2: Comparison of subtype specificity of different allosteric ligands to mGluRs. (I) 
indicates inactive model. (A) indicates active model.A dash (–) indicates that there was no 
binding of the ligand to the corresponding receptor model. 
 
 
mGluR 
Subtype 
EM-TBPC 
(-ve) 
MPEP 
(-ve) 
DFB-4,4` 
(-ve) 
mGluR1 (I) -8.08 -7.31 -7.54 
mGluR1 (A) -8.83 -7.56 -8.29 
mGluR2 (I) - - - 
mGluR2 (A) - -7.57 -7.6 
mGluR3 (I) - -8.33 - 
mGluR3 (A) - -8.21 - 
mGluR4 (I) - - - 
mGluR4 (A) - - -8.08 
mGluR5 (I) -6.69 -8.98 -8.39 
mGluR5 (A) - -8.83 -8.81 
mGluR6 (I) - -6.63 -7.86 
mGluR6 (A) -6.87 -7.94 -5.3 
mGluR7 (I) - -7.4 -6.78 
mGluR7 (A) - -8.58 -8.12 
mGluR8 (I) - -8.09 -5.42 
mGluR8 (A) - -8.27 -7.44 
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Table 4.3: List of predicted binding energies for mGluR subtypes 1, 2, 4, 5 and 7 with different positive and negative modulators shown in 
Figure 4.1.  
 
Binding energies 
ArgusLab 
Binding energies AutoDock 
Class Receptor Modulation Ligand Species 
Active 
model  
[kcal/mol] 
Inactive 
model 
[kcal/mol] 
Active 
model  
[kcal/mol] 
Inactive 
model 
[kcal/mol] 
I mGluR1 Positive 
Ro67-7476 (Knoflach, Mutel 
et al. 2001) Rat -10.02 -9.18 -8.56 -6.88 
      
Ro01-6128 (Knoflach, Mutel 
et al. 2001)  Rat -12.54 -11.06 -7.06 Did not dock 
      
Ro67-4853 (Knoflach, Mutel 
et al. 2001) Rat -11.16 -10.73 -7.53 Did not dock 
   Negative 
R214127 (Lavreysen, Janssen 
et al. 2003) Human -11.53 -12.09 Did not dock -7.34 
    
R214127 (Lavreysen, Janssen 
et al. 2003) Rat -11.09 -11.97 -9.24 -10.11 
      
Triaza-fluorenone (Zheng, 
Bhatia et al. 2005)  Human 
Did not 
dock -7.81 Did not dock -6.08 ± 0.15 
      
CPCCOEt (Lavreysen, 
Janssen et al. 2003)  Rat -8.60 -9.37 -6.8 -7.46 
      
YM298198 (Kohara, Toya et 
al. 2005) Rat -7.98 ± 0.09 -8.04 ± 0.02 -6.41 ± 0.25 -5.8 ± 0.08 
   
NPS2390 (Zheng, Bhatia et 
al. 2005) Rat -9.43 ± 0.01 -10.46 ± 0.17 -8.41 ± 0.00 -8.72 ± 0.03 
   
EM-TBPC (Malherbe, 
Kratochwil et al. 2003; 
Malherbe, Kratochwil et al. 
2003) Rat -8.51 Did not dock -6.68 ± 0.09 -6.82 ± 0.11 
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  mGluR5 Negative 
MPEP (Gasparini, Andres et 
al. 2002) Human -12.83 -13.14 -6.73 -7.77 
   
DFB-4,4` (O'Brien, Lemaire 
et al. 2003; O'Brien, Lemaire 
et al. 2004) Human -10.47 -11.28 -6.83 ± 0.03 -6.86  ± 0.03 
      
SIB-1757 (Gasparini, Andres 
et al. 2002) Human -9.41 -9.74 -6.44 -6.94 
      
SIB-1893 (Gasparini, Andres 
et al. 2002) Human 
-11.71 ± 
0.03 -11.82 ± 0.00 -5.83 ± 0.32 -6.63 ± 0.04 
   
MPEPy (O'Brien, Lemaire et 
al. 2003) Human -7.94 ± 0.00 -7.68 ± 0.11 -6.15 ± 0.03 -6.1 ± 0.02 
      
Fenobam (Porter, Jaeschke et 
al. 2005) Human -7.64 -9.20     
      
MTEP 
 (Anderson, Rao et al. 2002) Rat -9.03 -9.40 -6.2 ± 0.07 -6.21 ± 0.01 
  Neutral 
5MPEP (Rodriguez, Nong et 
al. 2005) Rat -9.52 ± 0.00 -9.41 ± 0.04 -7.04 ± 0.06 -6.66 ± 0.00 
    Positive 
DFB-3,3` (O'Brien, Lemaire 
et al. 2003; O'Brien, Lemaire 
et al. 2004)  Human -11.05 -10.06 -7.06 -6.43 
   
DFB-2,2` (O'Brien, Lemaire 
et al. 2003; O'Brien, Lemaire 
et al. 2004)  Human -10.70 -10.02 -6.87 ± 0.04 -6.81 ± 0.01 
   
CPPHA (O'Brien, Lemaire et 
al. 2004) Human -11.38 -9.96 -6.78 ± 0.41 -7.32 ± 0.37 
II mGluR2 Positive 
PTEB  (Pinkerton, Vernier et 
al. 2004) Human -13.94 -12.16 -5.83 -5.1 
III mGluR4 Positive 
PHCCC (Maj, Bruno et al. 
2003) Human -9.37 ± 0 -9.31 ± 0.003 -8.07 ± 0.08 -6.16 ± 0.09 
 mGluR7 Positive 
AMN082 (Mitsukawa, 
Yamamoto et al. 2005) Human -11.27 -13.11 Did not dock -7.56 
Table 4.3 (Continued) 
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Figure 4.3: Amino acid residues within 5Å of the docked ligands MPEP and DFB-3,3` in 
mGluR5. The active receptor conformation is shown in A,C and the inactive receptor 
conformation is shown in B,D. Models were docked with negative modulator MPEP (A,B) and 
positive modulator DFB-3,3` (C,D). The ligands are colored in blue for the active models and in 
red for the inactive models. Images were created using Pymol Software (http://www.pymol.org). 
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Figure 4.4: Differences in energy between active (ANM based) and inactive (rhodopsin 
crystal-structure based) models of mGluRs. The docked ligands are shown in Figure 1 and 
energies are listed in Table 2. Green bars indicate positive modulators, red bars negative 
modulators and the yellow bar represents a neutral ligand. Where values of 2 are shown, the 
ligand did not dock to the active model, where values of -2 are shown, the ligand did not dock to 
the inactive model. Error bars indicate standard deviation in three docking experiments each for 
the respective active and inactive models. If an error bar is placed at a -2 or 2 bar, the error 
represents the standard deviation of the ligand and model combination where docking was 
observed. A. Results from docking with Autodock software. B. Results from docking with 
ArgusLab software. 
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4.1.7. Discussion 
 
 
At the time when this work was undertaken, the only available three-dimensional structure of 
any GPCR was that of rhodopsin (Palczewski, Kumasaka et al. 2000). Previous approaches to 
docking of ligands to GPCRs have therefore used mostly receptor models based on the rhodopsin 
structure (Kassack, Hogger et al. 2000; Greasley, Fanelli et al. 2001; Lopez-Rodriguez, Murcia 
et al. 2001; Nikiforovich and Marshall 2001; Chambers and Nichols 2002; Deraet, Rihakova et 
al. 2002; Gao, Chen et al. 2002; Johren and Holtje 2002; Mehler, Periole et al. 2002; Stenkamp, 
Filipek et al. 2002; Anzini, Canullo et al. 2003; Becker, Shacham et al. 2003; Berkhout, Blaney 
et al. 2003; Bhave, Nadin et al. 2003; Hulme, Lu et al. 2003; Kim, Gao et al. 2003; Malherbe, 
Kratochwil et al. 2003; Petrel, Kessler et al. 2003; Ruan, Wu et al. 2003; Schulz and Schoneberg 
2003; Shim, Welsh et al. 2003; Trent, Wang et al. 2003; Man, Gilad et al. 2004; Miedlich, Gama 
et al. 2004). The advantages and disadvantages of this approach have been discussed (Archer, 
Maigret et al. 2003; Filipek, Teller et al. 2003) and it was shown that in some cases alternative 
approaches such as the Membstruk modeling approach provides more useful models than those 
based directly on homology to rhodopsin (Vaidehi, Floriano et al. 2002; Floriano, Vaidehi et al. 
2004; Freddolino, Kalani et al. 2004; Hall, Floriano et al. 2004; Trabanino, Hall et al. 2004; 
Hummel, Vaidehi et al. 2005; Floriano, Hall et al. 2006; Peng, Vaidehi et al. 2006; Spijker, 
Vaidehi et al. 2006; Vaidehi, Schlyer et al. 2006). In particular, it was observed recently that 
there is a difference in the structures obtained after short molecular dynamics simulations 
depending on whether receptor agonists or antagonists were docked (Kinsella, Rozas et al. 2005; 
Kinsella, Rozas et al. 2006). These observations indicate that the conformation of the receptor 
will be important for the stability and nature of a receptor-ligand complex. To our knowledge 
however there has been no previous attempt to predicting different conformations of the 
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receptors first, and then docking ligands to these conformations. We describe here the docking of 
ligands to two different conformations of mGluR receptors, active and inactive, using two 
docking programs, ArgusLab and AutoDock. 
AutoDock is a stochastic Grid-based approach that uses the genetic algorithm to sample 
different populations of ligand conformations in their binding to the receptor. Each bound 
conformation is energetically evaluated by a series of energy minimization steps, in which 
unsuccessful docking results are discarded. While the genetic algorithm is a widely used and 
reliable algorithm, it has known limitations (Morris, Goddsell et al. 1998), among the most 
significant is the possibility of the optimization of the ligand conformations getting trapped in 
local minima (Park, Lee et al. 2006). This is also confirmed by our observation that individual 
runs may give different results (Figure 4.4 and Table 4.3). ArgusLab therefore provides both 
algorithms, the stochastic search, analogous to the genetic algorithm provided by AutoDock, as 
well as an exhaustive search method based on identification of complementary shapes of the 
ligand and the receptor, referred to as “ShapeDock” or “ArgusDock”. When using ArgusLab 
with the ArgusDock algorithm, 12 of the 14 (86%) negative modulators were predicted to bind 
with more favorable energy to the inactive model. Due to the high reproducibility between 
different runs, the error margins are small and in all cases but one the errors were significantly 
smaller than the differences observed between docking to active and inactive models. Similarly, 
8/9 (89%) positive modulators bound significantly more favorably to the active model with 
ArgusLab. The results obtained for AutoDock were less correlated, as expected: 10/14 (71%) 
and 7/9 (78%) bound the predicted conformation more favorably. We consider the AutoDock 
results less reliable than those obtained with ArgusLab for several reasons. In six of the 
predictions, where the differences between docking to active and inactive models were small, 
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docking energy differences were close to or smaller than the noise level. There were also more 
incidences in which AutoDock was not able to predict binding for the ligands at all. Finally, the 
ligand binding pockets predicted by AutoDock showed less agreement with the experiments than 
ArgusLab. However, one should keep in mind that some ligand/binding site types are 
problematic because the shape does not match if the starting ligand conformation is not correct 
and/or if the scoring function is not appropriate. This could be the case in the prediction of 
AMN082, where both algorithms incorrectly predicted this ligand to be a negative modulator, 
because the ligand did not dock at all to the inactive conformation. Such difficulties may also 
give rise to larger errors when docking one ligand as compared to another. For example, the 
docking energies of ligand YM298198 were associated with a larger error when using both 
algorithms. If we were to equally weigh predictions made by ArgusLab and AutoDock, we 
would still have agreement between the two methods and strong preferences (i.e. strong 
differences in both AutoDock and ArgusLab) in 8 out of 14 cases (57%), where the negative 
modulators bound the inactive conformations with significant preference using both docking 
programs, and 6 out of 9 cases (67%), supporting the hypothesis. 
In addition to comparing predicted ligand binding energies, we also investigated the 
details of the interactions between the ligand binding pockets and the ligands for mGluR5. Of the 
experimentally known ligand binding residues of MPEP, our prediction identified all residues, 
except Ala-809, Thr-780 and Tyr-791 (colored in red in Table 4.1). These three residues are 
more than 6.2 Å away from any atom within the ligand, and are not simply missed due to a too 
short cut-off distance in the definition of ligand binding residues. Furthermore, Ala-809 and Thr-
780 are facing the outside of the helical bundle, and it is possible that the experimental effects 
reported might have been secondary effects. In the case of DFB-3,3` all known ligand binding 
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residues are also predicted. For both ligands on the other hand, we predict a number of residues 
to be important for ligand binding that have not been tested experimentally. Finally, we show 
that while there are several residues in the ligand binding pocket that are shared between active 
and inactive conformations, there are also residues that bind ligand only in one conformation, 
and that are specific for positive versus negative modulators. Thus, our models provide useful, 
experimentally testable hypotheses. 
The dependence of the properties of ligand binding on receptor conformation has 
important functional implications. Recently, it was shown for rhodopsin that the dark-state 
inactive structure already contains the information needed to form the light-activated structure 
(Isin, Rader et al. 2006). This supports the notion that all-trans retinal in rhodopsin stabilizes a 
conformation that is already partially accessible to the 11-cis retinal bound dark, inactive state of 
the receptor. Translated to other GPCRs, this suggests that receptors may partially form activated 
conformations and that agonists could stabilize such conformations, while inverse agonists 
would destabilize such conformations. In mGluRs, the situation is slightly different from other 
GPCRs because their ligand binding domain is located in an EC domain added to the conserved 
GPCR seven-TM helical scaffold. In this case, ligands also bind to the TM/EC domain interface 
but here they act as modulators for ligand binding in the EC domain. However, it was shown that 
in the absence of the EC domain, positive and negative modulators act as agonists and inverse 
agonists, respectively. Thus, the findings reported here for mGluRs are likely to have functional 
implications of the GPCR family in general, implying that agonists and antagonists are likely to 
prefer the active and inactive conformation of GPCRs, respectively.  
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4.1.8. Conclusions 
 
 
Here we proposed the idea that allosteric ligands can be docked to inactive and active 
conformational models of mGluRs based on rhodopsin structural models of inactive and active 
conformations, respectively. We found that the relative difference in binding energy between the 
two conformations is highly predictive of whether the ligand is a positive or a negative 
modulator. A positive modulator will bind more favorably to the active conformation, while the 
negative modulator will bind more favorably to the inactive conformation. Furthermore, we 
identified similarities and differences in the interactions made between ligand and receptor 
depending on the nature of the modulator and the conformation of the receptor. The findings are 
likely to have general utility in predicting functional classification of ligands, such as 
classification as agonists or antagonists. 
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4.2. IDENTIFICATION OF LIGAND(S) THAT BIND(S) TO RHODOPSIN 
IN THE TM DOMAIN, APART FROM RETINAL 
 
 
4.2.1. Evidence for 3,3`-Difluorobenzaldazine Interaction with Rhodopsin 
 
 
The high similarity between the mGluR allosteric ligand binding pocket and the retinal binding 
pocket in rhodopsin prompted us to investigate if rhodopsin may be able to bind mGluR ligands. 
We tested 3,3`-Difluorobenzaldazine (DFB-3,3`), a positive modulator of mGluR5. Because of 
the presence of fluorine atoms in this ligand, we used 19F NMR spectroscopy for this purpose. 
One-dimensional 19F NMR spectra recorded in the absence and presence of DFB-3,3` is shown 
in Figure 4.5. (In this experiment, ten other in-house synthesized fluorinated ligands were also 
tested alongside for putative binding).  
We investigated light-activated rhodopsin based on the assumption that the retinal would 
have to leave the binding pocket before DFB-3,3` could bind. Addition of 50μM DFB-3,3` to 
5mg of activated rhodopsin sample gave rise to a broad peak at -109.8 ppm (Figure 4.5A red 
trace) as compared to a sharp peak at -112.5 ppm in the absence of rhodopsin (Figure 4.5B red 
trace). Further, DFB-3,3` peak in the presence of rhodopsin (Figure 4.5A red trace) is downfield 
shifted by Δ+2.7 ppm and the signal is decreased in intensity. There was no indication for the 
presence of a free peak for DFB-3,3` in the presence of rhodopsin. These results suggest the 
presence of an interaction between DFB-3,3` and rhodopsin supporting the idea that the TM 
binding pocket might be in part structurally conserved across such diverse GPCRs as rhodopsin 
and mGluR5. 
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4.2.2. Docking Studies of 3,3`-Difluorobenzaldazine to Rhodopsin 
 
 
To investigate if DFB-3,3` would preferentially bind to the TM domain of rhodopsin, rather than 
the CP domain as was the case for Ce6 and C3G described in Chapter3, we docked DFB-3,3` to 
the inactive dark-state crystal structure ( PDB id: 1F88 (Palczewski, Kumasaka et al. 2000) ) and 
ANM generated activated model of rhodopsin (Isin, Rader et al. 2006). The top-scored 
conformations in both cases docked in a similar position (Figure 4.6), between helices III, V-VII 
in the TM domain. No pose in the CP domain was observed. Shown in Table 4.3 are the residues 
in mGluR5 that are critical for DFB-3,3` ligand binding identified with site-directed mutagenesis 
(Muhlemann, Ward et al. 2006) along with the predicted ligand pocket residues that are within 
5Å from DFB-3,3` in rhodopsin.  For the binding of DFB-3,3` to mGluR5 site-directed 
mutagenesis indicates that Met-801, Ser-657 and Thr-780 are critical for binding and modulatory 
function (Muhlemann, Ward et al. 2006). There was also evidence that Pro-654, Ser-657, Leu-
743 and Asn-733 may contribute to DFB-3,3` binding, albeit with less preference as compared to 
the residues described above. All the corresponding residues are predicted to be part of the 
analogous DFB-3,3` binding pocket in the dark state of rhodopsin, except for Ser-657 and Leu-
743. In the case of the ANM generated active state, the corresponding residues for Pro-654, Ser-
657, Leu-743, and Thr-780 are not predicted. Apart from this, several residues are predicted to 
be part of the binding pockets rhodopsin (Table 4.4, uncolored residues). In particular, Lys-296, 
an important residue involved in interacting through a Schiff base with 11-cis retinal is also 
predicted to be in the DFB binding pocket residues of both, the dark and activated models of 
rhodopsin. An aromatic cluster of residues on TM6 helix was shown to play an important role in 
the binding of ligands to mGluRs (Malherbe, Knoflach et al. 2001; Malherbe, Kratochwil et al. 
2003; Malherbe, Kratochwil et al. 2003). Such a cluster is also observed in the dark state 
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rhodopsin binding pocket. Phe-261, Trp-265, and Tyr-268 constitute the cluster in rhodopsin. 
Thus, the comparison of the predicted ligand binding pockets in the rhodopsin dark state crystal 
structure (Palczewski, Kumasaka et al. 2000) and ANM active models (Isin, Rader et al. 2006) 
with the available experimental site directed mutagenesis data carried out for mGluR5 
(Muhlemann, Ward et al. 2006) provide preliminary evidence that rhodopsin can accommodate 
the mGluR5 ligand, DFB-3,3`, in its retinal binding pocket. The predicted binding energies of 
interaction of DFB-3,3` to the rhodopsin dark-state and the Meta II activated ANM model 
without their retinal ligands present were almost identical with -6.81 and -6.88 kcal/mol, 
respectively  
Next, we investigated the overlap between the 11-cis and all-trans binding pockets with 
the DFB-3,3` binding pockets of rhodopsin  dark (Palczewski, Kumasaka et al. 2000) and ANM  
(Isin, Rader et al. 2006) generated active states, respectively (Table 4.5). Except for 4 out of 23 
residues (colored in green; Table 4.5), all those residues that were part of the 11-cis binding 
pocket (within 5Å) of rhodopsin dark state were predicted for DFB-3,3` binding to dark state 
rhodopsin (Palczewski, Kumasaka et al. 2000).  However, 8 out of 29 residues were not 
predicted to be part of the DFB-3,3` binding pocket of rhodopsin in comparison to the 5Å 
residues from all-trans retinal in the ANM generated Meta II state. In summary, the docking 
results strongly suggests that rhodopsin, a class A GPCR can accommodate DFB-3,3`, a positive 
modulator  of mGluR, a class C GPCR member in its endogenous retinal binding pocket. 
177 
CHAPTER 4: TRANSMEMBRANE (ALLOSTERIC) LIGANDS 
 
 
 
 
 
 
 
 
Figure 4.5: 19F NMR spectra of 3,3`-difluorobenzaldazine. (A) Overlay of the rhodopsin 
ligand screening sample with and without DFB-3,3`. (B) Overlay of the ligand screening mixture 
in 20mM sodium phosphate buffer, 5%DM and 10%D2O in the presence and absence of 50μM 
DFB-3,3`. The DFB-3,3` peak position is marked as ‘*’. 
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Figure 4.6: Location of 3,3`-difluorobenzaldazine binding to rhodopsin and mGluR5. 
Cartoon representation of the rhodopsin (A) dark state crystal structure (Palczewski, Kumasaka 
et al. 2000), (B) ANM model of the activated state of rhodopsin (Isin, Rader et al. 2006), (C) 
mGluR6 inactive and (D) mGluR6 active models docked with a positive modulator DFB-3,3`. 
Ligand docked is colored in red and is rendered in spheres. DFB-3,3` refers to 3,3`- Di-Fluoro-
Benzaldazine. Images were created using Pymol Software (http://www.pymol.org) 
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Table 4.4: Residues within 5Å distance from the 3,3`-difluorobenzaldazine ligand in the 
rhodopsin dark-state crystal and the ANM structures. Residues that overlap between the 
mGluR5 experimental mutational data and the rhodopsin ANM activated and dark state 
structures are highlighted in bold and colored in red. Residues colored in blue and highlighted in 
bold represent the corresponding positions in rhodopsin for the red highlighted residues in 
mGluR5. 
 
 
 
DFB-3,3` Data 
(Muhlemann, 
Ward et al. 2006) 
Rhodopsin ANM  
activated Model 
(Isin, Rader et al. 2006) 
Rhodopsin Dark state 
Crystal structure 
(Palczewski, Kumasaka et 
al. 2000) 
TM3 
Arg-647, Pro-654,  
Ser-657, Tyr-658 
Glu-113, Gly-114, Ala-117, 
Thr-118 
Glu-113, Gly-114, Ala-117, 
Thr-118, Gly-121, Glu-122, 
Leu-125 
EC2 Asn-733 
Pro-171, Lue-172, Arg-177, 
Tyr-178, Glu-181, Ser-186, 
Cys-187, Gly-188, Ile-189, 
Tyr-191 
Tyr-178, Glu-181, Ser-186, 
Cys-187, Gly-188, Ile-189 
TM5 Leu-743 Phe-203, Met-207 His-211, Phe-212 
TM6 
Thr-780, Trp-784, 
Phe-787, Val-788, 
Tyr-791 Trp-265, Tyr-268 Phe-261, Trp-265, Tyr-268
TM7 Met-801 Ala-292, Ala-295,  Lys-296 Ala-292, Lys-296 
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Table 4.5: Comparison of 3,3`-difluorobenzaldazine with retinal binding pockets in 
rhodopsin. Residues that overlap with the 11-cis and all-trans binding pocket are highlighted in 
bold and colored in green and blue, respectively. The residues that are unique to DFB-3,3` are 
colored in red and highlighted in bold. 
 
 
 
Rhodopsin dark state 
crystal structure 
(Palczewski, Kumasaka et al. 
2000) 
Rhodopsin ANM 
 activated model 
(Isin, Rader et al. 2006) 
  DFB pocket 
11-cis retinal 
pocket DFB pocket 
 
All-trans pocket 
TM3 
Glu-113, Gly-
114, Ala-117, 
Thr-118, Gly-
121, Glu-122, 
Leu-125 
Glu-113, Gly-
114, Ala-117, 
Thr-118, Gly-
121, Glu-122, 
Leu-125 
Glu-113, Gly-114, 
Ala-117, Thr-118 
Glu-113, Gly-114, 
Phe-115, Ala-117, 
Thr-118, Leu-119, 
Glu-122 
EC2 
Tyr-178, Glu-
181, Ser-186, 
Cys-187, Gly-
188, Ile-189 
Glu-181, Ser-186, 
Cys-187, Gly-
188, Ile-189 
Pro-171, Lue-172, 
Arg-177, Tyr-178, 
Glu-181, Ser-186, 
Cys-187, Gly-188, 
Ile-189, Tyr-191 
Pro-171, Lue-172,  
Val-173, Ser-176, 
Arg-177, Tyr-178, 
Ile-179, Glu-181, 
Ser-186, Cys-187, 
Gly-188, Ile-189, 
Asp-190,Tyr-191 
TM5 His-211, Phe-212 
Met-207, Phe-
208, His-211, 
Phe-212 Phe-203, Met-207 Phe-203, Met-207 
TM6 
Phe-261, Trp-
265, Tyr-268 
Phe-261, Trp-
265, Tyr-268, 
Ala-269 Trp-265, Tyr-268 Trp-265, Tyr-268 
TM7 
Ala-292, Lys-296 Ala-292, Phe-
293,Lys-296 
Ala-292, Ala-295,  
Lys-296 
Ala-292, Phe293, 
Ala-295,  Lys-296 
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4.2.3. Effects of DFB-3,3` Binding on Rhodopsin Regeneration 
 
 
The molecular modeling studies described above indicated that the DFB-3,3` binding pocket 
highly overlaps with that of the 11-cis and all-trans binding pockets in rhodopsin. This suggests 
the possibility that DFB-3,3` and 11-cis retinal might compete for the same binding pocket in 
rhodopsin. To test this, we investigated the total amount of rhodopsin that can be regenerated in 
the absence and presence of DFB-3,3`. The increase in 500nm absorbance by addition of 11-cis 
retinal 1.5 hours after light activation was followed using UV/Visible spectroscopy (Figure 4.7). 
The change in absorbance at 500nm of 0.5μM rhodopsin upon addition of 0.5μM 11-cis retinal 
1.5 hours after illumination (a state equivalent to opsin, ligand free rhodopsin) in the absence 
(black trace) and presence of 0.5μM (red trace) and 2.5μM DFB-3,3` (blue trace) is shown in 
Figure 4.7B. Shown in Table 4.5 is the total amount of rhodopsin regenerated in the absence and 
presence of various concentration of DFB-3,3`. The total amount of rhodopsin regenerated after 
1.5 hours of illumination was compared to the initial amount added (Table 4.6). In the absence of 
DFB-3,3`, a total of ~59% of rhodopsin could be regenerated. However, in the presence of 
0.5μM DFB-3,3` corresponding to a 1:1 ratio of DFB-3,3` to rhodopsin, the total amount of 
rhodopsin regenerated was decreased by 15.3% to a total of 43.5% efficiency as compared to 
rhodopsin alone (Figure 4.7B). Additionally, in the presence of a five-fold excess over 
rhodopsin, a decrease of 31.3% to a total of 27.5% regenerated material was observed. Thus, we 
find that the addition of DFB-3,3` decreases the extent of rhodopsin regeneration in a 
concentration dependent manner.  
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Figure 4.7: Comparison of rhodopsin regeneration in the absence and presence of various 
concentration of DFB-3,3`. (A). UV absorbance spectra of 0.5μM rhodopsin in the dark (black), 
immediately after light activation (red), after 11-cis regeneration (blue) and after reilluminating 
the regenerated rhodopsin (green). (B) the difference spectra of regenerated minus reilluminated 
rhodopsin, in the absence (black), and in the presence of 0.5μM (red) and 2.5μM (blue) DFB-
3,3`. 
 
 
4.2.4. Discussion and Conclusions 
 
 
The studies described in this chapter indicate that the GPCR TM binding pocket may be 
structurally conserved across GPCRs. Specifically for the comparison between mGluRs and 
rhodopsin, these findings indicate that what is an orthosteric binding pocket in one GPCR can 
become an allosteric ligand binding pocket in another GPCR. While the TM ligand binding 
pocket in mGluRs is the site for allosteric ligands, most other members of the GPCR family are 
shown to bind to endogenous ligands in this pocket. One such example is rhodopsin, a class A 
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GPCR. Rhodopsin binds to 11-cis retinal, the endogenous ligand in the TM domain. Prior to this 
thesis, there were no known ligands apart from different retinal isomers that can bind to 
rhodopsin. The studies presented in Chapter 3 of this thesis (Ce6 and C3G) and this Chapter, 
DFB-3,3`, provide the first evidence for other ligands having affinity for rhodopsin.  The 
evidence for DFB-3,3` binding is as follows. The 19F chemical shift of DFB-3,3` was shifted by 
2.7ppm and a decrease in intensity of the peak was observed upon addition of DFB-3,3` to light-
activated rhodopsin, suggesting that DFB-3,3` indeed binds to rhodopsin. While the novel 
ligands identified in Chapter 3 were found to bind in the cytoplasmic domain, we propose that 
DFB-3,3` binds to the TM domain. Docking studies indicated that DFB-3,3` binds in the TM 
region and occupies the 11-cis binding pocket. The comparison 5Å residues indicated that the 
DFB-3,3` binding pocket highly overlaps with that of 11-cis and all-trans binding pockets. A 
total of 19/23 were similar between DFB-3,3` and 11-cis retinal binding pocket in the dark state 
rhodopsin. Further, a total of 21/29 residues were predicted to be part of DFB-3,3` as compared 
to all-trans retinal pocket. Such a high overlap between retinal and DFB-3,3` binding pockets 
prompts for an competition between these ligands for the same binding pocket. 
 To test if DFB-3,3` is able to compete with 11-cis retinal, we measured regeneration of 
rhodopsin with and without DFB-3,3` by monitoring the changes in 500nm peak using UV/Vis 
absorbance spectroscopy.  These studies showed that the total amount of rhodopsin that can be 
regenerated 1.5 hours post illumination is decreased upon addition of DFB-3,3` in a 
concentration dependent manner. While the interaction affinity of DFB-3,3` to rhodopsin 
remains to be determined, these studies provide the first evidence for the novel observation that 
rhodopsin binds to DFB-3,3`, a positive modulator of mGluR5 in competition to 11-cis retinal. 
These studies support the idea that the TM ligand binding pocket in GPCRs might be structurally 
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conserved. The affinities of interaction are expected to be specific for receptor type. Thus, even 
though rhodopsin can accommodate DFB-3,3` in its retinal binding pocket, it has a higher 
affinity for 11-cis retinal. Thus, while GPCRs may have diverged evolutionarily to bind to 
specific endogenous ligand with higher affinity, at least some GPCRs appear to have retained the 
conformational flexibility to accommodate other GPCR ligands, which bind other receptors with 
higher affinity.  
 
 
Table 4.6: Effects of DFB-3,3` on regeneration of rhodopsin.  The total amount of rhodopsin 
regenerated after 1.5 hours of illumination was compared to the initial amount added.  
 
DFB  
Rho 
Conc 11-cis 
Regneration 
in (%) after 
1.5 hours 
Normalized
 (in %) 
decrease in 
regeneration 
 (in %) 
0 
 
0.5mM 
 
0.5mM 58.8 100 0 
0.5mM 
 
0.5mM 
 
0.5mM 43.5 73.9 26.02 
2.5mM 
 
0.5mM 
 
0.5mM 27.5 46.7 53.23 
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SUMMARY 
 
 
The results described in Chapters 3 and 4 suggest that rhodopsin has the conformational 
flexibility to accommodate accessory ligands at the CP domain as well as ligands from 
other GPCR members in the TM domain, respectively.  Because the endogenous ligand 
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binding domains in some class A GPCRs are the EC domains, we suspected that 
rhodopsin may also bind to ligands in the EC domain. One such class of receptors are the 
chemokine receptors. While we do not expect chemokines to bind to rhodopsin with as 
high an affinity as they would bind to their cognate chemokine receptors, evidence for 
weak binding would still provide a proof-of-principle for a partially conserved binding 
pocket. A recently developed computational approach to predict protein-protein 
interactions (Qi, Bar-Joseph et al. 2006) was applied to predict human membrane 
receptor-protein interactions for rhodopsin.  Amongst the potential binding partners were 
several members of the chemokine family, which are all protein ligands that interact with 
chemokine receptors at EC sites of the respective receptors.  Analysis of the docking of 
rhodopsin with CXCL11 indicated an interaction at the EC domain, similar to the 
chemokine-chemokine receptor model of ligand binding.  
The following experimental studies confirm the presence of an interaction 
between rhodopsin and CXCL11. First, the migration of B-cells in response to chemokine 
gradients showed that rhodopsin inhibits CXCL11-mediated chemotaxis. Furthermore, 
activation of Gt by rhodopsin was inhibited in the presence of CXCL11, indicating an 
antagonist-like effect. These findings provide a proof-of-principle that rhodopsin has an 
intrinsic ability to interact with chemokines, presumably in direct analogy to the 
interaction between chemokines and their cognate receptors. Further studies are needed to 
confirm the binding site and determine the affinity for the CXCL11-rhodopsin complex.  
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SIGNIFICANCE 
 
 
The studies presented in this chapter provide preliminary evidence for an EC allosteric 
ligand binding pocket in rhodopsin. The results obtained suggest that rhodopsin has the 
conformational flexibility to accommodate ligands at the EC domain similar to other 
class A GPCRs.  The fact that the EC domain in class A GPCRs can switch roles between 
a endogenous and allosteric binding pocket between different class A GPCR members is 
intriguing and suggests that the overall structure and the conformational sub-states 
available for different GPCRs may be conserved even at the EC domain. Moreover, as 
the EC domain is structurally coupled to the TM domain in rhodopsin, and mutations or 
alterations in this region often lead to malfunctions in rhodopsin, the allosteric 
modulators that bind specifically at the EC domain could be beneficial to rescue disease 
states that involve the EC domain. 
 
 
INTRODUCTION 
 
 
In our framework that integrates structural coupling between the three domains,  the CP, 
TM, and EC domains, and allosteric or orthosteric ligand binding (see Chapter 1), we 
proposed that in principle any GPCR can bind ligands in any of these three domains. 
Prior to this thesis, no CP ligands were known for any GPCR. We showed for rhodopsin 
that there are such ligands. Thus, we now know that rhodopsin can accommodate ligands 
in its TM domain (its orthosteric ligand pocket) and in the CP domain, which is therefore 
an allosteric ligand binding pocket. In other GPCRs, it is known that endogenous ligands 
bind in the EC domain. Furthermore, the analysis of high connectivity residues 
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(Christopher J R Illingworth 2008) described in Chapter 3, pg. 143, suggested that in 
rhodopsin in addition to the CP domain, there may also be potential interaction sites in 
the EC domain of rhodopsin. Finally, a recently developed computational approach to 
predict protein-protein interactions using the random forest classifier integrating diverse 
biological features (Qi, Bar-Joseph et al. 2006) was applied to predict human membrane 
receptor-protein interactions.  Amongst the potential binding partners for the dim-light 
photoreceptor rhodopsin, the prototypic member of the GPCR family, were several 
members of the chemokine family of ligands. All these independent lines of 
circumstantial evidences suggest that EC ligands such as chemokines may bind 
rhodopsin. This Chapter describes our preliminary results in supporting this hypothesis. 
Chemokines, by definition, are chemotactic cytokines.  These proteins exert their 
function by interacting with membrane proteins that belong to class A GPCRs – the 
chemokine receptors.  Chemokines have shown to play a major role in guiding migration 
of cells, immune system responses, and HIV infection (Rottman 1999; Scotton, Wilson et 
al. 2001; Le, Cui et al. 2003; Manzo, Caporali et al. 2003; Us 2003; Cartier, Hartley et al. 
2005; Yoshie 2005; Suresh and Wanchu 2006; Prado, Suetomi et al. 2007).  However, an 
interaction with rhodopsin has not been anticipated or observed previously.  Since the 
results presented in this thesis (Chapters 3 & 4) imply that GPCRs including rhodopsin 
may have the conformational flexibility to accommodate ligands other than their 
endogenous ligands, here 11-cis retinal, we tested if chemokines can bind rhodopsin.  We 
experimentally provide evidence for a physical interaction between the chemokine 
CXCL11 and rhodopsin.  For this we investigated whether the respective functions of 
rhodopsin and chemokine receptors can be altered in the presence of the predicted 
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binding partner.  In addition to this, we also performed docking studies to predict the site 
of interaction on rhodopsin.  
 
 
5.1. RHODOPSIN – CHEMOKINE LIGAND INTERACTION 
 
 
5.1.1. Effect of Rhodopsin Interaction with CXCL11 on Chemotaxis Assay in B-
Cells 
 
 
To validate the predicted interaction between rhodopsin and CXCL11, as a first step we 
measured binding of CXCL11 to rhodopsin indirectly through a chemotaxis assay 
commonly used to validate chemokine and chemokine receptor function.  The assay is 
such that B-cells expressing chemokine receptors specific to certain chemokines are used 
as migratory markers in response to certain chemokine.  In this assay, B-cells and 
chemokine are initially present in two individual chambers separated by a semi-
permeable membrane.  The B-cells are attracted to the chemokine gradient and move 
towards it by squeezing through the membrane into the chamber with chemokine.  Using 
a hemacytometer, cells present in the chemokine-containing chamber are counted and are 
presumed to migrate in response to the chemokine where chambers containing a negative 
control are used to correct for random or nonspecific migration.  The results for the 
chemokine ligands CXCL11 and CCL22 are shown in Figure 5.1.  In the absence of 
rhodopsin, B-cells expressing CXCR3, the receptor for CXCL11, migrated toward 
CXCL11 (final concentration of 100nM) as hypothesized.  But, in the presence of 75 μg 
of rhodopsin in asolectin lipid vesicles, corresponding to a molar ratio of 30:1 
rhodopsin:chemokine, a drastic decrease in the number of cells that migrated was 
observed in the rhodopsin containing chambers as compared to those without rhodopsin.  
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Some inhibition, but significantly less than in the presence of rhodopsin, was observed 
when asolectin lipid vesicles without rhodopsin were used as a control (Figure 5.1 B).  
Less inhibition of chemotaxis of CCR4-expressing cells was observed with CCL22 in 
identical experimental conditions.  These results suggest that the depletion of the 
chemoattractant CXCL11 by interaction with rhodopsin leads to the abolition of 
chemotaxis of the CXCR3 expressing B-cells.  
 
 
 
 
 
Figure 5.1:  Rhodopsin interaction with chemokines CXCL11 and CCL22. 
Chemotaxis of B-cells expressing CXCR3 (A) or CCR4 (B) towards chemokines 
CXCL11 (A) or CCL22 (B). 75 µg of rhodopsin was reconstituted in asolectin vesicles 
and kept in the dark prior to the assay.  Illuminated samples were used as a control and 
showed no difference as compared to the dark samples (data not shown).  A = asolectin; n 
= 3.    
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5.1.2. Effect of CXCL11 Interaction with Rhodopsin on G Protein, Gt Activation 
 
 
 
 
 
 
 Figure 5.2:  Effect of CXCL11 in G protein activation by rhodopsin.  (A). G protein 
activation was measured by fluorescence spectroscopy as described (Jastrzebska, Fotiadis 
et al. 2006).  (B) Normalized percentage of Gt activation in the absence and presence of 
CXCL11. 
 
 
As a next step we also monitored the effects of CXCL11 interaction with 
rhodopsin on rhodopsin function.  For this, we measured Gt activation by rhodopsin using 
fluorescence spectroscopy (Jastrzebska, Fotiadis et al. 2006).  Shown in Figure 5.2A are 
the fluorescence traces of Gt activation upon addition of light activated rhodopsin in the 
absence and presence of 20nM and 100nM CXCL11.  The initial activation rate of Gt in 
the absence of CXCL11 was 1.6e-3 seconds. In contrast, in the presence of 100nM 
CXCL11, the initial rate of activation of Gt was much slower as compared to rhodopsin 
alone.  A decrease of ~3.5 folds in the initial activation rate was observed.  In addition to 
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this, a greater than 40% decrease in total Gt activation was observed with 100-fold molar 
excess of CXCL11 over rhodopsin (Figure 5.2B).  
 
 
5.1.3.  Protein-Protein Docking of Rhodopsin and Chemokine Ligand, CXCL11 
 
 
To determine whether the chemokine ligand binding site in rhodopsin resembles that of 
chemokine receptors, we used the ClusPro docking software (Comeau, Gatchell et al. 
2004) for rigid docking of the NMR structures of CXCL11 (Booth, Clark-Lewis et al. 
2004) with the X-ray crystal structure of rhodopsin (Okada, Fujiyoshi et al. 2002) and a 
CXCR3 homology model based on the dark state of rhodopsin using Modeller software 
(Sali, Potterton et al. 1995).  Docking of rhodopsin (pdb id: 1L9H:A) and chemokine 
receptor CXCR3 with chemokine ligand – CXCL11 (PDB id: 1RJT) was performed 
using the DOT algorithm supplied by ClusPro docking software (Comeau, Gatchell et al. 
2004; Camacho and Zhang 2005).  In the case of CXCR3, CXCL11 was found to interact 
at the EC domain, as expected (Campanella, Lee et al. 2003; Colvin, Campanella et al. 
2006).  The position of the top scoring interaction along with the orientation is shown in 
Figure 5.3.  Further, this docked conformation was submitted to FastContact analysis 
(Camacho and Zhang 2005) in order to determine the residues which are located at the 
interface formed by the two proteins in the docked complex.  The stabilizing interactions 
between the CXCR3 and CXCL11 that contribute to the electrostatic and free energy 
interactions are listed in Table 5.1.  Many of these residues were found to overlap with 
the experimentally determined interface residues (Campanella, Lee et al. 2003; Colvin, 
Campanella et al. 2006), further validating the obtained docked conformation. 
Specifically, residues Arg-8, Lys-46 and Lys-47 of CXCL11were shown to play a major 
193 
CHAPTER 5: EXTRACELLULAR (ALLOSTERIC) LIGANDS 
 
194 
role in the interaction with CXCR3, where all of these residues are predicted to be part of 
the binding site (Table 5.1, colored red).  In addition to this, residues Tyr-27, Tyr-29, 
Asp-112, Arg-212, Asp278 and Glu-293 along with the N-terminal residues 1 - 18 in 
CXCR3 were shown to interact with CXCL11 (Table 5.1, colored blue).  These results 
strongly suggest that the predicted interface highly is consistent with the experimental 
results. 
 In the case of rhodopsin, all the top related orientations of CXCL11 were 
observed at the EC domain of rhodopsin, covering the top of helices 4 and 5 (Figure 5.4).  
The FastContact analysis (Camacho and Zhang 2005) of this conformation has shown a 
similar kind of interaction on CXCL11, with residues Arg-8, Lys-46 and Glu-47 (see 
above).  The comparison of the stabilizing residues on rhodopsin with that of CXCR3 
showed high overlap.  Like in CXCR3, the contribution from N-terminal residues of 
CXCL11 was also observed to be important in the interaction with rhodopsin.  In addition 
to this, in the case of CXCR3, residues from EC loop 1 and 2 were also shown to 
contribute to the interaction.  In striking similarity to CXCR3, the analysis of the 
contributing residues from rhodopsin clearly showed strong involvement of EC loop 2; 
two residues were found in the case of CXCR3 and the rhodopsin interaction with 
CXCL11 showed 5 residues from EC loop 2.  These studies support the hypothesis that 
the proposed interaction of rhodopsin with CXCL11 would be structurally similar to that 
of CXCR3.  EC loop 2 in rhodopsin is shown to play a major role in locking the receptor 
in an inactive state.  The CXCL11 interaction with rhodopsin is postulated to involve 
most of the accessible residues on EC loop 2, this may provide further evidence as to why 
the inhibition of Gt activation was observed.  
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Table 5.1:  Residues in CXCR3 and CXCL11 contributing for the stabilizing electrostatic and free energy contacts.  The 
residues at the interface of CXCR3 and CXCL11 were previously determined by mutagenesis studies (Campanella, Lee et al. 2003; 
Colvin, Campanella et al. 2006) are colored in blue for CXCR3 and in red for CXCL11. 
Electrostatic 
Contacts 
Free Energy 
Contacts 
Electrostatic 
Contacts 
Free Energy  
Contacts 
CXCR3  CXCL11 CXCR3  CXCL11 Rhodopsin CXCL11 Rhodopsin CXCL11 
ASP – 28 LYS - 5 ASP - 28 LYS - 5 GLU – 5 LYS - 46 GLU - 5 LYS – 46 
GLU – 33 ARG - 8 PRO - 42 PHE - 1 GLU – 201 LYS – 5 GLU - 196 CYS – 11 
PRO – 42 PHE - 1 GLU - 33 ARG - 8 GLU – 196 GLY - 13 GLU - 201 LYS – 5 
GLU – 15 LYS - 46 GLU - 15 LYS - 46 GLU – 196 ARG - 52 GLU - 196 GLY – 13 
GLN - 209 GLU - 47 VAL – 5 ILE - 29 GLU – 196 ILE – 12 GLU - 196 ARG – 52 
ASP – 35 ARG - 8 ASP - 46 PHE - 1 GLU – 197 SER - 33 GLU - 196 ILE – 12 
GLN – 9 SER - 33 ASP - 28 LYS - 38 GLU – 196 CYS - 11 GLU - 197 ARG – 8 
GLU – 31 GLN - 51 TYR - 29 PRO - 14 GLU – 197 ARG – 8 GLU - 197 SER – 33 
GLN - 116 PHE - 1 GLN – 9 SER – 33 MET – 1 GLU - 47 MET - 1 GLU – 47 
ASP – 46 PHE - 1 VAL – 5 ILE – 42 THR – 4 GLU - 47 PRO - 194 PRO – 14 
ASP – 28 LYS – 38 CYS - 43 MET – 3 GLU – 196 LYS – 5 GLU - 196 LYS – 5 
ASP – 28 ARG – 8 ASP - 28 ARG – 8 GLU – 5 ARG - 52 THR - 4 GLU – 47 
ASP – 28 LYS – 57 GLN - 116 PHE – 1 THR – 198 GLN - 51 GLU - 5 ARG – 52 
ASP – 7 ARG – 8 GLU - 31 GLN – 51 GLU – 196 LYS – 38 GLU - 196 LYS – 38 
ARG - 212 GLU – 47 TYR - 29 CYS – 11 GLU – 197 LYS – 38 GLU - 196 CYS – 53 
GLU – 31 ARG - 8 ASP - 28 LYS – 57 GLU – 196 CYS - 53 GLU - 197 LYS – 38 
GLU - 293 PHE - 1 ASP – 7 ARG – 8 ASP – 190 LYS - 46 ASP - 190 LYS – 46 
GLU - 31 LYS - 46 ARG - 212 GLU – 47 GLU – 196 LYS – 57 GLU - 196 LYS – 57 
TYR - 27 ARG - 8 GLN - 209 GLU – 47 GLU – 196 ARG – 8 HIS - 195 PRO – 14 
ASP - 28 ARG - 6 ASP - 35 ARG - 8 GLY – 6 LYS - 46 GLU - 196 ARG - 8 
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Figure 5.3:  Docking of chemokine receptor CXCR3 with CXCL11 NMR structures.  
CXCL11 NMR structures, pdb id code 1RJT: model 1 (Booth, Clark-Lewis et al. 2004) 
were docked to the CXCR3 homology model based on the dark-state rhodopsin crystal 
structure, pdb id code 1l9h (Okada, Fujiyoshi et al. 2002) using the ClusPro software 
(Comeau, Gatchell et al. 2004).  The interaction site is expanded to show tyrosine 
residues 27 and 29 of CXCR3 that were shown to be critical for the interaction of 
CXCL11 with CXCR3, where signalling may be sulfonation-dependent (Campanella, 
Lee et al. 2003; Colvin, Campanella et al. 2006). 
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Figure 5.4:  Interaction of rhodopsin with CXCL11 NMR structure.  CXCL11 NMR 
structures, pdb id code 1RJT: model 1 (Booth, Clark-Lewis et al. 2004) were docked to 
the dark-state rhodopsin crystal structure, pdb id code 1l9h (Okada, Fujiyoshi et al. 2002) 
using the ClusPro software (Comeau, Gatchell et al. 2004). The interaction site is 
expanded to emphasize the EC loop 2 in rhodopsin with that of CXCL11.  Residues 194-
197 of rhodopsin are labelled. 
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5.1.4. Discussion and Conclusions 
 
 
Evidence described in Chapters 3 and 4 suggests that rhodopsin has the conformational 
flexibility to accommodate ligands at different domains. The evidence described in this 
Chapter further support this notion.  Functional studies have shown that the interaction 
between rhodopsin and chemokines inhibits both chemokine and rhodopsin functions 
suggesting that in addition to its established function as the visual photoreceptor, 
rhodopsin may modulate other signaling pathways.  The interaction site of rhodopsin 
with CXCL11 was similar to that observed between CXCR3 and CXCL11.  In particular, 
the contribution of the N-terminus and EC loop 2 was essential for the interaction with 
CXCL11 in both receptor models.  These studies suggest that class A GPCRs may have 
conserved substates between different members of common or divergent origin to 
accommodate different ligands, given the possibility that the receptors have access to 
them.  Thus, while we propose that an interaction between rhodopsin and CXCL11 
occurs in vitro, such an interaction may be rare or non-existent in vivo. Although sharing 
similar structure and sequence, GPCRs have evolved to be specific to both tissues and 
ligands, suggesting specific functions.  Given this, the probability that chemokines may 
interact with other GPCRs non-specifically, rhodopsin included, is small.  Additionally, 
such an interaction may be difficult to observe and identify in real-time in a biological 
system, unless the system is reconstituted, as above.  However, growing evidence shows 
that various chemokines are expressed during retinal inflammation (McMenamin, 
Forrester et al. 1992; Crane, McKillop-Smith et al. 2001), and more recently, it was also 
shown that CXCL11 can pass the blood – retina barrier (Crane and Liversidge 2008), 
thus the interaction is possible from an accessibility point of view.  While further studies 
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would be needed to demonstrate the functional relevance of this observation in vivo, this 
was not the goal of this thesis. Here, we only aimed at obtaining a proof-of-principle that 
there may be a potential for an allosteric ligand binding site in rhodopsin involving the 
EC domain. While further work is needed to confirm the location and affinity of binding, 
the fact that chemokines are small proteins eliminates the possibility of a TM binding 
domain. A CP domain, while unlikely, still remains to be excluded experimentally.  
 In conclusion, the studies performed in this chapter suggest that rhodopsin can 
bind to ligands, either small molecules or proteins, from other members of GPCRs.  This, 
along with the studies from earlier chapters indicates that the overall structure and the 
conformational sub-states available for different GPCRs may be conserved, despite the 
sequence diversity observed in these receptors.  In addition to this, one may speculate that 
the diversity in sequences could have lead to subtype specificity in these receptors for the 
available endogenous ligands presented to them in the cells. 
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SUMMARY 
 
 
Membrane proteins in general, and G protein coupled receptors are no exception, pose 
problems for application of NMR-based ligand binding studies due to the need to 
maintain the proteins in a membrane mimetic environment such as detergent micelles. 
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The high intensity of detergent signals suppresses the signals from the protein. Here, we 
proposed to study ligand binding by two alternative approaches: 19F NMR spectroscopy 
and selective excitation using 1H NMR spectroscopy. Selective excitation of the 1H 
spectral region downfield of the water signal can reveal ligand-backbone and ligand-
tryptophan interactions. The use of this method to identify ligands that bind to rhodopsin 
was demonstrated in chapter 3 (refer section 3.1.1 and 3.2.2). The 19F nucleus provides an 
ideal NMR probe because of its high sensitivity and the lack of natural 19F background in 
biological systems. One dimensional 19F NMR spectra acquired on a set of ligands 
labeled with 19F, to show as a proof of principle that this probe can be used to screen 
ligands with similar chemical groups either in vitro or in vivo.  
 
 
SIGNIFICANCE 
 
 
Membrane proteins are encoded by up to 30% of typical genomes and constitute the most 
important class of drug targets: more than 60% of current drugs are targeting membrane 
receptors, channels or transporters. Amongst these, the G protein coupled receptors are 
the largest group of drug targets because of their important role in mediating 
communication between the inside and outside of the cell in response to an enormous 
variety of different ligands, ranging from small proteins and peptides to small organic 
molecules, ions and even light. These ligands can be hormones, odorants, 
neurotransmitters, or other functional classes of biologically active compounds. Despite 
the importance of membrane proteins as drug targets, they have not yet been amenable to 
the structure-based drug design. This is due to constraints such as the size of the molecule 
and the need for the detergent environment. Thus, the NMR spectroscopy methods for 
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example, employing selective excitation 1H and 19F based approaches, overcoming many 
of the challenges associated in applying conventional NMR spectroscopy methods to 
membrane proteins will be highly beneficial in identifying new drugs targets for these 
receptors. 
 
 
INTRODUCTION 
 
 
Although NMR based screening is only one of many screening tools in drug discovery, 
its simplicity and wide range of application (including protein-protein and protein-nucleic 
acid interactions) has attracted much attention. NMR allows measurement of multiple 
parameters at different levels of complexity and information content. Thus, NMR based 
methods differ significantly from one another as a result of the particular approach used. 
NMR techniques for drug discovery are high content methods: they potentially provide 
binding information, the location of the binding site and the conformation of the bound 
ligand. NMR can also supply structural information that enables docking of the ligand to 
the protein's binding pocket. In addition, NMR provides very valuable information about 
the general behavior of the ligands that other high throughput methods do not reveal, 
including solubility, binding behavior (promiscuous ligands), precipitation potential and 
aggregation. Because NMR based screening is biased toward finding medium to low 
affinity ligands, the approach can also serve as an effective prescreening tool for 
subsequent assay-based high throughput screening. Thus, NMR based screening for small 
molecular weight drugs are now well established in industry and can be used 
complementary to high throughput screening methods and computational screening 
methods. The major limitation of current high information content NMR based screening 
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methods is the applicability to small and well behaved proteins with limited background 
from solvent, thus essentially excluding membrane proteins and proteins in complex 
environments such as the cell. Here, we discuss these limitations in details and propose 
approaches to overcome them. 
 
 
6.1. LIMITATIONS IN APPLICABILITY OF NMR 
SPECTROSCOPY TO MEMBRANE PROTEINS 
 
 
While 1H NMR based methods to study ligand binding can be carried out with unlabeled 
protein, more sophisticated applications of NMR spectroscopic techniques such as SAR 
by NMR require labeling, typically the biosynthetic introduction of 13C and 15N nuclei. 
However, many proteins cannot be successfully expressed in E. coli or P. pastoris that 
make uniform 13C,15N labeling affordable. When proteins need to be expressed in 
mammalian or insect cell lines in order to obtain them in functional form, uniform 
labeling becomes prohibitively expensive when the protein expression levels are not 
unusually high. In such cases, specific 15N and / or 13C labeled amino acids are 
introduced (Klein-Seetharaman, Reeves et al. 2002; Klein-Seetharaman, Yanamala et al. 
2004). Such proteins are not amenable to structure determination by NMR spectroscopy. 
Mammalian membrane proteins often belong to this group e.g. when they are 
glycosylated or otherwise posttranslationally modified in their native form, and require 
the mammalian or insect cell machinery for proper folding. 
Another constraint on the applicability of NMR spectroscopy can be the presence 
of background signals. In the case of membrane proteins, a membrane mimetic is 
required, provided by detergent micelles when they are studied with solution NMR 
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methods. The detergent concentrations are typically 100 times higher than the protein 
concentrations to ensure that only one functional protein or protein complex is present 
per micelle for uniformity purposes. The high signal intensity originating from the 
detergent leads to the suppression of signal intensities from the protein (dynamic range 
problem) and also results in overlapping with that of protein peaks. An example is shown 
for a 0.7mM solution of the mammalian membrane protein and G protein coupled 
receptor rhodopsin in 1% octyl glucoside (Figure 6.1). A value of 1% is in fact relatively 
low; in many cases much higher detergent concentrations are used, making the dynamic 
range problem even more severe. 
 
 
 
 
 
 
 
 
Figure 6.1: One dimensional 1H NMR spectrum of rhodopsin in 1% octyl glucoside. 
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6.2. SELECTIVE EXCITATION 1H NMR SPECTROSCOPY 
 
 
Membrane proteins are generally excluded from 1H NMR-based ligand screening 
approaches because of the high background signals from detergents (see Section 6.1, 
above; Figure 6.1). Here, we propose a solution to extend the applicability of 1H NMR-
based approaches to membrane proteins. NMR approaches involving ways to selectively 
excite the protein signals while suppressing the detergent peaks can be applied to such 
systems. Here, we show selective excitation sculpting studies using full-length rhodopsin 
in octyl glucoside micelles as a model system. Rhodopsin is the most extensively studied 
G-protein-coupled receptor, and knowledge about its structure serves as a template for 
other related receptors.  
One dimensional 1H NMR spectra recorded by selectively exciting the protein NH 
region by applying a 90° pulse centered around 10-12 ppm shows 1H chemical shifts 
from both backbone and side chain regions of rhodopsin in octyl glucoside micelles 
(Figure 6.2A). Further, excitation of the same region using the hyperbolic secant shaped 
pulse to remove detergent and water signals significantly increased the intensities of the 
NH peaks in the range from 6.0 - 8.5 ppm (Figure 6.2B) (Hwang and Shaka 1995; Stott 
1995). Note, however, that the number of peaks observed in the 1D 1H NMR spectrum is 
significantly reduced. We tentatively propose that the observed signals arise mostly from 
the backbone C-terminus residues and other flexible loop regions (refer to Section 3.2.4 
(f), pg. 135). This hypothesis is based on the previous observation (Klein-Seetharaman, 
Reeves et al. 2002) that sharp, highly intense and thus slowly relaxing signals are found 
only for Lys339 in a uniformly 15N-lysine labelled rhodopsin sample. Furthermore, 
comparison between the observed signals and those obtained with a peptide 
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corresponding to the sequence of the C-terminal residues reveals extensive similarities 
between the rhodopsin C-terminus and the free peptide in solution (Werner, Lehner et al. 
2007).  
One-dimensional 1H NMR spectra of rhodopsin recorded at different 
concentrations of octyl glucoside indicated chemical shift dependence of the C-terminus 
backbone peaks (data not shown), highlighting the need to control the detergent 
environment quantitatively to obtain reproducible NMR results. To investigate possible 
detergent-protein interactions, we recorded one- and two-dimensional 1H-1H selective 
excitation NOE spectra. We observed differential interactions of the rhodopsin backbone 
signals with those of the detergent micelles (Figure 6.3) (Stott 1995). We did not observe 
intramolecular protein NOE peaks. A potential solution that may allow future 
measurement of such NOEs could be provided by detergent deuteration. However, the 
high cost of isotope labelled detergent will prohibit extension to high-throughput studies.  
The selective excitation approach described here can be used to investigate both 
NH backbone and tryptophan side chains and thus, in principle, the same innovative 
approaches developed for one-dimensional ligand screening using 1H NMR of soluble 
proteins can be extended to membrane proteins when combined with the selective 
excitation schemes proposed here. We have successfully identified novel ligands binding 
to rhodopsin and interacting with C-terminal residues by measuring signal intensity, 
chemical shift and line-broadening effects in selectively excited 1H spectra as a function 
of added ligand or protein (see Section 3.1.1 and 3.2.1).  
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Figure 6.2: One dimensional NMR spectra of unlabelled rhodopsin in octyl 
glucoside micelles. (A) Selective excitation of the NH region using 90 degree pulse. (B) 
Selective excitation of the NH proton peaks with sculpting using hyperbolic secant 
shaped pulse (Hwang and Shaka 1995; Stott 1995).  
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Figure 6.3: One- and two-dimensional 1H-1H selective excitation NOE spectra of 
rhodopsin. (A). One dimensional solution selective NOE 1H NMR spectrum of 
rhodopsin in 0.146% OG recorded at 600MHz, 25oC. (B). Two dimensional solution 1H - 
1H NOE spectrum of rhodopsin in 1% OG. The NOE’s from the detergent peak (marked 
with an arrow in Figure 6.3A) to the 1H peaks from Rhodopsin (represented in box in 
Figure 6.3A) are shown. 
 
 
6.3. APPLICATION OF 19F NMR SPECTROSCOPY TO SCREEN LIGANDS 
 
 
As selective excitation overcomes the dynamic range problems posed by the detergent 
background, the following considerations still makes it difficult to use 1H NMR based 
approaches for ligand screening. Often, It is not possible to clearly differentitiate the 
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multiple site binding modes of a ligand to a protein, i.e., if a ligand binds at more than 
one site on a protein with different affinities. In particular in the case of ligand-observe 
based screening, the ligands that have overlapping signals with protein peaks as well as 
that give rise signals upfield of water signal, the selective excitation approach cannot be 
successfully applied. 19F NMR spectroscopy can be a viable alternative for one-
dimensional NMR spectroscopic measurements, providing complementary results. 
Because there is no background from 19F nuclei in either biomolecules such as neither 
proteins nor detergents used to dissolve membrane proteins, the applicability range of 19F 
NMR to study ligand binding in soluble and in membrane proteins is identical.  
19F NMR studies of protein structure, dynamics and ligand binding offers several 
advantages over other NMR-spectroscopic approaches as a result of the unique chemistry 
of the 19F atom. 19F has 100% natural abundance and its sensitivity to NMR detection is 
83% that of 1H. The presence of nine electrons surrounding the 19F nucleus makes it very 
sensitive to minor changes in its environment, including both Van-der-Waals and 
electrostatic interactions, which is reflected in its wide range of chemical shifts. This 
characteristic increases the probability of obtaining well-resolved peaks of fluorine atoms 
in different environments. Another major advantage of 19F NMR over other conventional 
NMR techniques is the appearance of its NMR signals in the absence of any background 
signals, including membrane mimetic environments and even entire cells. These unique 
properties of the 19F nucleus suggest that 19F NMR spectroscopy could provide a highly-
desirable alternative to high-throughput screening by conventional NMR spectroscopic 
techniques, in cases where the latter methods are not applicable, such as for membrane 
proteins or for in-cell studies. Both, approaches involving changes in line shape and/or 
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chemical shift of a free fluorinated ligand on binding to a protein (ligand observed 
method) or that of a fluorinated residue in a protein on ligand binding (protein observed 
method) can be employed in the context of high throughput screening. Here we 
investigated the application of 19F NMR spectroscopy to screen for fluorine labeled 
ligands both in vivo and in vitro.  
 
 
6.3.1. Screening for 19F labeled Ligands for Membrane Proteins in vitro 
 
 
The fluorine atom of a free ligand on binding to a protein is expected to show restricted 
motion compared to its free state and hence give a broader line shape. The chemical shift 
change may be either upfield or downfield depending on the nature of the change of 
interactions of the fluorine atom with its environment. A downfield shift indicates a more 
hydrophobic environment or a greater extent of Van-der-Waals interaction of the fluorine 
atom. Changes in electrostatic interactions of the fluorine atom with its environment, 
such as a ring current effect, can influence either a downfield or an upfield shift (Gerig 
1989).  
The ease of obtaining information from ligand binding studies by 19F NMR has 
extended its applicability to high-throughput screening (HTS) of chemical libraries that is 
a routine procedure in the field of drug discovery. The broad chemical shift dispersion of 
the fluorine nucleus allows for identifying ‘hits’ in a screen with less chances of 
encountering the problem of spectral overlap from different chemical compounds. The 
simplicity of the 19F spectra, unlike 1H spectra, decreases the time for deconvoluting the 
spectra when a large mixture of chemicals is being screened. Changes in chemical shift 
values and/or line widths of the free fluorinated ligand upon addition of a protein will 
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indicate whether a compound is binding to the protein or not. Thus monitoring free ligand 
peaks allows the use of very low protein concentrations, in the tens of μM range. 
Information on binding constants and stoichiometry of binding from ligand titration 
experiments can be further used to rank order ligands in a screen. Such information was 
obtained while screening a library of compounds for chaperones PapD and FimC, 
involved in the assembly of pili on E. coli, and are essential targets for the development 
of antibacterial agents (Tengel, Fex et al. 2004). 19F NMR studies can also be used to 
provide further information on binding sites to optimize the lead compound by 
characterizing the structural changes induced by their binding. This is done by using 
proteins substituted at different positions by fluorinated amino acids and monitoring their 
chemical shift changes on ligand binding. This is much less expensive and easier 
compared to 1H NMR where the spectra are complicated and further deconvolution 
requires expensive isotope labeled samples of high concentration.   
As a proof-of-concept for extending these approaches to membrane proteins, we 
screened binding of 19F-labeled small molecules to rhodopsin by mixing the ligands with 
the receptor. Ligands were in a mixture of 10 compounds at 50μM concentration each. 
The receptor concentration was 0.2mM in detergent solution (5-fold excess). For a ligand 
with micromolar affinity, these conditions ensure that the majority of the ligand will be 
bound and therefore a maximal peak shift is expected for a hit. Excellent signal to noise 
ratio can be achieved with 7 min acquisition time (Figure 6.4). One-dimensional 19F 
NMR spectra were recorded in the absence (Figure 6.4, blue trace) and presence of 
rhodopsin (Figure 6.4, red trace) in the dark.  Due to the large chemical dispersion of 19F 
nuclei, even the ligands with minor modifications gave rise to distinct peaks (compare 
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compounds at positions 3, 4, and 8). The comparison of chemical shifts upon addition of 
protein indicated changes for a subset of ligands. In particular, an upfield shift in the 
signals for ligands corresponding to positions 1, 3, 5, and 8 were observed. The strongest 
effect was observed for signal at position 8.  These subsets of ligands from the first 
screen can be further analyzed at different concentrations to understand the kinetics and 
strength of ligand binding effects.  
 
 
 
 
Figure 6.4: Example for a screening of a 19F-labeled compound library against 
rhodopsin. NMR signals from eight compounds are visible in the particular range shown. 
 
 
6.3.2. Screening for 19F labeled Ligands for Proteins Expressed in Cells 
 
 
NMR techniques developed to date for understanding ligand binding interactions, 
including the 19F-NMR based approach described above, involve looking at purified 
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proteins in solution. When studying ligand-binding interactions with the goal of 
developing new drugs one has to consider that ligand binding in vivo is also influenced 
by drug uptake and crowdedness in the cells. One often reported observation in cancer 
drug discovery is that the measured cell based activities differ from the protein based 
screening activity. A potential explanation can be that a particular compound is a 
substrate for an efflux pump which are very active in cancer cells. Another reason could 
be that a particular compound cannot pass the cell membrane efficiently. In this section, 
we extended the studies described for purified proteins to proteins inside cells. As a proof 
of principle, we studied a soluble protein pair, Hdm2-p53. This interaction is important 
for cancer progression and its inhibition is desirable. A library containing fluorine labels 
to disrupt this interaction were given to us by collaborator Dr. Alex Doemling. To test for 
the uptake/efflux of representative fluorine labeled compounds targeting the Hdm2-p53 
interface, we studied HCT-116 cells expressing p53+/+. The representative compounds 
investigated are shown in Figure 6.5. Studies by the group of Dr. Alex Doemling 
identified that BEB-124 exhibits 40 folder affinity in comparison to BEB-125 towards 
Hdm2 isolated and purified from cells. However, the cell based activity assay for BEB-
124 was found to be inefficient in inducing apoptosis. To investigate if the two 
compounds were able to enter the cells, the uptake of these compounds by HCT-116 cell 
expressing p53+/+ and Hdm2 was measured by one dimensional 19F NMR spectroscopy. 
The two compounds BEB-124 and BEB-125 were titrated into HCT-116 cancer cells 
suspended in DMEM media in the NMR tube. One dimensional 19F NMR spectra 
recorded of the compounds alone in the absence of cells gave rise to single sharp peaks 
with chemical shifts at –114.9, and –110.0 ppm (in reference to TFE at -75.6 ppm) for 
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BEB-124 and BEB-125 respectively. To understand if these compounds can enter the 
HCT-116 cancer cells expressing Hdm2, we did a series of titrations of BEB-124 and 
BEB-125 ranging from 0.1 - 2.8mM. Addition of 100µM BEB-124 into the HCT-116 
cells gave rise to a single peak at -114.9 ppm, indicating no changes as compared to the 
control. The titration of BEB-124 (0.1, 0.2, 0.3, 0.4 and 1mM) compound indicated no 
changes in the spectrum except for an increase in the peak at -114.9 ppm. However, upon 
addition of 100μM BEB-125 we were not able to observe any signal in the NMR 
spectrum except for the TFE peak. Further titration of 0.2mM BEB-125 gave rise to a 
chemical signal at –108.2 ppm, downfiled shifted by 1.8 ppm as compared to free ligand 
peak at -110.0 ppm. This peak was broader as compared to free peak indicating that it 
might be experiencing a different chemical environment and viscosity as compared to 
free form. An overlay of NMR spectra of 0.1, 0.3, 0.7, 1.6 and 2.8mM BEB-125 into the 
HCT-116 cells is shown in Figure 6.6C. Initial titrations (until 300μM) of the BEB-125 
showed an increase in the peak at -108.2 ppm and the peak shifted downfield by 0.1 ppm. 
At higher concentrations of BEB-125, a peak at –110.0 ppm started appearing 
corresponding to the free peak. Comparison of the various titrations did not show any 
changes in chemical shift corresponding to the free peak but a total shift of 0.6 ppm was 
observed for the peak at -108.2 (Figure 6.6B). These results suggest that BEB-125 is 
taken up very rapidly into the cell up to very high concentrations. BEB-124 despite its 
higher affinity for Hdm2 does not reach a high intracellular concentration and cannot 
effectively induce apoptosis and cell death in these cells. 
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Figure 6.5: Chemical structures of the 19F labeled compounds designed to target 
Hdm2. 
 
To test if the binding of BEB-125 is specific to HCT-cells and to verify that the 
peak observed at -108.2 ppm is not due to unspecific binding of the compound to the cell 
membrane, we measured the interaction of these compounds with E. coli cells as a 
control. Shown in Figure 6.6B and 6.6D are the 1D NMR spectra representing the 
titration of BEB-124 (0.1, 0.3 and 1mM) and BEB-125 (0.1, 0.3 0.6 and 1.5mM) added to 
E. coli cells suspended in LB media. Addition of 0.1mM BEB-124 and BEB-125 
immediately gave rise to peaks at -114.7 and -110.0 ppm (in reference to TFE at -75.6 
ppm). The peak at -114.7 ppm corresponding to BEB-124 was shifted by 0.1 ppm as 
compared to ligand alone in LB at -114.8 ppm. Further, no change in peak corresponding 
to BEB-125 was observed.  The BEB-124 interaction with HCT-116 and E. coli cells was 
similar (Figure 6.6A and 6.6B). In contrast, the results of the BEB-125 titration to E. coli 
cells were different as compared to HCT-116 cells and showed no differences compared 
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to ligand alone controls.  These results indicate that BEB-125 specifically interacts with 
HCT-116 cells expressing Hdm2 and p53. 
 
Table 6.1: Comparison of the activity of compounds in vivo and in vitro 
 
Compound Name Activity invitro Active in cells
BEB-124 1μM No 
BEB-125 60μM Yes 
 
 
To investigate a possible mechanism for the results obtained, and further test if 
the broad peak observed around -108.1 to -108.7 ppm is due to the presence of ligand 
inside or outside of the cellular compartment, we measured the interaction of BEB-125 
with HCT-116 cells in the absence and presence of 0.1mM verapamil, an efflux inhibitor. 
An overlay of addition of the compound BEB-124 to HCT-116 cells is shown in Figure 
6.7A. Comparison of 1mM BEB-124 added to HCT-116 treated with (Figure 6.7A, red 
trace) and without (Figure 6.7A, black trace) verapamil showed no changes. In contrast, 
upon addition of 2.8mM BEB-125 to cancer cells treated with verapamil we observed an 
increase in the intensity of bound peak and a decrease in the free peak intensity as 
compared to untreated cells (Figure 6.7B). Additionally, the bound peak was shifted 
upfield by 0.1 ppm as compared to untreated cells. Addition of 100µM verapamil to a 
control of ligand alone did not have any effects on the spectrum nor on the peaks. These 
results suggests that by blocking the efflux receptors of cancer cells using verapamil, the 
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ligand that is present inside the cells is not shuttled out as in untreated cells.  Note, 
however, that the free peak was only decreased in intensity and did not disappear 
completely. This might be because not all efflux receptors are completely blocked at the 
concentration of 100µM verapamil used in this experiment. These results indicate that in 
vivo 19F NMR studies can be used to study complex interactions of ligands with their 
target cells in a realistic environment. 
 
6.4. CONCLUSION 
 
 
The prospects of NMR based screening of small molecule ligands binding to membrane 
proteins are very good: selective excitation 1H and 19F NMR spectroscopy can overcome 
many of the challenges associated with solution NMR studies of membrane proteins in 
detergent micelles. Fluorine is an extremely versatile element with many advantages in 
the drug discovery pipeline. At the screening stage, the 19F nucleus provides a sensitive 
ligand binding as well as conformational probe without background signals. At the more 
biological level, the cellular uptake and fate of 19F tagged compounds can be detected in a 
time- and space-resolved as well as otherwise label-free manner. In conclusion, it was 
shown that screening of 19F libraries could be fast and cost-efficient and the discovery of 
novel small molecular weight ligands by NMR may become possible even for difficult 
membrane bound targets such as GPCRs and ion channels. 
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Figure 6.6: Screening for 19F labelled ligands in E. coli and HCT-116 cancer cells. 
An overlay of one dimensional 19F NMR spectra of 100µM (black), 300µM (red) and 
1mM (blue) BEB-124 in (A) HCT-116 (B) E. coli cells and 100µM (black), 300µM 
(red), 900µM (green), 1.5mM (magenta) and 2.8mM (blue) BEB-125 in (C) HCT-116 
cells and (D) E. coli cells. 
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Figure 6.7: Monitoring the localisation of the 19F labelled ligands inside vs outside 
the cells using NMR. One dimensional 19F NMR spectra of (A) 1mM BEB-124 and (B) 
2.8mM BEB-125 added to the cells treated without (black) and with (red) 100µM 
verapamil. 
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SUMMARY  
 
 
 
This thesis investigated allosteric modulation of GPCRs. The emphasis was on allosteric 
modulation of the prototypic class A GPCR, rhodopsin. Using our understanding of 
structure and dynamics in rhodopsin, we were also able to explain allosteric modulation 
in other GPCRs. We developed a general framework in which we propose that GPCRs 
contain three potential binding sites, at the CP, TM and EC domains, and that depending 
on which of the ligand binding sites are occupied by the endogenous ligand, the other two 
sites can serve as allosteric sites. 
Analysis of the interaction of C3G and Ce6 ligands with rhodopsin described in 
Chapter 3 demonstrated the existence of a novel CP ligand binding domain in rhodopsin. 
The interaction of these accessory ligands at the CP region exerted differential effects on 
rhodopsin structure and dynamics. While one ligand (Ce6) strongly inhibited G protein 
activation; the other (C3G) only slightly did so. While the binding of C3G resulted in the 
destabilization of retinal protein interactions explaining its functional effect of enhancing 
rhodopsin regeneration rates, the other (Ce6) stabilized rhodopsin secondary structure. 
Both ligands  have in common that they  prove the existence of a structural coupling 
between the CP domain and the EC and TM domains, allosterically modulating 
rhodopsin. Thus, information transfer not only occurs from the EC or TM domain to the 
CP domain, but also from the CP to the TM and EC domains, indicating bi-directional 
information flow in GPCRs. During the writing of this thesis, it was discovered that other 
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independent lines of evidences also support the presence of CP allosteric ligand binding 
pockets in muscarinic receptors (Espinoza-Fonseca and Trujillo-Ferrara 2005), 
chemokine receptors (Andrews, Jones et al. 2008) and rhodopsin (Taylor, Barda et al. 
2008).  
 GPCR conformations differentiating active from inactive states are best 
understood for rhodopsin. We used this knowledge to explain allosteric modulation of 
mGluRs. Studies presented in Chapter 4 showed a preferential binding of positive and 
negative allosteric modulators to active and inactive states of receptors based on 
rhodopsin structures, respectively. This demonstrates the generality of the mechanisms of 
conformational flexibility for different GPCRs. Furthermore, while the endogenous 
ligand binding site in mGluRs is located in the EC domain, the allosteric ligand binding 
site in mGluRs was found to highly overlap with that of 11-cis retinal pocket in 
rhodopsin, suggesting for the structural conservation of the ligand binding pocket in the 
TM domain across diverse GPCRs.  
Finally, we also obtained preliminary evidence that rhodopsin contains an EC 
allosteric ligand binding pocket, supporting the idea that orthosteric ligand binding 
pockets in some GPCR can be allosteric binding pockets in others. Thus, rhodopsin 
would be a candidate receptor that shows the presence of all three pockets, in the CP, TM 
and EC domains. The effects of binding of chemokines, typical EC domain ligands 
endogenous for chemokine receptors, to rhodopsin are described in Chapter 5.  In 
particular, chemokine ligand CXCL11 is predicted to bind at the EC domain involving 
similar sites on rhodopsin as compared to chemokine receptor, and binding modulates the 
ability of rhodopsin to activate the G protein. While chemokines activate chemokine 
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receptors, in the case of rhodopsin, the modulation is a negative one, and binding results 
in negative allosteric modulation, inhibiting G protein activation by rhodopsin. 
 Collectively, the studies presented in this dissertation demonstrate that rhodopsin, 
and GPCRs in general, can accommodate accessory ligands at any of the domains, TM 
domain near at the interface with EC side, EC domain and CP domains. However, 
different GPCR members will likely show a preference for one of the sites to 
accommodate the endogenous ligand. The studies performed clearly suggested that the 
TM domain plays a major in communicating the signals from one side to the other and 
thus might be conserved across different GPCRs. While a direct coupling between the 
TM and CP domain or the EC and CP domain mediated through TM domain was shown 
previously, the studies presented in this thesis consolidate the reciprocal nature of this 
structural coupling.  
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FUTURE RESEARCH DIRECTIONS 
 
 
The evidence presented in this thesis for the existence of the novel cytoplasmic ligand 
binding domain in rhodopsin prompts for the immediate need to obtain crystal structures 
for the complexes between rhodopsin and Ce6 and C3G to confirm the location and mode 
of binding. This should include different activation states of the receptor, which is now 
feasible, given that several crystal structure representing such states have been 
successfully described in the literature. In addition to the structural details, other 
important questions that still remain to be investigated relate to the functional 
consequences of binding. The studies presented here only focused on the sensitization 
pathway (activation of the G protein), the effect of binding of Ce6 and other ligands in 
the CP domain on other signaling proteins involved in desensitization pathways will aid 
in better understanding the modulatory effects of these ligands on different pathways in 
visual signal transduction. Although our studies performed with Ce6 have shown that it 
has an inhibitory effect on signal sensitization in bovine rhodopsin, previous studies 
(Washington, Zhou et al. 2007) have proposed a signal enhancement mechanism in the 
presence of Ce6. The conclusions were derived at with very different approaches, and 
resolving this discrepancy is important for understanding the physiological relevance of 
this interaction, which has been proposed to enhance vision in deep-sea ocean fish. Thus, 
it is important to investigate if Ce6 has similar or different effects on Gt activation in 
deep-sea ocean fish-derived rhodopsin or rhodopsin from other related species. For 
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example, the recent dark state crystal structure of squid rhodopsin (Murakami and 
Kouyama 2008) resembles the Gt bound state, indicating that bovine signal transduction 
mechanisms could be different from more primitive rhodopsins. Since the signal 
transduction pathways in deep-sea ocean fish are not known and specimens are difficult 
to obtain, studies of squid rhodopsin are more feasible. 
 The observation that Gt activation by rhodopsin is inhibited in the presence of Ce6 
may have practical significance. Many residues in the proposed Ce6 binding site are 
highly conserved in class A GPCRs. Thus, Ce6 may be a G protein inhibitor for other 
GPCRs also. As described in Chapter 1, a broad GPCR activity inhibitor could be useful 
in diseases where several GPCRs are involved in parallel pathways, such as cancer. 
Further experiments using other GPCR members, at least other class A GPCRs, are 
needed to demonstrate if Ce6 can be developed into a ligand that can target multiple 
GPCRs simultaneously. This would also be a useful tool to study generality of the 
principles discovered in this thesis for the GPCR family in general. 
Also related to generality of the findings presented in this thesis for other GPCRs 
is the possibility to extend the studies presented in Chapter 4 on using rhodopsin 
conformations as templates to predicting positive versus negative allosteric modulation of 
mGluRs, to predict such functional outcomes for other GPCRs. Being able to predict in 
silico the nature of a given ligand, i.e. whether it will have an enhancing or suppressing 
effect on the receptor activation would be highly beneficial in designing new drugs 
targeted at GPCRs. Until recently, the only three dimensional information for any GPCR 
was that of rhodopsin, but over the past one and half year, the X-ray crystal structures of 
three other members of class A GPCRs along with the ligand free state of rhodopsin, 
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opsin, were published (Cherezov, Rosenbaum et al. 2007; Rasmussen, Choi et al. 2007; 
Jaakola, Griffith et al. 2008; Park, Scheerer et al. 2008; Scheerer, Park et al. 2008; 
Warne, Serrano-Vega et al. 2008). Although these receptors exhibit very similar overall 
structural architecture, the EC and CP loops exhibited striking changes in structure. In 
particular, EC loop 2 was found to be in the A2A, β1 and β2 Adrenergic receptors 
(Cherezov, Rosenbaum et al. 2007; Rasmussen, Choi et al. 2007; Jaakola, Griffith et al. 
2008; Warne, Serrano-Vega et al. 2008) in  a different secondary structure conformation 
as opposed to rhodopsin. Generating homology models of GPCR members based on 
these new receptor structures will aid in generating models that may be more diverse as 
opposed to rhodopsin alone, a receptor that follows a two state model and binds to a 
ligand covalently.  Since we showed in chapter 4 a preferential binding of ligands to the 
active and inactive conformations of mGluRs, similar studies of receptors with the 
different homology models may lead to more accuracy in the predictions. Thus, we 
propose that the studies presented in chapter 4 can be extended to other members of 
GPCRs and may lead to the development of a ligand classifier.  
In addition to binary classifications positive versus negative allostersic 
modulation, the detailed comparison between binding pockets can also be used to derive 
new hypotheses on ligand structures and effects. Our preliminary studies indicate that the 
mGluR5 ligand 3,3`-DFB interacts with rhodopsin probably at the same site as 11-cis 
retinal. However, it is not clear how similar or dissimilar the 3,3`-DFB bound structure  is 
compared to rhodopsin 11-cis bound state. This, along with the studies aimed at 
investigating the effects of 3,3`-DFB stabilized rhodopsin structure on signaling proteins 
will lead to understanding of as how different or similar is the TM domain between the 
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different GPCR class members. Such studies may shed light on the structural 
conservation of GPCRs, despite their sequence variability and further may lead to the 
understanding of the evolution of the specificity and diversity of GPCRs to different 
ligands. 
 Finally, the studies  on the interaction between the chemokine, CXCL11, and 
rhodopsin and the comparison to the corresponding interaction with CXCR3 suggests that 
EC loop 2 plays a major role in binding to the chemokine ligand in both cases. Since the 
recent crystal structures of class A GPCRs showed variability in the structure of EC loop 
2 in comparison to rhodopsin, research focusing on deciphering the secondary structure 
of EC loop 2 in CXCR3 would be beneficial to understand the specificity in binding of 
CXCL11 to chemokine receptors as compared to rhodopsin. 
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